Biostatistical Analysis of DNA Methylation Profiling in Ovarian Cancer by Dai, Wei & Dai, Wei
Biostatistical Analysis of DNA Methylation
Profiling in Ovarian Cancer
A thesis presented for the degree of
Doctor of Philosophy of Imperial College
and the
Diploma of Imperial College
by
Wei Dai
Department of Surgery and Cancer
Imperial College
IRDB Building, Du Cane Road, London W12 0NN
JULY 19, 2011
2I certify that this thesis, and the research to which it refers, are the product of my own work,
and that any ideas or quotations from the work of other people, published or otherwise, are
fully acknowledged in accordance with the standard referencing practices of the discipline.
Signed:
3Copyright
Copyright in text of this thesis rests with the Author. Copies (by any process) either in full,
or of extracts, may be made only in accordance with instructions given by the Author and
lodged in the doctorate thesis archive of the college central library. Details may be obtained
from the Librarian. This page must form part of any such copies made. Further copies (by
any process) of copies made in accordance with such instructions may not be made without
the permission (in writing) of the Author.
The ownership of any intellectual property rights which may be described in this thesis
is vested in Imperial College, subject to any prior agreement to the contrary, and may not
be made available for use by third parties without the written permission of the University,
which will prescribe the terms and conditions of any such agreement. Further information
on the conditions under which disclosures and exploitation may take place is available from
the Imperial College registry.
4Dedication
This thesis is deciated to my family who gave me enormous support in the past four years,
which is the source of my courage to start and to accomplish this PhD project.
5Acknowledgements
I am extremely grateful to my supervisor, Prof. Robert Brown for his encouragement, guid-
ance and support from the initial to the final stage of the study. His academic experience
and patience is invaluable for me to develop an understanding of the project. I would also
like to thank Mr. Jim Paul for offering advice in data analysis which has improved the qual-
ity of this work immeasurably, Dr. Sarah Blagden and Dr. Jenny Barrett for their thoughtful
and constructive comments, and Dr. Natalie Shenker for proofreading the thesis.
Funding from Cancer Research UK (CRUK), has made this research possible. Ovarian
Cancer Action (OCA) kindly provided the office space for this study. Scottish Gyneaco-
logical Clinical Trials (SGCT) group provided a high quality of ovarian tumour samples
and clinical information. Expression data of the candidate genes in serous ovarian cancer
and clinical information are provided by The Cancer Genome Atlas (TCGA) Pilot Project
established by National Cancer Institute.
I am also very grateful that Dr. Jens M. Teodoridis and Dr. Constanze Zeller generated
DMH data, and together with Dr. Janet Graham performed the bisulfite pyrosequencing
and methylation speicific PCR for the validation of methylation of candidate loci. Ms
Jenny Hersey performed qRT-PCR to examine the expression of candidate genes identified
in this study.
I wish to thank all my colleagues in Epigenetics Section at Department of Sugery and
Cancer, as well as Tucker family for their kindness and support.
6Abstract
Ovarian cancer is the most lethal gynaecological cancer. Although having good response to
chemotherapy, the majority of the patients with advanced disease will eventually relapse.
Aberrant DNA methylation in tumours has been proposed as biomarkers to predict patients’
clinical outcome and response to chemotherapy.
An algorithm, Methylation Linear Discriminant Analysis (MLDA), was developed for
large-scale methylation analysis using differential methylation hybridsation (DMH). MLDA
identified loci differentially methylated between cisplatin sensitive and resistant derivatives
of an ovarian tumour cell line with 89% accuracy and showed hypermethylation, rather than
hypomethylation, predominantly occurred during the acquisition of cisplatin resistance.
Customised microarrays targeting promoter CpG islands in 10 key signaling pathways
were designed for DMH analysis. Based on the power analysis epithelial ovarian tumours
(screening study n=120, validation study n=61) prospectively collected through a cohort
study, were firstly analysed by DMH at 302 loci spanning 189 promoter CGIs at 137 genes
in the Wnt pathways for the association with progression free survival (PFS). Increased
methylation of 6 loci, at FZD4, FZD9, DVL1, NFATC3, ROCK1 and NKD1 genes, were as-
sociated with shorter PFS independent from clinical parameters. A multivariate Cox model
incorporates only NKD1 and DVL1, identifying two groups differing in PFS (HR=2.72;
permutation test p = 4 × 10−3). Consistent with epigenetic regulation, reduced expres-
sion of FZD4 and DVL1 is associated with poor relapse free survival in an independent
7cohort (p<0.05,n=321).Analysis in further 9 pathways/families found 6 more independent
biomarkers relevant to PFS at PIK3R5, AKT1 and VEGFB from AKT/mTOR pathway,
PRDX2 and TR2IT2 from Redox pathway and MLH3 from MMR system.
The study shows DNA methylation changes are involved in acquired drug resistance,
and demonstrates the importance of methylation at multiple promoter CGIs in key signaling
pathways, especially in the Wnt pathway, for predicting clinical outcome in ovarian cancer
and their potential as stratification biomarkers in future clinical studies for personalised
treatment.
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Chapter 1
Introduction
1.1 A Brief Introduction of Ovarian Cancer 20
1.1 A Brief Introduction of Ovarian Cancer
Ovarian cancer is the most lethal and second most common of all the gynaecological can-
cers (Jemal et al., 2009). There are about 6850 new cases of ovarian cancer diagnosed
each year in UK (http://info.cancerresearchuk.org). About 70% of ovarian
cancers at diagnosis have spread beyond the pelvis into the abdominal cavity, near lymph
nodes (stage III) or distant organs such as liver, lungs and brain (stage IV). Patients with ad-
vanced disease undergo surgical cytoreduction followed by platinum-based chemotherapy
and most of them (>80%) are highly responsive to chemotherapy at the beginning of treat-
ment. However, the majority of patients with advanced-stage disease eventually relapse and
will acquire resistance to chemotherapy (Agarwal and Kaye, 2003). Therefore, the 5-year
survival rate of ovarian cancer is low (40%)(http://info.cancerresearchuk.
org).
Currently, the aetiology of ovarian cancer is still poorly understood. A strong family
history of ovarian or breast cancer, often related to inherited mutation in one or two genes
known as BRCA1 and BRCA2, is the most important risk factor (Holschneider and Berek,
2000), however, only about 5-10% of women with ovarian cancer have BRCA1 or BRCA2
mutation (Holschneider and Berek, 2000; Sowter and Ashworth, 2005).
Ovarian cancer is a heterogeneous disease and can develop from epithelial cells, germ
cells, stromal cells or sex-cord cells. Over 90% of ovarian cancers have been thought to
arise from the epithelial surface of ovary. However, recently there is evidence that some
epithelial ovarian cancers (EOC) arise from the fallopian tube epithelium (Crum et al.,
2007; Kindelberger et al., 2007). As EOC accounts for the majority of ovarian cancers, the
following sections are mainly focused on the pathology and biological properties, treatment
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response, as well as the prognostic factors of EOC.
1.1.1 Pathology and biology
Epithelial ovarian cancers are classified as serous, endometrioid, mucinous, clear cell and
undifferentiated (Rosen et al., 2009). The clinical behaviours of these subtypes of tumours
vary, which is most likely to reflect variations in their biological properties. A number
of studies have reviewed the clinicopathological features and molecular changes of these
types of ovarian cancer (Cho and Shih Ie, 2009; Rosen et al., 2009; Bast et al., 2009). Ta-
ble 1.1 summarises the frequency, 5-year survival rates and frequent molecular changes
for these subtypes. In brief, the serous tumour is the most common subtype (about 70%)
(Cho and Shih Ie, 2009). It is classified as high or low grade based on the extent of nuclear
atypia and mitosis (Malpica et al., 2004). The morphologically defined grade subtypes
are distinct diseases with different molecular alterations. TP53 mutation is common in
high grade serous ovarian cancer (HG-SOC). A recent comprehensive mapping study of
TP53 mutation shows a frequency as high as 96.7% and TP53 dysfunction can be observed
in 100% high grade serous carcinoma (Ahmed et al., 2010). BRCA dysfunction through
germline and somatic mutation, down-regulation of gene expression by promoter methyla-
tion and amplification of trans-acting factors are observed in more than 50% of HG-SOC
(Bowtell, 2010). A model that describes the genesis of high grade serous tumours pro-
posed by Bowtell (2010), which suggests that TP53 mutation followed by BRCA mutation
is the primary event in the genesis of this type of tumours. The common precursor lesion
of HG-SOC is not well recognised, although it may rise from ovarian surface inclusion
cyst, peritoneal mesothelium, or the distal portion of the fallopian tube (Cho and Shih Ie,
2009). Low grade serous type is characterised by KRAS and BRAF mutations, while TP53
mutation is rare. Endometrioid tumours comprise 10-20% of ovarian cancer cases. 5-year
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survival rate of endometrioid tumours is 40-63%, which is higher than serous tumours
(20-35%). TP53 mutation is also common in high grade endometrioid tumours but is un-
common in the tumours with Wnt and/or PI3K/PTEN signalling defects (Cho and Shih Ie,
2009). However, mutations of β-catenin (CTNNB1) in the Wnt pathway and of PTEN,
PIK3CA in the PI3K/PTEN pathway are frequently observed in low grade endometrioid
tumours that are typically lack of TP53 mutation. Mucinous and clear cell tumours account
for 5-20% and 3-10% ovarian cancer cases, respectively. Molecular changes associated
with these two tumour types have not been extensively studied yet. About 50% of muci-
nous tumours have KRAS mutation (Rosen et al., 2009). Mutations of KRAS, BRAF and
TP53 have been observed in clear cell tumours, but their frequencies are low (Rosen et al.,
2009). PIK3CA mutations are reported in 20-25% clear cell tumours, and a small num-
ber of patients (about 8%) with clear cell cancers have PTEN mutations (Cho and Shih Ie,
2009). Recently, mutation of AR1D1A was shown to be present in 46% of ovarian clear
cell carcinomas and 30% of endometrioid carcinomas, thus has become a new molecular
target for the treatment of these ovarian cancer subtypes (Wiegand et al., 2010).
1.1.2 Chemotherapy and acquired drug resistance
The recommended standard first line treatment for advanced ovarian cancer is platinum
(cisplatin or carboplatin) combined with paclitaxel (du Bois et al., 2005). Platinum-based
therapies can form intra- and inter-strand DNA adducts that inhibit replication and tran-
scription. DNA damage caused by platinum can result in apoptosis (Agarwal and Kaye,
2003). Paclitaxel belongs to the taxane class of therapeutic agent and can bind to intra-
cellular β-tubulin, which results in microtubule stabilization, growth arrest and apopto-
sis (Siddik, 2003). To monitor the response of treatment, the World Health Organisation
(WHO), the National Cancer Institute and the European Organisation for Research and
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Histology type Frequency 5-year survival rate Frequent molecular changes 
Serous ~70% 20-35% 
High grade: TP53 
Low grade: KRAS, BRAF 
mutation 
Endometrioid 10-20% 40-63% 
High grade: TP53 mutation 
Low grade: CTNNB1, PTEN and 
PIK3CA mutation with 
microsatellite instability 
Mucinous 5-20% 40-69% KRAS mutation 
Clear cell 3-10% 35-50% PTEN, PIK3CA, ARID1A mutation 
undifferentiated 1% 11-29% unknown 
 
Table 1.1: A summary of frequency, survival rate and molecular changes of malignant
epithelial ovarian cancer adapt from Cho and Shih Ie (2009)
Treatment of Cancer have adopted a set of response criteria, Response Evaluation Criteria
in Solid Tumours (RECIST) (Therasse et al., 2000). The RECIST criteria define response
as complete response (CR), partial response (PR), stable disease (SD) and progressive dis-
ease (PD) based on the changes of tumour size measured by radiological modalities, such
as computed tomography (CT) scanning and magnetic resonance imaging (MRI), at target
tumour lesions of which the longest diameter was recorded(Table 1.2).
Although up to 80% of patients with ovarian cancer have a good response (complete/partial
response) to initial chemotherapy, most of them will eventually relapse after a median pe-
riod of 18 months (Greenlee et al., 2001). Although many tumours at the time of relapse
are still chemo-responsive, they will eventually acquire resistance to treatment (Sood and
Buller, 1998; Lister-Sharp et al., 2000; Greenlee et al., 2001). Therefore, an understanding
the mechanisms of drug resistance, especially acquired drug resistance, have become very
important for the successful treatment of ovarian cancer.
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Response Description 
Complete response the disappearance of all target lesions 
Partial response 
at least a 30% decrease of in the sum of the longest diameter of 
target lesions, taking as reference the baseline sum longest 
diameter 
Progressive response 
at least a 20% increase in the sum of the longest diameter of 
target lesions, taking as reference the smallest sum longest 
diameter recorded since the treatment started or the appearance 
of one or more new lesions 
Stable disease 
neither sufficient shrinkage to qualify for partial response nor 
sufficient increase to qualify for progressive disease, taking as 
reference the smallest sum longest diameter since the treatment 
started 
 
Table 1.2: Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
Drug resistance can be intrinsic or acquired. Intrinsic resistance refers to tumours that
do not respond to first-line chemotherapy and is conferred by the genotype of pretreat-
ment clone, while acquired resistance is caused by mutations in progeny tumour cells after
chemotherapy though the tumours initially respond (Balch et al., 2004). A number of
studies have shown multiple mechanisms are involved in either intrinsic or acquired drug
resistance in ovarian cancer. Generally, these mechanisms include decreased drug influx,
increased drug efflux, altered drug target, drug metabolism, DNA damage repair, changes
in cell cycle checkpoint mediators, and changes in downstream mediators of the apoptotic
pathway (Hazlehurst et al., 2003). An inverse resistance relationship has been frequently
observed between cisplatin and paclitaxel (Stordal and Davey, 2009), which adds another
layer of complexity to drug resistance. As reviewed by Balch et al. (2004) altered gene
expression levels have been found in resistant tumours compared to sensitive ones. Most
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of those genes are involved in cell proliferation, DNA repair, angiogenesis, and cell migra-
tion. The changes of the gene expression are not only caused by mutation and copy number
gain or loss, but aberrant epigenetic regulations, such as DNA methylation (see section 1.2
and 1.3) and histone deacetylation, also play a role. Several genes including tumour sup-
pressors and genes involved in apoptosis have been shown epigenetically down-regulated
in ovarian cancer (Balch et al., 2004). For example, the acquisition of methylation of the
mismatch repair gene, MLH1, has been shown in 25% of plasma samples from the pa-
tients with ovarian cancer relapse (Gifford et al., 2004). The silencing of MLH1 expression
has previously been associated with resistance to platinum-based reagents (Brown et al.,
1997). It is likely that the loss of MLH1 expression results in defects in the mismatch
repair system. This system can detect platinum-DNA adducts and activate apoptotic re-
sponse. Therefore, the reduced levels of apoptosis in the cancer cells would contribute to
the resistance to platinum-based drugs. Given epigenetic alterations have been shown to
contribute to silencing of the genes associated with chemosensitivities, it has been proposed
that the reversal of epigenetic silencing could resensitise ovarian tumours to chemotherapy
(Balch et al., 2004). Our group has shown that the combination of DNA methyltransferase
(DNMT) inhibitor and histone deacetylase (HDAC) inhibitor dramatically up-regulated a
number of genes, including MLH1, in ovarian cancer cell line resistant to cisplatin (microar-
ray data unpublished). Steele et al. (2009) also demonstrated that treatment with these two
inhibitors resulted in a marked increase in the expression of epigenetically silenced MLH1
both in vitro and in vivo. This further indicated the potential of using this combination to
re-sensitise resistant ovarian tumours, as had previously been shown for a demethylating
agent alone (Plumb et al., 2000).
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1.1.3 Prognostic and predictive factors of EOC
As reviewed by Gasparini et al. (1993) in the context of breast cancer, a prognostic factor
can be defined as ”at a certain time point gives information about the subsequent clinical
outcome”. Accurate prognostic factors can identify the patients who are more likely to
have an early-relapse and/or death, even though they have achieved complete response at
the beginning of the treatment. Such patients are candidates for maintenance or consolida-
tion therapy strategies. A predictive factor ”gives information about selection of patients
who will be benefit from treatment” (Gasparini et al., 1993). Accurate predictive biomark-
ers can identify the patients who are potential candidates for novel targeted therapy given
that they have a high chance of exhibiting resistance to the conventional treatment, thus
aiding personalised medicine strategies and potentially leading to more effective treatment.
A prognostic factor is not necessarily predictive and vice versa, although certain factors
can be both prognostic and predictive.
Currently, the established prognostic factors for EOC at clinical presentation before pri-
mary chemotherapy are residual disease, patient age at diagnosis, histology, stage, grade
of tumour and performance status of the patient (Table 1.3) (Thigpen et al., 1993; Eisen-
hauer et al., 1999; Clark et al., 2001; Bristow et al., 2002; Cannistra, 2004). One of the
most significant prognostic factors is stage of disease at diagnosis. Most cases already
have advanced-stage tumours (Stage III or IV) at diagnosis. Patients with early-stage
tumours have much better prognosis than the patients with advanced-stage tumours. It
has been reported that five year survival rates for ovarian cancers are 90% in Stage I,
50% in Stage II, 20% in Stage III and 6% in Stage IV, respectively (http://info.
cancerresearchuk.org). However, Clark et al. (2001) found the patients with Stage
III and Stage IV have no difference in the risk of death, indicating in those patients stage
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does not remain as an effective prognostic factor. Nevertheless, those clinical prognostic
factors are imperfect predictors of outcome, and do not provide insights into the biological
mechanisms that underlie the clinical behaviour of tumours. Therefore, the identification
of reliable prognostic/predictive biomarkers would be of potential clinical value, provide
the biological basis of tumour aggressiveness and resistance to chemotherapy, and identify
drug targets for novel drug development strategies.
Although the potential prognostic value of individual biomarker in ovarian cancer have
been investigated (Berchuck et al., 1990; Eisenhauer et al., 1999; Havrilesky et al., 2003;
Verri et al., 2005; Bast et al., 2009; Lee and Park, 2009), to date, none of them have been
clinically translated as independent prognostic biomarkers of sufficient value to direct clin-
ical management of patients. There are many reasons that this may be the case, such as the
lack of standardisation or reproducibility of the assays, poor study designs and inappropri-
ate or misleading statistical analyses. Among these various reasons, study design has been
a major issue, resulting in the study being underpowered or overly optimistic estimation of
the effect size. Sample size is a major problem when complex data sets including thousands
of biomarkers are examined simultaneously and where multiple testing caused a high false
positive rate. As well as the small size of the samples, the following statistical problems are
also common in these studies: (1) new biomarkers were examined individually without the
simultaneous evaluation of prognostic value compared with conventional clinicopatholog-
ical markers by performing a multivariate analysis; (2) the long-term clinical information
were incomplete; (3) different chemotherapy treatment regimens were used, which would
be likely to influence the prognostic value of the biomarkers, which was not accounted for
in the analysis (Hall et al., 2004). Since, many prognostic biomarker studies have not been
reported with sufficient information to allow for the adequate assessment of the quality of
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the study, REMARK guidelines (Table 1.4) (McShane et al., 2005) have been developed
to encourage transparent and complete reporting in prognostic studies. These guidelines
summarised key information on study design, patient characteristics, assay methods, data
presentation and statistical analyses. In these guidelines, a clear objective of the study is
required. The number of total patients and events (effective sample size) are the key items,
and the rationale for the sample size should be given to determine the power of the study.
Items 2, 3 and 6 of the guidelines recommend that the patient characteristics should be
reported, including the treatment received and how the patients are selected in the study.
This could help the reader understand how the study result can be applicable in a clinical
situation, and to evaluate whether there was any selection bias in the study. The clinical
endpoints examined in the study should be precisely defined as recommended in item 7.
For overall survival, it should be defined whether the death referred to all deaths or only
cancer-related deaths; with regards to progression free survival, the definition of disease
progression should be clearly stated. In terms of statistical analysis, item 10 and 11 recom-
mend that the statistical model methods and test of the assumption should be reported, for
example if the Cox proportional hazard model is used, the assumption of the proportional
hazards should be tested. Furthermore, the study should clarify how the marker values
were handled, such as the use of a continuous variable or categorical variable. If a cat-
egorical variable was used, the paper should describe how the cut-point was determined
should be stated. In data presentation (item 12 and 13), the flow of patients including the
inclusion and exclusion criteria through the study should be described, and the distribution
of clinical parameters should be reported to define the studied patients cohort further. In
terms of data analysis (item 14 to 18), the relationship between the biomarkers and standard
prognostic variables should be estimated. A univariate analysis is used to evaluate the cor-
relation between biomarkers and outcome. The estimated effect of the biomarkers should
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be adjusted in the multivariate analysis including standard prognostic factors, to assess if
the biomarkers are independent or not. The hazard ratio, 95% confidence interval of the
hazard ratio and p value should be reported for both biomarkers and standard prognostic
factors. Internal validation or independent validation should be performed to evaluate how
good the model is when fitting with new dataset. Finally, the limitations and implications
of the study should be discussed (item 19 and 20).
Following REMARK guidelines, Mallett and his colleagues (2010) evaluated the prog-
nostic studies published between January 2006 and April 2007 (the earliest publication
of REMARK is in 2005, and very few studies referred REMARK criteria during the first
two years). They found that the reporting of these key information was poor prior to the
publication of the REMARK guidelines. A REMARK profile based on these guidelines
was recommended by Mallett et al. (2010) to improve reporting and enhance prognostic
research studies.
Compared to prognostic factors, the identification of predictive factors is more compli-
cated and difficult. Although REMARK mentions the reporting of predictive markers, as
claimed by the authors, the guidelines are not adequate for predictive studies. Therefore, a
more specific set of guidelines for the investigation of predictive markers is required.
1.1.4 Gene expression profiling in EOC
With advances in DNA-microarray technology, it has become possible to analyse expres-
sion of thousands of genes simultaneously in ovarian tumour tissues, allowing the identifi-
cation of gene expression profiles that are associated with clinical outcome and/or chemother-
apy response in patients with EOC. This has provided insights into molecular changes
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Table 1.4: REporting recommendations for tumour MARKer prognostic studies (RE-
MARK) from McShane et al.(2005)
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during cancer growth and chemotherapy resistance. Some of these studies have been re-
viewed by Konstantinopoulos et al in 2008 (Konstantinopoulos et al., 2008). Later that
year, Tothill et al. (2008) reported on microarray gene expression profiling in 285 serous
and endometrioid tumours of the ovary (GEO accession ID: GSE9899) and identified 6
molecular subtypes of ovarian cancer. Two subtypes predominantly represent the serous
low malignant and low grade endometrioid subtypes. The remaining subtypes represent
higher grade and advanced stage cancers of the serous and endometrioid subtypes. Crijns
et al. (2009) (GEO accession ID: GSE13876) profiled the gene expression of 157 advanced
stage serous ovarian cancers and identified a survival-related gene signature that invovled
17 key signalling pathways as well as 13 transcription factors associated with overall sur-
vival. The majority of thess gene expression signatures have been validated in an indepen-
dent patient cohort, although most of validation sets are small. The Cancer Genome Atlas
Project (http://cancergenome.nih.gov/) has accomplished the gene expression
profiling of over 300 serous ovarian tumours, which has provided a valuable source for the
further validation of these signatures. Meanwhile comprehensive catalogues of mutations,
copy number variations and methylation profiling have also been developed in the same pa-
tient cohort. The integration of these ”omics” datasets would be useful to identify patients
who gain less benefit from conventional treatment strategies, and therefore are potential
candidates for novel targeted treatments.
1.2 Biological Functions of DNA Methylation
In humans, DNA methylation usually occurs at CpG dinucleotides with the addition of a
methyl-group to the 5’ position of cytosine. This reaction is catalysed by members of DNA
methyltransferase (DNMT) family (Figure 1.1). The DNMTs implicated in DNA methy-
lation in humans include DNMT1, DNMT3a and DNMT3b. DNMT1 is involved in the
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maintenance of methylation, primarily acting on hemi-methylated DNA during DNA repli-
cation, while DNMT3a and 3b are thought to be involved in de novo methylation facilitated
by another protein DNMT3L, which is primarily expressed during development (Pradhan
and Esteve, 2003; Jia et al., 2007). CpG dinucleotides are under-represented in the human
genome (only 21% of the expected CpG sites)(Illingworth and Bird, 2009). This is mainly
because the spontaneous deamination of cytosine residues gives rise to uracil residues
that are recognised and repaired by the cell, but deaminated 5-methylcytosine resembles
thymine and is left unrepaired (Lander et al., 2001). It was estimated that 70% of cytosines
in CpG dinucleotides are heavily methylated, predominantly at repetitive elements to pre-
vent chromosomal instability (Suzuki and Bird, 2008). However, some CpG-rich regions
(on average 1 CpG per 10bp, which is much higher than the ratio of 1 per 100bp in the
genome), accounting for<2% of CpG dinucleotides, are known as CpG island (CGI). CGIs
are frequently located in the promoters and the first exons, generally remain unmethylated.
Exception to this are methylated CGIs, which are found close to genes on the inactive X
chromosome, imprinted genes, and tissue-specific genes (Baylin and Jones, 2006). To de-
fine a CGI a mathematical model was proposed by Gardiner-Garden: CG content is greater
than 50%, the sequence length is over 200bp and the ratio of observed to expected CpGs
is larger than 0.6 (Gardiner-Garden and Frommer, 1987). Using this model, genome-wide
CGIs have been predicted in humans in silico and information about these CGIs is available
on the UCSC Genome Bioinformatics website (http://genome.ucsc.edu/).
The mechanism by which CGI remain unmethylated compared to the global methy-
lation is still unclear. It could be that CGIs are targeted by certain DNA demethylation
mechanisms, which results in the removal of the methyl-group from cytosines (Frank et al.,
1991). Another possible alternative is that since CGIs are often co-localised to the promoter
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Figure 1.1: Cytosine methylation. DNA methylation is catalysed by DNA methyltrans-
ferase (DNMT)
region and are therefore bound by transcription factors, this precludes the association of
DNMT at the CGIs (Illingworth and Bird, 2009).
Only about 3% of transcription start sites that are associated CGI are normally methy-
lated in somatic tissue (Weber et al., 2007). Methylation of promoter CGIs is often asso-
ciated with transcriptional silencing (Bird, 2002). Methylation could prevent transcription
by the presence of the methyl-group in the major groove, which would directly prevent the
binding of transcription factors. This possibility has been supported by the observation that
several transcription factors cannot bind when the DNA recognition sequences of the tran-
scription factors are methylated (Eden and Cedar, 1994). However, methylation is often
capable of repressing transcription only after chromatin has been assembled, suggesting
that this direct effect is not the main mechanism by which methylated DNA inhibits gene
expression (Curradi et al., 2002). The other proposed mechanism involves the interaction
between DNA methylation and histone modifications to determine gene expression status
(Klose and Bird, 2006). It has been shown that methylated DNA can recruit methyl-CpG
binding domain (MBD) proteins that associate with histone deacetylases (HDACs) and hi-
stone methyltransferases (HMTs). Histone deacetylation increases the positive charge of
histones, which are then attracted by the negative charge of the DNA back bone, leading
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to compression of the chromatin. Histone methylation, particularly H3K9 methylation an-
other repressive histone marker, binds with heterochromatin protein-1 (HP1) (Jenuwein and
Allis, 2001). This establishes a repressive chromatin structure that represses of gene ex-
pression. Meanwhile, DNMTs participate in multi-protein complexes that contain HDACs
and HMTs causing the methylation of DNA. This further reinforce the repression of tran-
scription (Feinberg and Tycko, 2004). Whether DNA methylation or histone modifications
are the initiation event in the regulation of gene expression remains unclear.
1.3 Aberrant DNA Methylation in Ovarian Cancer
Two major types of aberrant DNA methylation changes occur in cancer compared to nor-
mal cells (Barton et al., 2008). One is global hypomethylation, which is mainly detected at
repetitive elements. This could lead to chromosome instability. The other is hypermethy-
lation at CGIs, which is associated with gene inactivation, and particularly affects tumour
suppressor genes (Feinberg and Tycko, 2004). Since the methylation of CGI at the pro-
moter region of the gene can cause gene silencing and aberrant methylation patterns have
been observed in cancer cells, Peter A. Jones and Peter W. Laird (1999) suggested that pro-
moter CGI methylation is the third type of hit that can cause the loss of function of tumour
suppressor gene that are involved in tumorigenesis. Therefore, Knudson’s two-hit hypoth-
esis has been revised to include direct mutations in the coding regions, partial or complete
loss of gene copies, and epigenetic silencing, which participate in different combinations
to cause a complete loss of activity of a specific gene.
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1.3.1 Promoter CGI methylation and ovarian cancer
As reviewed by Barton and his colleagues (2008), a number of genes have been found to be
hypermethylated and become silenced in ovarian cancer compared to the normal ovarian
surface tissues. The methylation frequencies of those genes varies widely in independent
studies: the variation observed could be due to many reasons including difference in the
composition of patients studied, different regions of interest examined and methods used to
measure methylation. The genes with aberrant methylation in ovarian cancer are involved
in multiple biological processes relevant to cancer development and progression including
cell cycle, DNA repair, cell adhesion, microtubule stability, and cell proliferation amongst
others. For instance, the tumour suppressor genes, p16, (CDKN2A), BRCA1, RASSF1A and
APC have been found methylated in ovarian cancer tissues (Teodoridis et al., 2005). The
methylation of tumour suppressor genes can serve as the second hit, thus leading to the
initiation of cancer. As well as causing the direct inactivation of tumour suppressor genes,
methylation can also silence transcription factors, such as GAGT4 and GAGT5 (Wakana
et al., 2006), and cause the inactivation of downstream targets. In addition, the hyper-
methylation of genes in the DNA repair systems, such as, BRCA1, GSTP1 and MGMT,
is associated with a good response to chemotherapy in ovarian cancer (Teodoridis et al.,
2005).
1.3.2 DNA methylation as a biomarker in ovarian cancer
There is an increasing amount of literature about the use of DNA methylation as a biomarker
for the early detection of cancer, as well as the prediction of clinical outcome, and the pa-
tient response to chemotherapy. The use of DNA methylation as a biomarker has several
advantages: (1) DNA is a more stable molecule than RNA or protein; (2) the detection of
DNA methylation can focus on a small region, such as a CpG island, rather than screening
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the whole gene; and (3) DNA methylation are detectable in body fluids such as serum or
plasma (Cottrell and Laird, 2003; Gifford et al., 2004).
Table 1.5 lists the studies since 2004 reported on individual DNA methylation as prog-
nostic or predictive biomarkers in malignant ovarian cancer at tumour presentation and
response to first-line chemotherapy. Very few methylation prognostic biomarkers in ovar-
ian cancer were reported before 2004, probably as a result of technological limitations. In
spite of certain common problems in studies about prognostic biomarkers, such as small
sample size, incomplete clinical information, no consideration of clinical parameters and
treatment, and no further validation in an independent patient cohort (see section 1.1.3),
other issues in many of these studies would confound the analysis regarding the biological
features of DNA methylation, as outlined: (1) the promoter CGI is not well defined, and
therefore, the regions that are methylated in the primary tumours are often unclear, with
exception of the MCJ study (Strathdee et al., 2005); (2) expression of the candidate genes
is not always evaluated in these studies, however, confirmation of the prognostic/predictive
value at two molecular levels (e.g. methylation and expression) would increase the reliabil-
ity of the biomarker and provide a better understanding of the function of methylation in the
candidate genes; and (3) methylation is used as a categorical variable in the analysis rather
than as a continuous measurement. This could reduce the statistical power of the analysis,
especially when sample size is small. Furthermore, methylation cut-offs for a continuous
variable can be arbitrary and are not always biologically relevant.
A panel of multiple biomarkers may be more informative given that cancer is a com-
plex disease involving multiple biological mechanisms. Such a panel could improve the
predictive accuracy since an individual biomarker is more likely to give a false negative
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result than multiple biomarkers due to the limitations of the detection methods. Table 1-5
details some of the studies that have used the methylation levels of a panel of genes as the
predictor of clinical outcome in ovarian cancer patients. Teodoridis et al. (2005) showed
that methylation of at least one of three genes (BRCA1, GSTP1 and MGMT) is correlated
with good response to chemotherapy. Later, Su et al. (2010) showed the methylation of at
least one of three genes (SFRP1, SOX1 and LMX1A) is a predictor of overall survival, while
methylation of at least one gene of SFRP1, SFRP2 and SOX1 is a predictor of disease recur-
rence in ovarian cancer patients. Since measurement of methylation at a panel of genes is
very labour-intensive, array-based approaches have been utilized to identify the prognostic
methylation signatures that can predict patients’ clinical outcome. Wei et al. (2002) identi-
fied such a methylation signature including 956 loci that can stratify the late-stage patients
into two distinct groups with different clinical outcome. Later, the signature was reduced
to 112 loci to predict patient progression free survival with 95% accuracy using bioinfor-
matics algorithms (Wei et al., 2006). Although all these studies still need further validation
in randomised controlled trials, the identification of a panel of methylation biomarkers in
ovarian cancer has become possible.
1.4 High-throughput DNA Methylation Analysis
Lots of efforts have been made to develop methods for large-scale DNA methylation anal-
ysis, since it has been realised that DNA methylation plays an important role in multiple
processes of various diseases including cancer. Genome wide studies on DNA methylation
primarily rely on three techniques based on restriction enzyme, sodium bisulfite conver-
sion, or affinity purification with methylation binding domain proteins or a methyl-cytosine
antibody. These methods can be combined with global approaches, such as DNA microar-
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rays, for methylation pattern study or high-throughput sequencing for single-base-pair res-
olution methylation analysis in the whole genome (Schones and Zhao, 2008). Although
next-generation sequencing combined with these three local techniques is more powerful
as it provides single-base resolution, and allele-specific readout and does not require the
design of an appropriate microarray, array-based technology is still popular due to its low
cost and the simplicity of down-stream data analysis. Therefore, only microarray-based
technologies are discussed here, as they are more relevant to the content of this thesis.
1.4.1 Restriction enzyme
This approach uses a methylation-sensitive restriction enzyme, such as HpaII (CCCG),
BtUI (GCGC), MspI (CCGG), Acil (CCGC and GCGG), Hhal (GCGC) and Tail (ACGT),
which only recognizes a specific unmethylated DNA sequence. These sequences are then
cleaved if unmethylated or remain uncleaved if methylated. One example of the use of
this method is differential methylation hybridisation (DMH). In this method, the sample
digested by methylation-sensitive restriction enzyme and the mock digested sample are
labelled with different fluorescent dyes and competitively hybridised on the two-colour mi-
croarray. DNA methylation is measured by the relative fluorescent signal intensities. In
DMH, genomic DNA is pre-digested by MseI, which recognises the site T/TAA. TTAA is
rare in CGIs, so digestion by MseI could deplete the CpG-poor DNA. The advantage of
this method is that it allows the methylation profiling of genome-wide regions by the iden-
tification of cleaved sites. The disadvantages of this method are as follows: (1) methylation
analysis can only take place within the recognition sites, (2) it is prone to false negatives
caused by incomplete digestion rather than DNA methylation, and (3) the size of MseI
fragment introduces the bias in the detection of methylation.
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In an adapted DMH method, the methylation-specific restriction enzyme, McrBC, is
used to specifically recognise methylated DNA sequences. McrBC recognises two half-
sites of the G/AmC, which are generally separated by about 55-103bps but can be sepa-
rate by up to 3kb (Sutherland et al., 1992). This adaption can increase the sensitivity to
densely methylated regions and reduce the false positives. This method was further mod-
ified in MethylScope using sheared DNA rather than MseI fragments to avoid the size
bias in methylation analysis (Lippman et al., 2004). The McrBC-based method is further
improved by comprehensive high-throughput arrays for relative methylation (CHARM)
(Irizarry et al., 2008) by optimizing the workflow for microarray design and data process-
ing. To overcome the regional limitations of using restriction enzyme and improve the sen-
sitivity and specificity of methylation detection, a cocktail method, known as microarray-
based methylation assessment of single samples (MMASS) (Ibrahim et al., 2006), was de-
veloped. In MMASS, one half of the DNA sample is digested by a number of methylation-
sensitive enzymes and the other half is digested by McrBC, the two parts of sample are
then competitively hybridized on the microarray.
1.4.2 Methylation antibody/methylation binding domain
Another popular method for achieving methylation enrichment is using methyl-binding
proteins, such as MeCP2, or antibodies specific for 5-methylcytosine. The enrichment of
methylated regions by the immunoprecipitation of genomic DNA with a 5-methylcytosine
specific antibody, followed by hybridisation on the microarray is known as MeDIP (Weber
et al., 2005). This method has been implemented by Agilent Technology for genome-
wide methylation analysis by a CpG island tiling microarray. Recently, higher affinity
methyl-binding proteins including multimerized MBD domains (Jorgensen et al., 2006) and
a protein complex of MBD2b (short isoform of MBD2) and MBD3L (Rauch and Pfeifer,
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2005) have been used to improve the affinity enrichment. However, this method requires
the appropriate adjustment of the down-stream data analysis for avriable CpG densities in
different regions of the genome.
1.4.3 Bisulfite conversion
Treating with sodium bisulphite can convert cytosine to uracil, but leave the 5 -methylcytosines
intact. This method has been combined with bead arrays manufactured by Illumina (CA,
USA) to obtain a DNA methylation profile in a large scale. The first Illumina assay for
methylation studies was the GoldenGate Methylation assay (Bibikova et al., 2006), which
covered 1505 CpG sites selected from cancer-related hot spots. Two primers that targeted
the unmethylated and methylated sequences were labelled by different florescent dyes and
the PCR products were hybridised on the microarray. Later, this assay was adapted to have
a genome-wide resolution by using Infinium assay on HumanMethylation27 BeadChip,
and targeted 27,578 CpG sites. In this assay, after bisulfite conversion, genomic DNA
is amplified and enzymatically fragmented, and then hybridised on the BeadChip. DNA
molecules are annealed to the oligos on the BeadChips that are linked to two different bead
types- one links to the methylated sites and the other to the unmethylated CpG sites. After
single-base extension using DNP- and Biotin-labeled dNTPs, both bead types incorporate
the same type of labelled nucleotides, depending on the methylation status of the cytosine
in the targeted CpG site. Both platforms achieve a single-base resolution read out and have
been applied in methylation studies of various cancers (O’Riain et al., 2009; Christensen
et al., 2010; Deneberg et al., 2010; Thirlwell et al., 2010; Wilhelm-Benartzi et al., 2010).
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1.4.4 Comparison of array-based DNA methylation profiling platforms
To combine genome-wide technologies with local techniques, various microarrays have
been designed. Many of them have competing strengths and weaknesses in human DNA
methylation study. In this section, the advantages and disadvantages of five types of mi-
croarrays including HCGI12K, Illumina Infinium HumanMethylation27 BeadChip, Agi-
lent 244K CpG island microarray as well as two custom-designed microarrays on the Agi-
lent platform (see below) are discussed.
1. HCGI12K two-channel microarray: HCGI12k microarray (University Health Net-
work, Toronto, Canada) includes about 12,000 probes from a library of CGIs purified
by methyl-CpG binding domain (MBD) column (Cross et al., 1994).
2. Agilent 244K CpG island two-channel microarray: Agilent 244k CpG island mi-
croarray (product number: G4492A, array design ID: 014791, Agilent, UK) contains
about 244,000 probes in or within 95bp of 27,800 CGIs fulfilled Gardiner-Garden
criteria (Gardiner-Garden and Frommer, 1987) and were predicted by UCSC algo-
rithm generated using a modification of a program developed by G. Miklem and L.
Hillier (unpublished).
3. Illumina infinium HumanMethylation27 BeadChip: Infinium Human Methylation27
BeadChip (Illumina, CA, USA) simultaneously interrogates 27578 CpG sites within
the promoter regions across more than 14000 genes. The methylation of each CpG
site is represented by β value, a continuous variable ranging from 0 (unmethylated)
to 1 (methylated).
4. Agilent custom-designed 15K two-channel microarray: this array was customised
for this PhD project targeting about 800 promoter CGIs within 2kb of transcription
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start sites of genes identified to be associated with acquired drug resistance and 10
key signalling pathways (see feasibility study in Chapter 3 and the screening study
in Chapter 4). The 60-mer probes on the microarray were mainly selected from
OligomeTM database (OGT, UK) and fabricated on an Agilent 8x15K platform (Ag-
ilent, UK).
5. Agilent custom-designed 60K two-channel microarray: this array was also designed
in this PhD project targeting the regions from -2kb to +8kb of the transcription start
site of the genes in 10 key signalling pathways (see validation study in Chapter 4 and
5). Similar to custom-designed 15K microarray, the 60-mer probes on the microarray
were mainly selected from OligomeTM (OGT, UK) and fabricated on an Agilent
8x60K platform (Agilent, UK).
Among the five types of microarrays, the HumanMethylation27 BeadChip using an In-
finium assay is based on bisulfite conversion, while the other 4 arrays have two-channel
outputs and can be either combined with restriction enzyme or affinity enrichment ap-
proaches to achieve a methylation profile. The choice of techniques and microarrays are
mainly influenced by the reproducibility and accuracy of the approaches, genomic cover-
age and read out resolution, input sample requirement, the number of samples that can be
assayed on the microarray, the specificity of the probes, the quality of microarray anno-
tation, and the purpose of the study. A summary of the features of these microarrays are
shown in Table 1.7.
Sample requirements and throughput
Generally, restriction enzyme-based approaches require that the DNA is of high purity,
quantity and integrity; while affinity-enrichment techniques are more tolerant to DNA im-
purities. However, the latter method requires substantial quantities of genomic input DNA
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in order to achieve sufficient enriched output DNA. As low quantities of input DNA can
be increased by PCR amplification after the DNA methylation-dependent step, Illumina In-
finium assay only requires 0.5-1µg DNA. Furthermore, the Illumina Infinium platform has
been shown to be compatible with degraded DNA extracted from formalin-fixed, paraffin-
embedded samples (Thirlwell et al., 2010).
Restriction enzyme and affinity-based methods are very labour-intensive, which limits
the use of these two types of method to small scale experiments only. Highly automated
techniques have low labour costs but consume a large amount of reagents. Therefore, the
semi-automated method of the Illumina Infinium assay is often reported in methylation
studies that use a large number of samples.
Reproducibility, accuracy and quality controls
Variations can be introduced from any of the multiple steps of array-based approaches,
including DNA preparation, hybridisation and image scaning. In particular, restriction
enzyme-based methods, such as McrBC, involve extra steps of digestion, ligation and PCR
amplification. Incomplete restriction is also one of the various factors that can influence
the reproducibility and accuracy of the approach. On our custom-designed microarrays
(Agilent custom-designed 15K and 60K microarrays), extra methylation controls were de-
signed to monitor this bias. The introduction of unmethylated controls for normalisation
purposes across the arrays in the data analysis could reduce systematic variations from var-
ious sources.
The HumanMethylation27 BeadChip is based on bisulfite conversion and tends to be
more reproducible, although the result can be influenced by incomplete bisulfite conversion
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and different PCR amplification efficiencies for the methylated and unmethylated versions
of the same sequence. Successful bisulfite modification can be monitored by adding an
extra quality control step by testing with calponin-specific primer sets prior to the Illumina
Infinium assay (Teodoridis et al., 2005). In addition, as shown in Table 1.7, a variety of
controls have been used on the HumanMethylation27 BeadChip to monitor multiple steps
in the Infinium assay.
Influence of copy number changes
Three local techniques are influenced by copy number changes to various extents. MeDIP
is particularly prone to measurement error due to the relative enrichment of gene-depleted
genomic regions, because it is obvious in the unmethylated version of a sequence. Enzyme-
based methods that rely on the balanced enrichment of methylated and unmethylated ver-
sions of a sequence, such as MMASS, are less prone to error than the methods that invovle
the unbalanced enrichment of methylated or unmethylated regions. Furthermore, bisulfite-
based methods are less susceptible to copy number alterations.
Genomic coverage
In terms of genomic coverage and resolution, the comparison of three technologies with
varying DNA fragment size and non-uniform distribution of the regions is complicated de-
pending on the distribution of recognition sites of affinity targets/restriction enzyme, and
composition of the assays.
Agilent CpG island 244k microarray targets 27,800 CGIs of about 20000 genes. In av-
erage, each gene has 13 probes covering promoter region, inside and/or downstream of the
genes, while the Human methylation27 BeadChip targets only single CpG site within/out
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of CGI close to the transcription start site (TSS) of about 14,000 RefSeq genes. Clearly,
the coverage of Methylation27 BeadChip is not satisfactory since each gene has only two
CpG sites targeted on in average, while 8 CpG sites is maximum in the selected cancer
genes. There is no external information about the design and selection of the beads on
the BeadChip. Although studies have supported the hypothesis that the adjacent CpG sites
have similar methylation status (Eckhardt et al., 2006), there is no concrete evidence that
the measurement of methylation in two CpG sites within a CGI is sufficient to estimate
the methylation level of the whole CGI sufficiently. To overcome the poor coverage of the
microarrays currently available, our Agilent 15K custom microarray was designed to cover
promoter CGIs in about 620 genes. In average, each gene is covered by 22 probes. Later,
this coverage was extended from promoter CGIs to the regions from -2kb to +8kb to TSS
of the genes on the 60K custom-designed microarray. The average number of the probes
for each gene increased to 35. The coverage of five microarrays is illustrated in Figure 1.2
for two genes DVL1 and FZD4, which are both involved in Wnt signalling transduction.
The BED files containing the custom tracks of microarrays that can be uploaded into UCSC
genome browser to visualise the genomic locations of the probes are in Appendix 1.1 to
1.6.
Probe quality and repetitive elements
An appropriately designed microarray can improve the accuracy of the three local tech-
niques. In principle, the selected probes should have a specific affinity to the targets with
minimum bias introduced by polymorphisms and repeats. In our previous study, cross-
hybridisation has been identified as a severe problem on the HCGI12K DNA methylation
microarray (Dai et al., 2008). On this microarray, about 40% of probes target multiple
sequences, in contrast, only about 2% of such probes are found on the Agilent 244K CGI
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Figure 1.2: Coverage of five types of microarrays at gene DVL1 and FZD4. Green block:
CGI. Dark blue line: Refseq gene. Light blue line: UCSC known gene. OGT phase I and
II indicate the probes designed on Agilent 15K microarray associated with acquired drug
resistance and key signalling pathways, respectively; OGT phase III indicates the probes
designed on Agilent 60K microarray with expand the coverage of key signalling pathways.
Agilent 244k and custom-designed 15K microarrays cover the CGIs only. Illumina Human-
Methylation27 BeadChip has poor coverage and is not always targeting the CGI. No probes
are found on HCGI12K arrays close to these two genes. Agilent custom-designed 60K
microarray covers +2 to -8kb of TSS of the genes and the alternative transcripts without
promoter CGI are also covered by this array. The figure was generated in UCSC genome
browser by uploading the custom tracks of the microarrays.
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microarray, 7% on the HumanMethylation27 BeadChip, and 4% on the Agilent custom-
designed 15K microarray. The intensive coverage of the Agilent custom-designed 60K
microarray might reduce the specificity of the array, as 25% of its probes are not unique.
The sequences that contain repetitive elements, such as long interspersed nuclear elements
(LINE) and short interspersed nuclear elements (SINE), could also influence the specificity
of the probes leading to the low accuracy of methylation measurement. On the Illumina
HumanMethylation27 BeadChip, about 10% of the probes map to the repetitive elements
at the targeted CpG sites, while repetitive elements have only a very small influence on the
rest of the arrays, especially in the Agilent 244K CpG island microarray which only has
0.1% such probes.
In addition, if the MseI restriction enzyme is used to fragmentise the genomic DNA, the
existence of MseI recognition site (T/TAA) within the sequences targeted by the probes can
also influence the affinity of the probes (see Chapter 3). The Agilent custom-designed 60K
microarray has the lowest percentage of such probes (about 2%), while the Agilent 244K
CpG island and custom-designed 15K arrays associated with acquired drug resistance or
key signalling pathways have about 8% and 10% of such probes, respectively.
Annotation of the microarrays
The complete and accurate annotation of microarrays is of importance in order to enable the
interpretation of the methylation analysis results. Unlike gene expression microarrays that
only target unique genes (though sometimes with multiple transcripts), the CGIs/regions
targeted by DNA methylation microarrays are sometimes associated with the regulation of
more than one gene, normally two genes that are transcribed in two directions as shown in
Figure 1.3. The single-gene annotation can be misleading in the down-stream data analysis
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Figure 1.3: An illustration of a CpG island that is possibly regulated the expressions of two
genes that are transcribed in two directions. Green block: CpG island. Arrow: direction of
transcription. The figure was generated in UCSC genome browser.
such as the functional analysis since the annotation is incomplete. In addition, inconsistent
definitions of CGIs used on different DNA methylation microarrays causes the difficulties
in comparing the results across platforms. For example, the Agilent 244K CpG island
microarray uses the definition for CGIs proposed by Gardiner Garden (1987) ) (see Section
1.2), while the Illumina HumanMethylation27 uses the definition published by Takai and
Jones (2002), in which the following more stringent criteria were used: length over 500bps,
CG content larger than 55% and the ratio of expected to observed CpG over 0.65. This
definition could exclude the most of Alu-repetitive elements with an average CG frequency
52% and a CpG expected/observed ratio 0.62, as well as some small CGIs not located in
promoter regions (Wang and Leung, 2004).
1.5 Bioinformatics Challenges in DNA Methylation Profiling Study
The application of bioinformatic approaches plays an important role in several aspects of
DNA methylation profiling studies in cancer, as follows: (1) identifying DNA methylation
profiling targets in silico, such as CGIs, depending on the purpose of DNA methylation
analysis; (2) improving the quality of selected probes in microarray designs, such as the
OGT Oligome databaseTM ; (3) enhancing the DNA methylation analysis pipeline, in-
cluding reduction of image and scanning artefacts, background correction, the exclusion
of problematic probes, batch and array normalisation, and adjustment for GC content and
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CpG density (especially in MeDIP); (4) improving the annotation of DNA methylation mi-
croarrays and simplifying the use of annotations, such as generating annotation packages
that can be used in R (http://www.r-project.org/); and (5) integrating various
sources of information with methylation data, such as expression profiling dataset, copy
number changes and other epigenetic information like histone modifications and methy-
lation patterns, to achieve a comprehensive view of the epigenetic and genetic changes in
tumour initiation and progression.
As a result of the lack of the coverage of the Illumina BeadChip at potential regions
of interest, and because MeDIP requires high quality DNA and introduces a CpG density
bias, these two methods have not been used in this study. Instead, DMH was applied on
a customized microarray that can measure the DNA methylation of targeted regions with
multiple probes and only a moderate requirement for DNA quality. However, bioinfor-
matic and statistical issues in terms of DNA methylation analysis remained while using
this approach. The potential solutions have been evaluated and implemented in this study
as described in the next section.
1.6 Aims of This Project and Outline of Thesis
Given the crucial roles of methylation at promoter CGIs in ovarian cancer development
and progression, as well as the association of methylation with chemosensitivity in ovarian
cancer, the major aim of this study was to identify the potential loci/CGIs that can be
used as DNA methylation prognostic/predictive biomarkers that would be of clinical use
in the management of ovarian cancer patients. Meanwhile, this project aimed to gain a
further understanding of the biological mechanisms of ovarian tumour progression and
the development of drug resistance. To achieve this goal, there were four primary sub-
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aims of this PhD project that were relevant to bioinformatics and statistical issues in DNA
methylation profiling studies of ovarian tumour samples using a DMH assay.
1. The development of an algorithm tailored for DNA methylation profiling studies
based on DMH to identify differential methylation associated with acquired drug
resistance: Methylation Linear Discriminant Analysis (MLDA). The principle and
implementation of this algorithm is described and discussed in Chapter 2.
2. The design of custom-designed microarrays with intensive coverage of the targeted
CGIs associated with acquired drug resistance and/or crucial signalling pathways that
have been implemented in ovarian tumour development and progression. The target
selection of the microarrays is detailed in Chapter 3 and Chapter 4, respectively.
3. A feasibility and quality assurance study of using DMH with customised microarray
to identify differential methylation associated with acquired drug resistance in ovar-
ian cancer cell lines. Chapter 3 gives the details about this feasibility study, and
shows use of DMH on the custom-designed microarray with appropriate quality con-
trols and data pre-processing method can identify differential methylation in ovarian
cancer cell lines with high accuracy.
4. The evaluation of the prognostic values of 10 important signalling pathways/families
in ovarian cancer by DMH on Agilent custom-designed 15K microarray and the
cross-platform validation of those DNA methylation prognostic biomarkers by DMH
on an Agilent custom-designed 60K microarray. The significant prognostic value of
the Wnt pathway is addressed in Chapter 4 and the prognostic values of the other
nine key signalling pathways/families are discussed in Chapter 5.
A general discussion and future prospective for methylation analysis and the potential
use of DNA methylation as biomarkers for ovarian cancer are given in Chapter 6.
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Methylation Linear Discriminant
Analysis (MLDA): An Algorithm
Tailored for DNA Methylation Profiling
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2.1 Introduction
DNA methylation frequently occurs in mammalian DNA at the 5 position of cytosine in
CpG dinucleotides. It has been estimated that over 70% of cytosines of CpG dinucleotides
are methylated in the human genome. CpG dinucleotides are under-represented in the
genome and methylated CpG dinucleotides predominantly occur within repetitive elements
(Cooper and Krawczak, 1989). However, there are CpG rich regions of the genome which
generally remain unmethylated (Bird, 1986). These CpG rich regions are known as CpG
islands and are frequently located in the promoter or the first exon regions of approximately
60% of all genes (Antequera and Bird, 1993). The unmethylated status of CpG islands is
thought to be a prerequisite state to maintain the linked gene in an active transcribed and
transcriptional permissive state (Illingworth and Bird 2009).
Differential Methylation Hybridisation (DMH) is one of several techniques for examin-
ing CpG island methylation at a genome-wide scale that has been applied to identify aber-
rantly methylated gene promoters in various cancers (Huang et al., 1999; Yan et al., 2001;
Wei et al., 2002; Yan et al., 2002a,b,c; Rahmatpanah et al., 2006; Zighelboim et al., 2007)
(see also Chapter 1, section 1.4). Nouzova et al. (2004) modified the original method by us-
ing digestion with a methylation-dependent enzyme, McrBC. This enzyme cleaves methy-
lated CpG DNA sequences containing two half-sites of the G/AmC generally separated by
about 55-103bp but can be up to 3kb (Sutherland et al., 1992). Within-sample compari-
son is applied after competitive hybridisation with McrBC digested DNA and undigested
(mock digested) DNA labelled with Cy3 (green) and Cy5 (red). If a locus is unmethy-
lated the signal intensities of Cy3 and Cy5 are equivalent, while if methylated the Cy5/Cy3
(undigested/digested) ratio is greater than one. However, no common reference is gener-
ally used in the modified DMH method, and the unequal representation of methylated and
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unmethylated sequences due to competitive hybridisation may reduce sensitivity and speci-
ficity to detect differential methylation.
Currently, Significance Analysis of Microarrays (SAM) (Tusher et al., 2001) and Pre-
diction Analysis for Microarrays (PAM) (Tibshirani et al., 2002) are commonly applied in
DNA methylation analysis. Based on the change in hybridisation relative to the standard
deviation of repeated measurements, SAM assigns each gene a score that is an extension
of the t-statistic. For significant genes with a score over a certain threshold, SAM uses
permutations to estimate the false discovery rate (FDR). It has been implemented in many
studies of gene expression data (Cheishvili et al., 2007; Goold et al., 2007; Lapointe et al.,
2007; Lau et al., 2007; Flavell et al., 2008) as well as DMH data, e.g. Wei et al. (2006)
applied SAM to detect differential methylation of CpG island loci between ovarian can-
cer patient groups with short and long progression-free survival (PFS). However, using a
modified t statistic, SAM assumes that the microarray data conform to approximate nor-
mality and symmetry, leading to the loss of power in the analysis of DMH data that are
inherently skewed (Figure 2.1), This is especially relevant to the analysis of methylation in
cancer where many CpG islands that are generally unmethylated in normal cells become
hypermethylated. This asymmetric change is different from the assumptions made in the
analysis of changes of gene expression in cancer, where the numbers of genes up-regulated
and down-regulated are similar.
In the modified DMH method, the ratios of raw signal intensities (undigested/digested)
greater than 1 reflect the various methylation levels (Nouzova et al., 2004). A ratio cut-off
is generally used to identify the hypermethylated loci (Wei et al., 2002). However, this is
an arbitrary value and does not necessarily accurately reflect the various sources of varia-
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Figure 2.1: Distribution of log-transformed ratio of gene expression data in breast can-
cer and DMH data in A2780 cell line. The left histogram shows the distribution of log-
transformed ratios (cy3/cy5) in gene expression profiling data from a previous study of
breast cancer (van ’t Veer et al., 2002) which is symmetric, while the right histogram shows
the log-transformed ratios (undigested/digested) of DMH data from the present study which
is skewed
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tion in the experiment. It is therefore desirable to develop an algorithm to more objectively
assess the methylation status of loci from DMH data.
PAM is a nearest centroid shrinkage method that identifies those genes that discrim-
inate best between classes. This technique shrinks the class gene centroid towards the
overall centroid by a ”threshold” amount after standardising each gene by its within class
standard deviation. The ”threshold” is identified by cross-validation. This approach was
applied in the study by Wei et al. (2006) and showed certain power in the identification
of differentially methylated loci, but PAM is designed for class prediction rather than class
comparison. Although the class predictor used in PAM can reflect the difference between
classes, a large number of loci actually differentially methylated between the classes are
excluded to improve the accuracy of prediction.
Although normalisation has become a standard procedure for the study of microarray
data and is necessary for SAM and PAM analysis, unbalanced shifts in methylation status
between class samples in DMH limit the use of between-class normalisation which assumes
the changes are roughly symmetric. Thus, the differential methylation can be masked by
the over-correction of normalisation and it would be preferable to use a method of analysis
that does not require normalisation of the data.
Since PAM and SAM may have limitations for analysing DMH data, an alternative ap-
proach based on the specific features and known biological properties of the arrays used
for DMH analysis is required. Therefore, the aims of the study in this chapter are (1) to
identify the sequences that can be used as unmethylated controls to establish a methylation
base line (unmethylated status) instead of using an arbitrary DMH ratio cutoff without con-
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sidering the variations introduced in the DMH assay; (2) to develop an algorithm tailored
for data from DMH assays to identify differential methylation between two groups of sam-
ples without between-group normalisation; (3) to develop an R package for this algorithm
(named as Methylation Linear Discriminant Analysis, MLDA), that is publicly available at
the Comprehensive R Archive Network (CRAN) (http://cran.r-project.org/);
(4) to implement the MLDA package to identify a set of loci differentially methylated be-
tween ovarian cancer cell lines sensitive and resistant to cisplatin analysed by DMH using
HCGI12K arrays (http://data.microarrays.ca/cpg/) and Agilent custom-designed 15K CpG
island arrays (see Chapter 3).
2.2 Methods
Cell lines were grown in RPMI-1640 supplemented with glutamine (2mM) and 10% fetal
bovine serum in humidified 5% CO2 in air incubators at 37◦C. Genomic DNA was ex-
tracted using Qiagen DNA extraction kits (Qiagen, UK) following manufacture’s instruc-
tion.
All signal intensities from the McrBC digested and mock digested samples were extracted
by GenePix Pro 6.0. A multiplicative background correction was applied to correct signal
intensities for the background noise in each array. After background correction, the log-
transformed signals from digested and mock digested samples show three approximately
parallel linear patterns (Figure 2.2a). The first pattern (digested/undigested is close to 1)
represents the unmethylated sequences. The second pattern is assumed to represent either
hemi-methylated (mono-allelically methylated) sequences or the unmethylated sequences
cross-hybridised with the methylated ones on the panel. This pattern could also be due to
cell heterogeneity in the cell line population, but since the cell lines used in this study were
clonal in origin, this is unlikely. The third pattern is assumed to represent bi-allelically
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methylated sequences in the target DNA. Based on this observation an algorithm Methyla-
tion Linear Discriminant Analysis (MLDA) using three univariate linear regression models
was developed in R (version 2.7.0).
MLDA is detailed in section 2.2.1 to 2.2.3. In brief, the first model is constructed by
the log-transformed signal intensities of unmethylated features and used as the reference
for unmethylation (Figure 2.2b). The second one is the intermediate model constructed
through the point corresponding to the 97.5-quantile of the residuals below the first linear
regression line (Figure 2.2c). The features with a standardised residual less than 2 from this
intermediate model are used to generate the third model which is used as the reference for
methylation (Figure 2.2d). The log likelihood ratio of a locus being methylated is then pro-
portional to the difference between the squared standardised residual from the methylated
line and that from the unmethylated line (see Section 2.2.1). The log likelihood thresh-
old of zero then provides a more rational basis for distinguishing between methylated and
unmethylated loci than a robust undigested/digested ratio of 1.5, as it takes into account
the observed variability in the experiment. Then, the consistency and inconsistency scores,
ranging from 0 (no consistency) to 2 (complete agreement), of log likelihood ratios on dye-
swapped/duplicate arrays are used to determine methylation and unmethylation cut-offs,
which keep the consistency score (CR) relatively high (about 1.4) and the inconsistency
score (IR) low (about 0.01). Each locus is assigned a score based on the cut-offs using
the weighted methylation scoring scheme (Figure 2.3). The feature consistently identified
as methylated candidates on dye-swapped/duplicate arrays are scored as 1; similarly un-
methylated features are scored as -1; the rest of the feature are assigned a weighted score
corresponding to their location on the plot of log-likelihood ratios (Figure 2.4) (see Section
2.2.2). The averaged score for each locus is calculated in each sample class (e.g. resis-
tant or sensitive) and plotted against each other. A robust regression model is then fitted
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to these data. The standardised residuals from the robust regression model are assumed to
follow a normal distribution. The outliers of the standardised residuals are identified as the
differentially methylated loci between the class samples (see Section 2.2.3, an example in
Figure 2.7).
2.2.1 Log-likelihood ratio transformation
1. An univariate linear regression model was constructed for the unmethylated probes
(e.g. mitochondrial derived features) using formula 2.1 where α is the intercept, β
is the slope of the model, and ζ is the error representing the unpredicted or unex-
plained variation in the model (Figure 2.2b). The parameters of regression line were
estimated by the method of least squares (formula 2.2 and 2.3).
Gi = α + βRi + ζi i = 1, 2, 3 . . . k (2.1)
βˆ =
∑(
Ri − R¯
) (
Gi − G¯
)∑(
Ri − R¯
)2 (2.2)
αˆ = βˆR¯− G¯ (2.3)
k is the number of unmethylated controls on DMH array. Gi andRi are the logarithmic-
transformed digested and undigested intensities of microarray probes for mitochon-
drial sequences, respectively. G¯ and R¯ are the averaged logarithmic-transformed
undigested and digested intensities of the k unmethylated controls.
2. The scale estimate σmito associated with the error term in the linear regression model
was estimated from the residuals from the observed points to the fitted line. The most
extreme 10% of residuals was omitted from either end of the distribution to minimise
the impact of extreme residuals on this estimate.
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3. The standardised residuals (SRmito) of all the microarray probes to the unmethylation
regression line were calculated as formula 2.4.
SRmito =
residualsmito
σmito
(2.4)
4. The point corresponding to the 97.5-quantiles residual below the unmethylation line
is represented as X (R.975, G.975). The intermediate linear model (Figure 2.2c) was
constructed through point X with a slope assumed to be 1 and the intercept estimated
as formula 2.5.
αˆ = G.975 −R.975 + 1.96σmito (2.5)
5. The standardised residuals (SR.975) of all the microarray probes to the line with slope
1 and intercept estimated from formula 2.5 were calculated as formula 2.6. The
variance of the residuals to the intermediate model was assumed to be similar as that
in the unmethylated model established in step (1).
SR.975 =
residuals.975
σmito
(2.6)
6. The microarray probes with standardised residuals less than 2 were included for later
robust regression analysis. The line estimated from this regression analysis repre-
sents the methylation regression line (Figure 2.2d).
7. The scale estimate σmeth of the methylation regression line was estimated using only
those microarray probes below the line, with the most extreme 5% removed.
8. The standardised residuals (SRmeth) of all the microarray probes to the methylated
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regression line were calculated as formula 2.7. The log likelihood ratio (LR) of all
the microarray probes was estimated by formula 2.8 for further analysis.
SRmeth =
residualsmeth
σmeth
(2.7)
LR = SR2mito − SR2meth (2.8)
2.2.2 Determination of log likelihood ratio cut-offs
Two inconsistency scores (IRmeth and IRunmeth) and two consistency scores (CRmeth and
CRunmeth) between dye-swap/duplicate arrays were used to determine the log like like-
lihood ratio threshold. IRmeth (formula 2.9) represents the rate of the microarray probes
identified as methylated in one array but as unmethylated in the other one, while IRunmeth
(formula 2.10) is the rate of the microarray probes identified as unmethylated in one array
but as methylated in the other one. CRmeth (formula 2.11) and CRunmeth (formula 2.12)
are the rates for the spots identified as methylated (CRmeth) and unmethylated (CRunmeth)
in both dye-swap/duplicate arrays (Figure 2.3).Therefore, the consistency/inconsistency
score is within a range from 0 (no consistency) to 2 (complete agreement).
Results from 2nd 
duplicate array 
Results from 1st duplicate array 
unmethylated uncertain methylated 
unmethylated a b c 
uncertain d e f 
methylated g h i 
 
IRmeth =
c
c+ f + i
+
g
g + h+ i
(2.9)
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Figure 2.2: An illustration of unmethylated and methylated model construction in MLDA
in A2780 cell line. a: Three patterns can be observed on the scatter plot of log-transformed
Cy3 (undigested) against log-transformed Cy5 (digested) intensities. b: The unmethylated
model constructed using 94 mitochondrial sequences as a unmethylation reference. c: The
intermediate model constructed through the 97.5 quantile residual. The point X is the 97.5
quantile residual. The microarray probes in blue (standardised residual to the intermediate
model is less than 2) are selected to construct the methylated model. d: Methylated (in
blue) and unmethylated (in red) models in A2780 cell line.
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IRunmeth =
g
a+ d+ g
+
c
a+ b+ c
(2.10)
CRmeth =
i
c+ f + i
+
i
g + h+ i
(2.11)
CRunmeth =
a
a+ b+ c
+
a
a+ d+ g
(2.12)
The log likelihood ratio thresholds (LRmeth and LRunmeth) for methylated and un-
methylated microarray probes, which kept the inconsistency score low (at or close to 0.01)
and the consistency score high (at or close to 1.4), were used as the cut-offs for methy-
lated and unmethylated loci. IR tends to rise with the increase of CR slowly, but starts to
increase dramatically when the CR goes above 1.4, at which point the inconsistency score
is generally about 0.01. We have therefore used CR>1.4 and IR<0.01 as the criteria for
determining the methylation cut-offs.
2.2.3 Identification of robust regression outliers
Each microarray probe was scored based on the cut-offs of likelihood ratios for methyla-
tion and unmethylation on dye-swap arrays using the weighted methylation scoring scheme
shown in Figure 2.4. The microarray probes consistently identified as methylated candi-
dates on dye-swap arrays were scored of 1; similarly unmethylated microarray probes were
scored of -1. The rest of the microarray probes were assigned a weighted score based on
their location on the plot.
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Figure 2.3: Determination of methylation and unmethylation cut-offs of likelihood ratios on
dye-swapped arrays. LRmeth: log likelihood ratio cut-off for methylated spots; LRunmeth:
log likelihood ratio cut-off for unmethylated spots.
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A robust regression model (Tukey, 1977) was constructed with the averaged scores in
one class of samples as the explanatory variable, and the corresponding scores in the other
class of samples as the dependent variable. The degree of trimming was determined ac-
cording to Barnett et al. (Wilcox, 2005a) when estimating the variance of residuals to the
robust linear regression model. It was assumed that the standardised residuals (SRs) from
the robust regression line followed a normal distribution N(µ, σ2). µ and σ were estimated
excluding outliers using the MAD-Median Rule (Wilcox, 2005b). The p value for each SR
cut-off was calculated as described by Simon et al (2003). This p-value reflects the prob-
ability of observing a group of more extreme residuals from the fitted normal distribution.
Microarray probes were identified as outliers if their SRs were larger than the cut-off for
which the p-value was less than 0.01 (see an example in Figure 2.7).
2.2.4 Estimation of misclassification rate
The misclassification rate was estimated by drawing bootstrap samples 500 times with
replacement from the two classes (sensitive and resistant) and carrying out hierarchical
clustering based on the loci identified as differentially methylated using weighted scores
for MLDA and log ratios without between-group normalisation for SAM and PAM, re-
spectively. Clustering was carried out using Euclidean distance as the distance metric, and
clusters were agglomerated using the average linkage criterion. The clustering tree was cut
into two groups and the number of misclassified cell lines was counted. The misclassifica-
tion rate was obtained from the averaged number of misclassified samples in 500 bootstraps
divided by the total number of samples.
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Figure 2.4: Weighted scoring scheme. The microarray probes consistently identified as
methylated candidates on dye-swap arrays were scored 1; similarly unmethylated microar-
ray probes were scored -1. The rest of the microarray probes were assigned a weighted
score based on their location on the plot. LRmeth: log likelihood ratio cut-off for methy-
lated loci; LRunmeth: log likelihood ratio cut-off for unmethylated loci. LR: log likelihood
ratio on dye-swapped arrays.
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2.2.5 SAM and PAM analysis
The raw signal intensities of each channel were subtracted by the median signal intensi-
ties of corresponding channel of controls on HCGI12K array. After this correction, SAM
in samr package [samr(data, resp.type = ”Two class unpaired”, testStatistic = ”standard”,
nperms = 100, center.arrays = FALSE)] and PAM in pamr package with default arguments
were applied in the unpaired two groups comparison using logarithmic-transformed DMH
ratios (digested/undigested) in R version 2.7.0. Between-group normalisation was not used
in SAM and PAM to avoid masking the true differential methylation by over-correction.
False discovery rate (FDR) less than 5% was used as the cut point to indentify the loci
significantly differentially methylated between two groups.
2.2.6 Making MLDA package under Windows
The desktop used to construct the package has Microsoft Window XP (service pack 3)
operating system with Intel Core Duo CPU E6859, and 2.99 GHz, 1.96 GB of mem-
ory. The components in Windows required to make MLDA package are (1) A minimal
set of Unix utilities, so called ”Rtools” (http://www.murdoch-sutherland.com/
Rtools/), (2) ActivePerl 5.10.0 Building 1003 (http://www.activestate.com/
activeperl), (3) the Microsoft html help compiler (http://msdn.microsoft.
com/en-us/library/ms669985.aspx) and (4) MikTex 2.7 (http://www.miktex.
org/). The process of package construction followed the manual ”Writing R Extension”
(http://www.r-project.org/). Briefly, it has 7 steps: (1) create the directory
tree using package.skeleton(); (2) modify the DESCRIPTION FILE and NAMESPACE
file; (3) check R functions; (4) create and debug documentation files; (5) check the pack-
age using /textitR CMD check package test; (6) Build the package using the command R
CMD build –binary package; (7) upload to CRAN (ftp://cran.r-project.org/
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incoming/).
2.3 Results
In this study, we have developed a novel approach, named MLDA, for analysing CpG island
microarray hybridisation data that allows the identification of differentially methylated loci
without normalisation. MLDA was programmed in R (version 2.7.0) and the package is
available at CRAN (http://cran.r-project.org/).
2.3.1 DMH dataset on HCGI12K arrays
MLDA was applied to identify the CGIs differentially methylated from DMH data on
HCGI12K arrays derived from sensitive A2780 derivatives (A2780, A2780p3, A2780p5,
A2780p6, A2780p13, A2780p14) and isogenically matched, cisplatin resistant lines ((An-
thoney et al., 1996)) derived by multiple exposures to cytotoxic levels of cisplatin and
which are 2-5 fold resistant to cisplatin in clonogenic assays (A2780cp70, A2780/MCP1,
A2780/MCP2, A2780/MCP3, A2780/MCP4, A2780/MCP5, A2780/MCP6, A2780/MCP7,
A2780/MCP8, A2780/MCP9). After background correction, the log-transformed digested
and undigested intensities of the 13056 microarray probes show three approximately par-
allel linear patterns (Figure 2.2a). The first pattern (digested/undigested is close to 1) rep-
resents the unmethylated sequences. The second pattern represents either hemi-methylated
sequences or the unmethylated sequences cross-hybridised with the methylated ones on the
panel. The third pattern represents the methylated sequences in target DNA. The methy-
lated and unmethylated loci in target DNA can be characterised by a linear regression model
for each pattern. As previously mentioned, normalisation may not be appropriate for DMH
data, so the log ratios of signal intensities in two classes of samples are not at the same
level (Figure 2.5). Normalisation is not required for MLDA as the determination of the
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methylation score is based on the data within each experiment.
Mitochondrial DNA is unmethylated (Maekawa et al., 2004), therefore, the signal inten-
sities of both channels of microarray probes for mitochondrial sequences are expected to be
equal. However, a bi-modal distribution is observed in the log-transformed fluorescence ra-
tios (digested/undigested) of 121 mitochondrial sequences, representing the unmethylated
mitochondrial sequences and the mitochondrial sequences assumed to be cross-hybridised
with other methylated sequences on the panel. Thus, we selected 94 of 121 mitochondrial
sequences that were consistently unmethylated through all the cell lines and used them as
the unmethylation reference in target DNA.
The parameters of unmethylated and methylated models in all 16 cell lines were esti-
mated (Table 2.1). The slope of the unmethylated regression line constructed by 94 mi-
tochondrial sequences is indeed close to 1. After computing the log-likelihood ratios, the
methylation and unmethylation cut-offs and associated IRs and CRs were determined from
the dye-swapped array pairs (details in Method section). As shown in Figure 2.6, IR tends
to rise with the increase of CR slowly, but starts to increase dramatically when the CR goes
above 1.4, at which point IR is generally about 0.01. We have therefore used CR>1.4 and
IR<0.01 as the criteria for determining the methylation and unmethylation cut-offs. Each
locus was scored using the weighted scoring scheme based on those cut-offs. The aver-
aged scores in 6 cisplatin-sensitive cell lines and 10 cisplatin-resistant cell lines were used
to construct a robust regression model. Figure 2.7a shows that the standardised residuals
( residual
σ
) from the robust regression model roughly follow a normal distribution. The posi-
tive and negative outliers are determined as described in Method section.
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Figure 2.5: Box plot of log ratios of undigested signal intensities against digested sig-
nal intensities in 16 cell lines (dye-swapped arrays). The boxes in red are the A2780
sensitive cell lines; in blue are the A2780 resistant cell lines. Each cell line has
duplicates. From 1 to 16, the cell lines are A2780 (1), A2780p3(2), A2780p5(3),
A2780p6(4), A2780p13(5), A2780p14(6), cp70(7), MCP1(8), MCP2(9), MCP3(10),
MCP4(11), MCP5(12), MCP6(13), MCP7(14), MCP8(15) and MCP9(16). As normali-
sation is not applied, the centre and scale of log ratios for the 16 cell lines are not at the
similar level.
2.3 Results 74
Figure 2.6: CR against IR in 16 cell lines. X axis is the consistency score (CR) and y axis
is the inconsistency score (IR). IR tends to rise with the increase of CR slowly, but starts to
increase dramatically when the CR goes above 1.4, at which point the inconsistency rate is
generally about 0.01. Not all cell lines could reach this point e.g. MCP3
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Unmethylated linear regression model
cell line Intercept (α) slope (β) σ R2 Interceptds (σ) slopeds(β) σds R2ds
A2780 -0.0003 1.0122 0.1727 0.9829 0.0005 1.0574 0.1897 0.9780
A2780p3 -0.0003 1.0343 0.1212 0.9897 0.0018 1.1065 0.1425 0.9882
A2780p5 -0.0003 1.0138 0.1684 0.9840 -0.0002 1.0728 0.1425 0.9883
A2780p6 0.0002 0.9914 0.1605 0.9778 -0.0001 1.0012 0.1638 0.9747
A2780p13 -0.0012 1.0240 0.1628 0.9786 -0.0005 1.0744 0.1436 0.9852
A2780p14 -0.0022 1.0499 0.1523 0.9809 -0.0009 1.0340 0.2069 0.9691
A2780/cp70 0.0013 0.9604 0.2532 0.9524 -0.0002 1.0119 0.2402 0.9479
MCP1 0.0002 0.9946 0.1450 0.9803 -0.0023 1.1120 0.1452 0.9836
MCP2 0.0000 0.9980 0.1370 0.9727 -0.0028 1.0475 0.1719 0.9653
MCP3 0.0004 0.9932 0.2253 0.9183 -0.0023 1.0517 0.2795 0.8978
MCP4 0.0006 0.9838 0.1739 0.9718 -0.0028 1.0770 0.1947 0.9751
MCP5 0.0009 0.9857 0.2464 0.9639 -0.0008 1.0170 0.2166 0.9692
MCP6 -0.0022 1.0352 0.1220 0.9751 -0.0068 1.1283 0.1540 0.9752
MCP7 -0.0005 1.0079 0.1379 0.9791 -0.0045 1.1529 0.1588 0.9764
MCP8 -0.0028 1.0578 0.1903 0.9431 -0.0068 1.1193 0.1885 0.9575
MCP9 -0.0017 1.0331 0.1834 0.9614 -0.0091 1.1538 0.1691 0.9674
Methylated linear regression model
cell line Intercept (α) slope (β) σ R2 Interceptds (σ) slopeds(β) σds R2ds
A2780 -0.8839 0.8917 0.1491 0.9438 -0.8055 0.9086 0.1706 0.9260
A2780p3 -1.1672 0.9797 0.1518 0.9553 -0.7414 0.9774 0.1790 0.9438
A2780p5 -0.8991 0.8978 0.1515 0.9476 -0.9246 0.9766 0.1673 0.9523
A2780p6 -0.9455 0.9562 0.1838 0.9378 -1.1995 0.9641 0.1788 0.9324
A2780p13 -1.8918 0.9807 0.2535 0.8962 -1.8049 0.9652 0.2936 0.8512
A2780p14 -1.5637 0.9142 0.2549 0.8857 -1.4468 0.9066 0.2128 0.8837
A2780/cp70 -1.0317 0.8501 0.1581 0.9115 -1.3074 0.8967 0.1541 0.9265
MCP1 -1.1990 0.9781 0.1692 0.9467 -1.0935 1.0384 0.1775 0.9525
MCP2 -0.8037 0.9292 0.1486 0.9557 -0.9739 0.9381 0.2176 0.8848
MCP3 -1.1244 0.9151 0.1755 0.9482 -0.9303 0.9205 0.2599 0.8098
MCP4 -1.4326 0.9171 0.1418 0.9660 -1.6205 0.9610 0.2348 0.8323
MCP5 -1.1187 0.9425 0.1839 0.9404 -1.2007 0.9546 0.1757 0.9295
MCP6 -1.2460 0.9250 0.1966 0.9294 -1.2182 0.9826 0.2248 0.8989
MCP7 -1.8972 0.9909 0.1977 0.9442 -1.4894 1.0139 0.2458 0.8886
MCP8 -1.0219 0.9905 0.1975 0.9468 -0.4735 0.9421 0.2280 0.8761
MCP9 -1.3399 0.9837 0.2073 0.9352 -1.1497 1.0078 0.1967 0.9115
Table 2.1: Parameters of linear models in MLDA for 16 cell lines in DMH dataset. ds:dye
swap;σ: standard deviation; R2:coefficient of determination
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Finally, 115 loci were identified as candidates differentially methylated between A2780
sensitive and these resistant cell lines (Appendix 2.1). Noticeably, 113 of 115 loci (p =
8.8 × 10−3, outlier detection test (Simon et al., 2003)) were hypermethylated, but only 2
loci ( p < 1.0 × 10−3, outlier detection test) lost methylation in the resistant cell lines
(Figure 2.7b). This is consistent with the unbalanced shift in DMH data and indicates
cisplatin treatment of cells selects preferentially for hypermethylation of loci, rather than
hypomethylation in these tumour cells.
To compare the results from MLDA, SAM and PAM, we analysed the DMH dataset by
all three methods. MLDA identified 115 loci (113 hypermethylated and 2 hypomethylated
loci, misclassification error<0.001) (for details of 115 loci, see Appendix 2.1), SAM iden-
tified 152 loci (149 hypermethylated and 3 hypomethylated loci, misclassification error =
0.227, FDR = 6.17 × 10−3 ), and PAM found 24 hypermethylated loci (misclassifica-
tion error = 0.084,FDR < 0.001) in the resistant cell lines. The lists of loci identified by
MLDA, SAM and PAM are detailed in Appendix 2.2. Twenty-four loci identified by all
three methods are listed in Table 2.2.
2.3.2 Validation of differential methylation
To confirm the differential methylation of loci identified in this study, we experimentally
tested the methylation of 26 loci by methylation-specific PCR (MSP) and/or pyrosequenc-
ing of bisulphite modified DNA (Herman et al., 1996) in sensitive A2780 derivatives and
cisplatin resistant derivatives. MSP and bisulfite pyrosequencing were performed by Dr.
Janet Graham, Dr. Constanze Zeller and Dr. Jens M Teodoridis in Imperial College Lon-
don. Twenty-three out of the 26 loci have been confirmed as differentially methylated. It
should be noted that MSP and pyrosequencing only examine methylation at a limited num-
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ber of CpG sites of the sequence present on the DMH analysis. It is possible that the loci
which were not confirmed as differentially methylated are methylated at other CpG sites
which are detected by DMH but not targeted by MSP and/or pyrosequencing primers and
so 23 out of 26 loci confirmed as differentially methylated is a minimum estimation.
2.3.3 Implementation of MLDA on Agilent 15k custom-designed CpG is-
land microarray
MLDA was also implemented in DMH assay on another CpG island microarray, which was
custom-designed for targeting the loci associated with acquired drug resistance in ovar-
ian cancer (see Chapter 3), to identify the loci differentially methylated between A2780
cisplatin-sensitive derivatives (A2780p3, A2780p5 and A2780p6) and A2780 cisplatin-
resistant derivatives (CP70, MCP1 and MCP6) (Chapter 3). Unmethylated controls se-
lected from mitochondrial sequences on HCGI12K array (yellow spots on Figure 2.9a)
and from chromosome 16 that are underrepresented for CG regions and contain very few
McrBC recognition sites (ACG or GCG) (blue spots on Figure 2.9a) were used to construct
the unmethylation linear model in MLDA. Out of 26 loci tested by bisulfite pyrosequenc-
ing/MSP, 9 loci that show consistent differential methylation between these three A2780
sensitive and resistant derivatives were selected as a test set, and 9/9 (100%) were identi-
fied by MLDA (see ’validation’ in Table 2.3). This indicates the high sensitivity of MLDA
using methylation scores of individual probes on the DMH arrays. Meanwhile, the perfor-
mance of both SAM and PAM using the corrected DMH ratios by the method implemented
in MLDA as described in section 2.3.4 are as good as MLDA at least at these 9 loci on
the custom-designed microarray in terms of sensitivity (see ’validation’ in Table 2-3), indi-
cating the corrected DMH ratios could reflect the differential methylation between groups.
Chapter 2. Methylation Linear Discriminant Analysis (MLDA): An Algorithm
Tailored for DNA Methylation Profiling Dataset 79
m
ic
ro
ar
ra
y
ID
st
at
us
va
lid
at
io
n
M
L
D
A
ra
nk
PA
M
ra
nk
SA
M
ra
nk
C
G
I
ge
ne
sy
m
bo
l
G
en
B
an
k
A
cc
es
si
on
C
hr
om
os
om
e
66
G
6
hy
pe
rm
et
hy
la
te
d
Y
es
1
1
1
Y
es
12
1
D
9
hy
pe
rm
et
hy
la
te
d
Y
es
2
5
6
Y
es
C
R
A
B
P1
N
M
00
43
78
15
39
E
1
hy
pe
rm
et
hy
la
te
d
N
D
3
2
2
N
o
12
2
D
9
hy
pe
rm
et
hy
la
te
d
N
o
4
11
11
Y
es
SO
X
12
N
M
00
69
43
20
12
3
D
9
hy
pe
rm
et
hy
la
te
d
N
o
5
10
10
Y
es
SO
X
12
N
M
00
69
43
20
51
H
8
hy
pe
rm
et
hy
la
te
d
Y
es
6
18
19
N
o
FE
Z
F2
N
M
01
80
08
3
58
A
1
hy
pe
rm
et
hy
la
te
d
N
D
7
22
22
Y
es
80
H
5
hy
pe
rm
et
hy
la
te
d
N
D
8
14
16
N
o
21
A
11
hy
pe
rm
et
hy
la
te
d
Y
es
9
17
18
Y
es
N
T
N
4
N
M
02
12
29
12
38
D
7
hy
pe
rm
et
hy
la
te
d
Y
es
11
23
24
Y
es
A
G
B
L
2
N
M
02
47
83
11
40
E
1
hy
pe
rm
et
hy
la
te
d
N
D
12
19
17
N
o
18
A
7
hy
pe
rm
et
hy
la
te
d
N
D
13
20
20
N
o
E
D
IL
3
N
M
00
57
11
5
55
F
8
hy
pe
rm
et
hy
la
te
d
Y
es
14
9
9
Y
es
B
C
12
78
81
B
C
12
78
81
7
12
2
B
1
hy
pe
rm
et
hy
la
te
d
N
D
15
16
14
N
o
10
9
A
6
hy
pe
rm
et
hy
la
te
d
N
o
18
12
13
Y
es
41
D
9
hy
pe
rm
et
hy
la
te
d
Y
es
22
8
8
Y
es
W
N
T
1
N
M
00
54
30
12
42
D
9
hy
pe
rm
et
hy
la
te
d
N
D
23
4
4
N
o
11
9
A
6
hy
pe
rm
et
hy
la
te
d
Y
es
24
6
5
Y
es
N
R
2E
1
N
M
00
32
69
6
63
A
8
hy
pe
rm
et
hy
la
te
d
N
D
26
15
15
N
o
6
D
4
hy
pe
rm
et
hy
la
te
d
Y
es
31
3
3
Y
es
L
M
X
1A
N
M
17
73
98
1
17
H
9
hy
pe
rm
et
hy
la
te
d
Y
es
34
13
12
Y
es
H
R
A
SL
S3
N
M
00
62
90
6
5
D
4
hy
pe
rm
et
hy
la
te
d
Y
es
35
7
7
Y
es
L
M
X
1A
N
M
17
73
98
1
24
D
3
hy
pe
rm
et
hy
la
te
d
Y
es
75
24
23
Y
es
SP
5
N
M
00
10
03
84
5
2
12
2
G
1
hy
pe
rm
et
hy
la
te
d
N
D
10
1
21
21
Y
es
Ta
bl
e
2.
2:
24
lo
ci
id
en
tifi
ed
by
M
L
D
A
,
PA
M
an
d
SA
M
as
di
ff
er
en
tia
lly
m
et
hy
la
te
d
ca
nd
id
at
es
in
th
e
co
m
pa
ri
so
n
be
tw
ee
n
A
27
80
ci
sp
la
tin
se
ns
iti
ve
an
d
ci
sp
la
tin
m
ul
tip
le
-s
el
ec
te
d
re
si
st
an
tc
el
ll
in
es
.
N
D
:n
ot
do
ne
.
Y
es
:
va
lid
at
ed
.
N
o:
no
tv
al
id
at
ed
.
M
L
D
A
ra
nk
*:
th
e
ra
nk
of
st
an
da
rd
is
ed
re
si
du
al
st
o
th
e
ro
bu
st
re
gr
es
si
on
lin
e
co
ns
tr
uc
te
d
by
th
e
av
er
ag
ed
se
ns
iti
ve
sc
or
es
ag
ai
ns
t
av
er
ag
ed
re
si
st
an
ts
co
re
s;
G
en
e
sy
m
bo
l*
*:
on
ly
th
e
ge
ne
of
w
hi
ch
tr
an
sc
ri
pt
io
n
st
ar
ts
ite
(T
SS
)
is
w
ith
in
5
kb
sp
an
of
th
e
lo
ci
;
C
G
I*
**
:C
pG
is
la
nd
de
fin
ed
by
G
ar
di
ne
r-
G
ar
de
n
an
d
Fr
om
m
er
2.3 Results 80
The loci identified by all three methods are listed in Table 2.3. A full list of loci identified
by three methods is detailed in Appendix 2.3.
2.3.4 Modification of MLDA for within-array Normalisation
Normalisation is not required in MLDA since it converts the continuous DMH ratios into
ordinal variables using a scoring system. However, DMH ratio is generally used in the
literature which requires within-array normalisation to reduce the influence of dye bias.
MLDA was modified for this purpose using the univariate linear regression model con-
structed by unmethylation probes. The slope of the linear regression model is adjusted to
1 and intercept adjusted to 0 in this method, since the log transformed signal intensities of
the unmethylated controls are assumed to be equal. The log transformed signal intensities
of entire probes on the microarray are adjusted correspondingly as shown in formula 2.13
and 2.14.
 log2 (G)
′ = log2 (G)− b
log2 (R)
′ = log2 (R)
 (2.13)
 log2 (G)
′′ = log2(G)
′ sin pi
4
sin(tan−1 k)
log2 (R)
′′ = log2(R)
′ cos pi
4
cos(tan−1 k)
 (2.14)
G and R are the background subtracted signals from the Green and Red channels, re-
spectively. In formula 2.13 ad 2.14 above, b and k are the intercept and slope respectively
of the linear regression model fitted to these original values (logged to the base 2). In 2.13
these values are initially adjusted to have 0 intercept and in 2.14 they are further adjusted
to have a slope of 1 by rotating the coordinate using the origin as centre as shown in Figure
2.8. The signals of the probes were transformed from Figure 2.9a to Figure 2.9b. After this
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CGI ID status1 chro start end gene GeneBank Accession # MLDA hit2 # SAM hit2 # PAM hit2 # total3 validation
OGT_14 up 1 59020049 59023528 JUN NM_002228 6 8 8 45
OGT_19 up 1 94779425 94780639 F3 NM_001993 6 6 6 19
OGT_23 up 1 111690661 111691062 C1orf88 NM_181643 6 13 10 16
OGT_34 up 1 163590110 163590435 LMX1A NM_177398 4 12 9 13 MSP
OGT_35 up 1 163590815 163592952 LMX1A NM_177398 5 5 5 34
OGT_38 up 1 210846774 210849709 ATF3 NM_001674 4 7 4 46
OGT_39 up 1 219117071 219117487 HLX NM_021958 3 8 7 16
OGT_40 up 1 219118589 219120296 HLX NM_021958 4 9 8 25
OGT_53 up 2 30307070 30309159 LBH NM_030915 5 8 5 31
OGT_55 up 2 45014931 45016562 102_D_11* 1 6 2 14
OGT_60 up 2 95054584 95056158 MAL NM_022438 6 5 4 16
OGT_70 up 2 171278123 171282150 SP5 NM_001003845 2 1 1 33 BP
OGT_72 up 2 174916661 174917322 2_A_6* 4 1 3 15
OGT_88 up 3 27731216 27731426 66_A_7* 6 8 7 11
OGT_89 up 3 37009232 37010360 EPM2AIP1 NM_014805 8 18 18 20
OGT_89 up 3 37009232 37010360 MLH1 NM_000249 8 18 18 20 MSP
OGT_98 up 3 57179209 57179457 IL17RD NM_017563 4 4 4 23
OGT_125 up 4 30330302 30333940 PCDH7 NM_032456 1 1 1 51
OGT_126 up 4 75183520 75184143 CXCL2 NM_002089 1 2 2 15
OGT_129 up 4 84474750 84475423 HPSE NM_006665 8 10 7 26
OGT_131 up 4 85722570 85723917 CDS1 NM_001263 5 4 4 20
OGT_154 up 5 139115773 139116160 47_H_6* 1 2 2 16
OGT_161 up 5 172130088 172132212 DUSP1 NM_004417 5 6 6 22
OGT_169 up 6 3172024 3174687 TUBB2B NM_178012 10 11 8 62
OGT_169 up 6 3172024 3174687 RDBP NM_002904 10 11 8 62
OGT_169 up 6 3172024 3174687 SKIV2L NM_006929 10 11 8 62
OGT_170 up 6 3174225 3174676 TUBB2B NM_178012 6 7 4 30
OGT_170 up 6 3174225 3174676 RDBP NM_002904 6 7 4 30
OGT_170 up 6 3174225 3174676 SKIV2L NM_006929 6 7 4 30
OGT_187 up 6 108592364 108597232 NR2E1 NM_003269 21 20 18 66 MSP
OGT_190 up 6 138229518 138230834 TNFAIP3 NM_006290 1 2 2 19
OGT_202 up 7 27170440 27172987 HOXA9 NM_152739 4 2 1 167
OGT_203 up 7 27241580 27242151 15_E_8* 2 3 2 18
OGT_222 up 8 13034461 13035285 DLC1 NM_006094 7 3 3 16
OGT_239 up 8 96029927 96031560 TP53INP1 NM_033285 7 6 6 14
OGT_243 up 8 121205045 121205322 COL14A1 NM_021110 6 9 7 11
OGT_249 up 9 106701 108177 FOXD4 NM_207305 1 6 3 85
OGT_260 up 9 71848656 71849097 MAMDC2 NM_153267 11 5 4 16
OGT_262 up 9 89302334 89303637 DAPK1 NM_004938 1 1 1 30
OGT_265 up 9 95747937 95748308 66_G_6* 6 10 9 13 MSP
OGT_272 up 9 125813067 125820774 LHX2 NM_004789 15 9 9 81
OGT_278 up 10 8131380 8138335 FLJ45983 NR_024255 4 4 2 86
OGT_278 up 10 8131380 8138335 GATA3 NM_002051 4 4 2 86
OGT_298 up 10 102974172 102980053 LBX1 NM_006562 24 26 23 78
OGT_314 up 11 22170748 22171896 ANO5 NM_213599 1 4 2 20
OGT_319 up 11 27698635 27698849 BDNF NM_001143807 3 3 3 16
OGT_322 up 11 44282233 44283093 33_C_10||40_C_10** 4 8 7 18
OGT_324 up 11 47693315 47693682 AGBL2 NM_024783 3 1 1 18
OGT_329 up 11 63137719 63138672 HRASLS3 NM_006290 6 6 6 26 MSP
OGT_358 up 12 47657957 47661817 WNT1 NM_005430 8 13 12 49 MSP
OGT_374 up 12 112393270 112395064 LHX5 NM_022363 4 4 3 22
OGT_375 up 12 112513701 112514135 35_A_11* 6 6 5 20
OGT_meth_587 up 13 19664208 19665779 GJB2 NM_004004 3 2 1 23
OGT_388 up 13 100866117 100867259 NALCN NM_052867 2 6 2 27
OGT_393 up 14 37137197 37138958 32_F_11* 2 9 6 19 BP
OGT_408 up 15 43193759 43194174 DUOX2 NM_014080 8 9 8 11
OGT_408 up 15 43193759 43194174 DUOXA2 NM_207581 8 9 8 11
OGT_409 up 15 60243307 60244940 C2CD4B NM_001007595 8 8 8 40
OGT_412 up 15 76419724 76420163 CRABP1 NM_004378 0 2 1 15
OGT_413 up 15 76420377 76421144 CRABP1 NM_004378 10 15 15 19
OGT_448 up 17 34111804 34115223 MLLT6 NM_005937 12 9 7 33
OGT_473 up 18 45341073 45341444 LIPG NM_006033 7 8 6 20
OGT_511 up 20 1731824 1732552 115_H_11||116_H_11** 10 14 11 19
OGT_513 up 20 10600573 10603611 JAG1 NM_000214 2 2 2 33
OGT_520 up 20 54633686 54640196 TFAP2C NM_003222 1 9 7 78 BP
OGT_547 up X 1615879 1616123 P2RY8 NM_178129 10 12 8 14
OGT_551 up X 13866071 13866982 GPM6B NM_001001994 1 4 2 12
OGT_287 down 10 70747952 70749383 HK1 NM_033496 2 4 4 16
OGT_431 down 16 65143769 65144220 TK2 NM_004614 7 12 13 20
OGT_431 down 16 65143769 65144220 CKLF NM_016326 7 12 13 20
OGT_534 down 22 49310474 49317634 SCO2 NM_005138 1 1 3 61
OGT_534 down 22 49310474 49317634 NCAPH2 NM_152299 1 1 3 61
Table 2.3: CGI differentially methylated between A2780 cisplatin sensitive and resistant
derivatives identified by MLDA, SAM and PAM on Agilent custom-designed 15K mi-
croarray. Abbreviation: MSP methylation specific PCR; BP bisulfite pyrosequencing.-1up:
hypermethylated locus; down: hypomethylated locus.-2number of probes identified by the
method. -3number of probes targeting the whole CGI.*CGI identified on HCGI12K array
but not within 2kb span of TSS of the genes.**Two loci related to the same CGI
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Figure 2.8: Rotation of the coordinates using the origin as the centre. After this adjustment,
the log-transformed signals of the unmethylated controls from both channels were similar,
and the distances of all the spots to the origin remain the same as before.
correction, the unmethylated model constructed using the corrected signals coincides with
the diagonal. The median correlation of unmethylated controls in 20 dye-swap duplicates
dramatically increased from 0.36 to 0.54 after this correction (p = 2.09×10−7, see Chapter
3), indicating the reduction of variations mainly introduced by dye-swap labeling. As an
alternative of methylation scores, the log DMH ratios calculated from the corrected signals
of McrBC digested and mock digested samples can be used in SAM and PAM analysis in-
stead of the log ratios normalised across arrays using global method which could possibly
mask the differential methylation between groups.
2.4 Discussion
Hypermethylation of promoter CpG islands is strongly correlated to transcriptional gene
silencing and epigenetic maintenance of the silenced state and is a potential rich source
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of biomarkers of cancer. Differential Methylation Hybridisation (DMH) is one technique
used for genome-wide DNA methylation analysis. The study of such microarray data sets
should ideally account for the specific biological features of DNA methylation and the
non-symmetrical distribution of the ratios of unmethylated and methylated sequences hy-
bridised on the array. We have therefore developed a novel algorithm tailored to this type
of data, Methylation Linear Discriminant Analysis (MLDA). MLDA utilises log likelihood
ratios representing the relative probability that loci are methylated instead of log ratios of
signal intensities used in previous studies (Yan et al., 2001; Wei et al., 2002; Yan et al.,
2002a,b,c; Wei et al., 2003). Validation of 23/26 identified loci using independent methods
of methylation analysis shows that MLDA can robustly identify differentially methylated
loci between ovarian cancer sensitive and resistant cell lines without requiring the data to
be normalised.
2.4.1 Unmethylation controls and cross-hybridisation
Data on methylation status for 121 mitochondrial derived sequences were available in this
study. Mitochondrial sequences would be expected to be unmethylated. We used 94 mito-
chondrial sequences to construct unmethylated linear model at the beginning of the study,
and indeed, 93 of 121 mitochondrial loci were defined as unmethylated and 25 loci being
of uncertain methylation status by MLDA. However, three mitochondrial loci were iden-
tified as hypermethylated candidates in the resistant ovarian carcinoma cell lines by both
MLDA and SAM. One explanation of this discrepancy is that all these three loci have more
than one BLAT hit indicating the existence of homology with nuclear DNA sequences,
raising the possibility of hybridisation with these nuclear DNA sequences which may be
differentially methylated. As shown in Figure 2.2a, the loci in the middle pattern repre-
sent either hemi-methylated sequences (only one allele is methylated) or the unmethylated
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sequences cross-hybridised with the methylated ones on the panel. No specific allowance
is made for these intermediate points in analysis by SAM and PAM, whereas MLDA at-
tempts specifically to down-weight these points in the identification of the methylation
regression line. By giving a lower weighted score (close to 0) (Figure 2.4) to those loci,
MLDA reduces the influence of cross-hybridisation among this group of sequences. Of
course cross-hybridisation may also occur in the loci in the other two patterns (methylated
and unmethylated patterns), but it is not possible for any mathematical approach to identify
this.
2.4.2 Limitations of the study
The selection of the weighted scores was arbitrary only based on the consistency of log
likelihood ratios observed in duplicates. However, the validation result from bisulfite py-
rosequencing shows 23 out of 26 loci (88%) identified using this weighted score scheme
are truly differentially methylated between groups, indicating this score scheme is valid
and useful, although ideally the loci identified using a series of weighted scores should be
tested by bisulfite pyrosequencing and the scores that could identify differential methyla-
tion with highest sensitivity and specificity should be used in the algorithm.
Misclassification rate was estimated using weighted scores for MLDA and log ratios
without between-group normalisation for SAM and PAM. Although it has been shown that
MLDA has extremely small misclassification error (<0.001) compared to SAM (=0.227)
and PAM (=0.084) using the training dataset described in this study, it is necessary to
examine the misclassification error of these three methods in an independent DMH dataset
to avoid the potential risk of over-fitting issue leading to the over-optimistic estimation of
the performance of MLDA.
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2.4.3 Comparison of MLDA, SAM and PAM
The misclassification error of MLDA (error<0.001) based on the methylation score is much
lower than that for either SAM (error=0.227) or PAM (error=0.084) based on the log ra-
tios, indicating the potential of MLDA methylation scores to be used as a reliable discrim-
inator between classes of samples.
Validation by bisulfite pyrosequencing/MSP, showed that out of 26 loci randomly se-
lected from 115 loci identified by MLDA, 23 loci have shown differential methylation be-
tween A2780 sensitive (A2780, A2780p3, A2780p5, A2780p6, A2780p13, A2780p14) and
resistant derivatives (A2780cp70, A2780/MCP1, A2780/MCP2, A2780/MCP3, A2780/MCP4,
A2780/MCP5, A2780/MCP6, A2780/MCP7, A2780/MCP8, A2780/MCP9) , indicating
MLDA has high positive predictive value (88.5%) to identify differential methylation in
DMH assay
Figures 2.10 shows the number of loci identified by MLDA, SAM and PAM, respec-
tively as well as the number of loci that have been validated by bisulfite pyrosequenc-
ing/MSP. 35 loci were found by MLDA, but not by SAM and PAM. 2 loci randomly se-
lected from these 35 loci have been validated by bisulfite pyrosequencing/MSP. The methy-
lation status of 35 loci identified by MLDA only and 72 loci identified by SAM only were
further examined in cisplatin sensitive cell line A2780p5, A2780p6, and cisplatin resistant
cell line A2780cp70, MCP1 and MCP6 assayed by Illumina Infinium on HumanMethyla-
tion27K chips (more details about HumanMethylation27K are given in Chapter 1). Only
7 loci from MLDA and 6 loci from SAM were targeted by this array. Four out of seven
(57.1%) loci from MLDA and only 2/6 (33.3%) loci from SAM showed increased methyla-
tion in at least two cisplatin resistant cell lines compared to sensitive cell lines (Figure 2.11).
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Figure 2.10: Venn diagram of the numbers of loci identified by MLDA, SAM and PAM.
The numbers of loci identified by three methods are in black and the numbers of the loci
that have been tested and validated by bisulfite pyrosequencing/MSP are in red
In conclusion, a novel method named MLDA for large scale DNA methylation study
was developed in this study. This approach can transform the signal intensities to log-
likelihood ratios through three linear regression models on two-channel DNA methylation
microarrays, thus allowing to determine the methylation status of a locus based on dye-
swapped/duplicate arrays. MLDA has been applied to identify the loci exhibiting differ-
ential methylation between A2780 sensitive and resistant cell lines and the high sensitivity
of this method in DMH assay has been validated by bisulfite pyrosequencing and/or MSP,
and showed hypermethylation, rather than hypomethylation, predominantly occurred dur-
ing the acquisition of cisplatin resistance.
2.4 Discussion 88
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
52_E_8 72_H_5 50_F_1 102_D_7 5_C_8 115_D_2 51_A_9
M
e
th
y
la
ti
o
n
 (b
e
ta
 va
lu
e
)
A2780p5
A2780p6
cp70
MCP1
MCP6
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
e
th
y
la
ti
o
n
 (b
e
ta
 va
lu
e
)
A2780p5
A2780p6
cp70
MCP1
* *
*
* * *
M
e
th
y
la
ti
o
n
 (b
e
ta
 va
lu
e
)
0
0.1
0.2
104_G_6 100_A_10 108_G_6 17_D_11 13_B_12 22_E_10
M
e
th
y
la
ti
o
n
 (b
e
ta
 va
lu
e
)
MCP6
Figure 2.11: Methylation of loci identified by MLDA or SAM on Illumina HumanMethy-
lation27 BeadChip. Methylation is represented as beta value ranging from 0 (unmethy-
lated) to 1 (fully methylated). A: 7 loci identified by MLDA. B: 6 loci identified by
SAM.*Methylation of loci increased in at least two resistant cell lines compared to sen-
sitive ones. The significance of increased methylation (15%) was determined by the upper
95% CI estimated by bootstrapping from the null distribution of the difference among 4
biological replicates on the BeadChips.
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3.1 Introduction
DNA methylation is an important epigenetic mechanism in the normal biological pro-
cesses of X chromosome inactivation, imprinting genes and the inactivation of parasite
DNA elements (Baylin and Jones, 2006). Although mitotically heritable and stable over
time, changes of methylation have often been observed in cancers including ovarian cancer
(Feinberg and Tycko, 2004; Barton et al., 2008; Sharma et al., 2010). Recent advance of
technology have enabled quantitative assessment of DNA methylation at a genome wide
level. For instance, Wei et al. (2002, 2006) obtained methylation profile on HCGI12K
arrays (Cross et al., 1994) in advanced ovarian tumours to attempt to identify the methyla-
tion signatures that can distinguish patients with short and long progression-free survival.
Similarly, we have obtained methylation profiling on the same array in 6 cisplatin sensitive
derivatives and 10 cisplatin resistant derivatives of a human ovarian cell line and identi-
fied 115 loci associated with acquired drug resistance by Methylation Linear Regression
Analysis (MLDA) (Dai et al., 2008). Teschendorff et al. (2009) analysed the methyla-
tion profile of blood cells from 148 healthy volunteers and 113 age-matched ovarian can-
cer patients prior to receiving chemotherapy in order to evaluate the diagnostic/risk value
of methylation, Houshdaran et al. (2010) performed methylation profiling in 27 primary
epithelial ovarian tumours and 15 ovarian cancer cell lines on the Illuimina GoldenGate
platform (Illumina, CA, USA) and showed the difference in methylation between ovarian
cancer cell lines and tumours, as well as between different histological subtypes of ovar-
ian cancer. Therefore, the methylation profile of tumours could be utilised to understand
the epigenetic changes in tumourigenesis and progression better, and to discover candidate
biomarkers for disease diagnosis/risk assessment, classification, prognosis and prediction
of response to chemotherapy.
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Currently, high-resolution methylation analysis relies on several existing technologies
mainly based on (1) the use of methylation-sensitive and/or methylation-specific restriction
enzyme that differentially recognise the methylated/unmethylated DNA, (2) the use of anti-
bodies or other proteins that bind 5-methyl-cytosine (5mC) to enrich for methylated regions
of DNA, or (3) the use of sodium bisulfite to convert the unmethylated cytosines to uracils
but leave the methylated cytosines intact (Laird, 2010). High-throughput DNA methy-
lation profiles can be obtained by combining these three methods either with microarrays,
such as Illumina Infinium assay on HumanMethylation27k BeadChip (Illumina, CA, USA)
and Agilent methylated DNA immunoprecipitation assay on Agilent 244k CpG island mi-
croarray (Agilent, UK) or with direct sequencing, for example bisulfite pyrosequencing
and methylC-seq (Lister et al., 2009). Although sequencing, especially next generation se-
quencing, has the advantage of providing a single-base resolution DNA methylation map,
microarray hybridisation has been widely used in DNA methylation profiling studies be-
cause it is more cost-effective and requires less down-stream data processing. The strengths
and weaknesses of different types of methods for analysing DNA methylation combined
with microarray hybridisation have been described in Chapter 1. In brief, the two major
problems of the commercially available microarrays are the lack of sufficient coverage of
loci of interest for the aims of a given study and low quality of annotation, leading to the
wrong interpretation of the methylation analysis results. In addition, the reasons for the
selection of regions targeted by commercial microarrays for large-scale DNA methylation
studies are often unclear. Therefore, a custom-designed DNA methylation microarray, with
well pre-defined targets based on known biological concepts or pathways, comprehensive
annotation and good coverage of the probes is often the preferred option.
The objective of the work described in this Chapter is to test the feasibility of (1) cre-
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ating a custom designed promoter CGI microarray targeting the genes involved in multiple
cellular pathways and/or associated with acquired drug resistance in ovarian cancer, and (2)
using differential methylation hybridisation (DMH)(Nouzova et al., 2004) to detect differ-
ential methylation of samples with this array. In this initial feasibility study, human ovarian
cancer cell lines generated in vitro or in vivo, were used to address five major questions
below.
1. What is the variability of DMH on the custom-designed microarray? As with any
microarray experiment, variations can be introduced from any of the multiple steps
of DMH: such as, DNA preparation, hybridisation and image scan. In particular,
DMH analyses based on McrBC restriction enzyme, involves the extra steps of di-
gestion, ligation and PCR amplification. Therefore, the estimation of DMH variabil-
ity is necessary to understand a given DMH dataset and identify the loci statistically
differentially methylated in cell lines and later in tumours.
2. Does a dye-swap design have any influence on the variability of DMH assays? As
a result of the differential rates of incorporation of nucleotides labelled with the flu-
orescent dyes Cy3 (green) or Cy5 (red) into the labelling reaction and differences
in relative fluorescence between the two dyes, labelling dye bias is often observed.
Dye-swap design was recommended to remove the dye bias described by Ordway
et al. (2006). However, Irizarry et al.(2008) showed the benefit of dye swap design
did not exceed the extra cost. Therefore, the variation of dye-swap duplicates was
estimated in this study to evaluate if the variation introduced by the dye swap step
could possibly cover the true differential methylation between cisplatin sensitive and
resistant cell lines.
3. Are the pre-selected unmethylated and methylated controls appropriate for the mi-
croarray? In previous DMH studies there has been an absence of control features
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on the microarray leading to two main obstacles. The first one is that no criteria
have been used to determine if the assay works appropriately to detect differences
in methylation. Secondly, the performance of appropriate within-array and between-
array normalisation was impossible to assess in DMH dataset pre-processing (see
Chapter 2). The selection of control sequences as features on the microarray that are
consistently unmethylated or methylated in samples is helpful to solve both prob-
lems. In this study, the selected sequences were evaluated by Methylation Linear
Discriminant Analysis (MLDA, see Chapter 2) as unmethylated/methylated controls
and were subsequently used in data pre-processing and down-stream data analysis.
4. How can the methylation level of a CpG island targeted by multiple probes to be
measured? The DMH ratios of the probes targeting the same regions are not inde-
pendent. A previous study has shown that the methylation levels of adjacent CpG
sites are similar, especially within 50bps (Nautiyal et al., 2010), but the question of
how the methylation level of multiple CpG sites within a CpG island/locus of>50bps
can be summarised to reduce the number of data points has not been studied yet. An
average value is often used to summarise multiple data points. Therefore, using the
average DMH ratio, measured as a continuous variable, to measure the methylation
level of a fragment was evaluated, as well the estimation of the optimal length of
fragment for analysis in the proposed study.
5. Are the loci known to be differentially methylated in cell lines identified by DMH
assay on the custom-designed microarrays? The methylation levels of a set of genes
have been previously determined by bisulfite pyrosequencing (England and Petters-
son, 2005) or methylation specific PCR (Herman et al., 1996) in cell lines. Using this
set of genes as a test set, the DMH assay was evaluated in terms of sensitivity and
specificity to detect differential methylation between cisplatin sensitive and resistant
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cell lines after the four points mentioned above was taken into consideration.
3.2 Methods
3.2.1 Samples
In vitro generated cell lines
DNA was isolated from A2780 cisplatin sensitive derivatives: A2780p3, A2780p5 and
A2780p6, and A2780 cisplatin resistant derivatives: A2780/CP70, A2780/MCP1 and A2780/MCP6
(Louie et al., 1985) using Qiagen DNA extraction kits (Qiagen, UK) following the manu-
facturer’s instructions. The DNA from each cell line had dye-swap duplicates. In total, 12
samples underwent hybridisation (6 cell lines x 2=12).
In vivo generated cell line pairs
DNA was isolated from matched isogenic chemo-sensitive and resistant cell line pairs:
PEO1 and. PEO4, PEO14 and PEO23, PEA1 and PEA2 (Langdon et al., 1988) using Qia-
gen DNA extraction kits (Qiagen, UK) following the manufacturer’s instructions. Each of
these cell lines had dye-swap duplicates hybridised to the arrays. To evaluate the variation
of technical replicates of microarrays and DNA independent preparations in the DMH as-
say, independent DNA duplicates and hybridisation duplicates were made from PEO1 and
PEO4. Therefore, the total number of samples for hybridisation was 20 (6 cell lines x 2
(dye-swap duplicates)+ 2 cell lines x 2 (DNA independent duplicates) + 2 cell lines x 2
(hybridisation duplicates) = 20).
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3.2.2 Agilent custom-designed 8x15k microarray
Target selection
The workflow used to select the targets on the microarrays is shown in Figure 3.1. The
loci targeted by the oligos on the microarray were mainly selected from our previous work
and the published literature associated with acquired drug resistance: 1) CGIs identified
from the DNA methylation profiling study by the DMH assay on a HCGI12K microarray
between A2780 sensitive and resistant derivatives generated in vitro as well as between in
vivo generated cell line pairs (PEO1 vs. PEO4, PEA1 vs. PEA2, PEO14 vs. PEO23) per-
formed by Dr. Jens M. Teodoridis; 2)a prognostic DNA methylation signature associated
with progression free survival in ovarian cancer (Wei et al., 2006); 3) and 4) CGIs identified
from DNA methylation profiling study on an Orion MethylScope (Lippman et al., 2004)
two-channel microarray based on McrBC restriction enzyme to detect differential methy-
lation between A2780 sensitive and resistant cell lines (data not published); 5) candidate
genes collected from the studies about acquired drug resistance in ovarian cancer through
our collaborations (Professor Hani Gabra and Dr. Euan A. Stronach from Ovarian Cancer
Action); and 6) other loci/genes differentially expressed before and after cisplatin treatment
from gene expression profiling studies published from 2001 to 2008 (see Appendix 3.1 for
the gene list and reference). Promoter CGIs within 2kb of the transcription start site (TSS)
of the selected genes were defined by Gardiner-Garden (1987) by the following criteria:
CG content greater than 50%, length of sequence over 200bp and the ratio of observed to
expected CpGs is larger than 0.6. The genes without any promoter CGI were not taken into
consideration. The CGIs that were not close to the TSS of the genes were also selected in
the study if they showed differential methylation between the in vitro and in vivo generated
cisplatin sensitive and resistant cell lines identified by MLDA on HCGI12K arrays (see
Chapter 2) or on Orion MethylScope microarrays (data not published). In total, about 600
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loci were covered by the custom-designed microarray.
Controls on the microarray
Three major types of controls were designed on the microarray (Table 3.1). Firstly, the
sequences from the human mitochondrial genome which are generally unmethylated in
human (see Chapter 2), and sequences from chromosome 16 that are underrepresented for
CG regions and which contain very few McrBC recognition sites (ACG or GCG) were
selected as unmethylated controls. Secondly, the sequences on HCGI12K microarray (see
Chapter 2) that showed high methylation levels in our previous DMH work were selected
as positive methylation controls. Finally, sequences from non-human genome (see Table
3.1) were used as the negative controls which mainly reflected the background noise.
Controls # probes Source
Unmethylation 266 Mitochondrial genome
Unmethylation 400 Chr16: 59000000-61000000
Methylation 172
methylated probes on UHN12K microarray;
promoter CGIs of GAGE family
Negative 577 Structural negatives (3xSLv1)
1
Biological negatives2
Table 3.1: Controls on the custom-designed microarray.1This probe forms a hairpin and
does not hybridize well with labelled samples of any species.-2This probe has been shown
not to have significant signal from any sample tested by Agilent.
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Figure 3.1: Workflow of target selection on Agilent custom-designed microarray in the fea-
sibility study. 1CGIs identified from DNA methylation profiling study by DMH assay on
HCGI12K microarray between A2780 sensitive and resistant derivatives generated in vitro
as well as between in vivo generated cell line pairs (PEO1 vs. PEO4, PEA1 vs. PEA2,
PEO14 vs. PEO23) performed by Dr. Jens M. Teodoridis; 2the prognostic DNA methy-
lation signature associated with progression free survival in ovarian cancer (Wei et al.,
2006); 3,4CGIs identified from DNA methylation profiling study on an Orion MethylScope
(Lippman et al., 2004) two-channel microarray based on McrBC restriction enzyme to
detect differential methylation between A2780 sensitive and resistant cell lines (data not
published); 5candidate genes collected from the studies about acquired drug resistance in
ovarian cancer through our collaborations (Professor Hani Gabra and Dr. Euan A. Stonach
from Ovarian Cancer Action); 6other loci/genes differentially expressed before and after
cisplatin treatment from gene expression profiling studies published from 2001 to 2008
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Annotation of custom-designed microarray
The genomic annotation of human genes was obtained from the Refseq database (http:
//www.ncbi.nlm.nih.gov/RefSeq/) and the UCSC known gene database (http:
//genome.ucsc.edu/). Promoter CGIs within a 2kb of the transcription start site of
the genes were obtained from UCSC database (Rhead et al., 2010) and from a genome-
wide prediction of CGIs (Bock et al., 2007) as a supplementary set, both of which fulfil
the mathematical model proposed by Gardiner-Garden to define a CGI (Gardiner-Garden
and Frommer, 1987). MseI fragments were predicted by searching for the recognition sites
(T/TAA) against the whole human genome sequence, masking the assembly gaps, intro-
contig ambiguities and repeat regions. The prediction was performed in R using two pack-
ages: BSgenome and BSgenome.Hsapiens.UCSC.hg18. The genomic positions of targets
were specified by Human Mar. 2006 (NCBI36/hg18) assembly. All the information was
stored in an in-house MySQL database (http://www.mysql.com/). An R package,
RODBC, provides an interface between R workspace and MySQL database.
The annotation pipeline is shown in Figure 3.2. The genomic locations of the probes
were compared to the transcript start sites of the genes collected from Refseq database and
UCSC known gene database, the genomic location of CGIs and MseI fragments. Any gene
for which the TSS was within 2kb span of the probes was added into the annotation table.
If multiple transcripts or different genes were related to the same probe, the annotation
table included multiple official gene symbols, Entrez gene IDs, TSSs, and strands in the
record for the corresponding probe. The genomic location and length of CGIs and MseI
fragments targeted by the probes were also added in the annotation table. If the probes were
in the 150nt flanking region of a CGI, it was annotated as a ”flanking” probe. R functions
[mseI.anno( ), cgi.anno( ) and gene.anno( )] for the microarray annotation are shown in the
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Figure 3.2: Annotation workflow of Agilent custom-designed microarray. *The probes
are annotated as NA (not available) if they cover the MseI recognition site (T/TAA). CGI
database 1 is from UCSC database and CGI database 2 is from Bock et al. (2007)
Appendix scripts and a complete annotation of this array is given in Appendix 3.2.
3.2.3 Differential methylation hybridisation (DMH)
Samples were assayed on Agilent custom-designed microarrays by DMH in duplicates
(Nouzova et al., 2004). Briefly, DNAs were digested with MseI and fragments were ligated
to annealed H12 (TAATCCCTCGGA) and H24 (AGGCAACTGTGCTATCCGAGGGAT)
linkers. One fraction of linked fragments was digested with McrBC(5’ (A/G)C(N40-3000)(A/G) 3’)
which cleaves methylated DNA sequences but leaves unmethylated sequences intact, the
other fraction was mock digested. Both fractions were amplified using linker specific
primers with only uncleaved fragments being amplified. A dye-swap design was used.
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The amplicons from McrBC digested and mock digested samples are coupled either with
Cy5(red) or Cy3(green), respectively, and then competitively hybridised on the microarray.
Labelling of DNA, microarray fabrication, array hybridisation and image scanning was
performed by Oxford Gene Technology (Oxford, UK).
The images of microarrays were scanned by Agilent C scanner at 5µm resolution and
the raw signal intensities were extracted by Agilent Feature Extraction software (version
9.5.3.1) using CGH-v4 95 Feb07 protocol. The flagged probes were detected by Agilent
Feature Extraction software. The probes flagged in more than 10% of the total samples
were excluded from further analysis (Figure 3.4A). Otherwise, they were treated as miss-
ing data points (about 2%) and imputed by k-nearest neighbour (KNN) algorithm (k=10)
(see section 3.2.4). The probes with signal intensities over 65000 were removed from the
analysis due to the signal saturation. The probes with low intensities were also not taken
into consideration. The MA-plot is a plot of the distribution of the signal intensity ratio
(M) of the undigested (mock) sample to digested sample against the average signal inten-
sity (A). M and A are defined as equations below.
 M = log2(undigest)− log2(digest)A = (log2(undigest) + log2(digest))/2

In a MA-plot, any probes with A ≤ A¯control + 1.96SDcontrol(A¯control denotes the av-
eraged A values of negative controls on the array, and SDcontrol is the standard deviation
of A values of negative controls) are considered as low intensity probes, and were thus
excluded from the study (Figure 3.4C). Ultimately, about 90% of probes on the microarray
were included in the subsequent analysis (Figure 3.4D).
Within-array normalisation was performed to reduce the influence of dye bias in MLDA
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package (see Chapter 2 section 2.3.4), using a univariate linear regression model con-
structed using unmethylated probes selected from a poor CG region in chromosome 16,
as well as from the mitochondrial genome. The slope of the linear regression model was
adjusted to 1 and the intercept was adjusted to 0, since the log transformed signal inten-
sities of the unmethylated controls were assumed to be equal. The log transformed signal
intensities of all the probes on the microarray were adjusted correspondingly, as shown in
formula 2.13 and 2.14 in Chapter 2.
3.2.4 Statistical analysis
The significance level was set at two-sided p < 0.05, unless it is stated as one-sided. All
calculations and statistical analyses were performed in R (version 2.9.1) and SPSS (version
16.0).
Imputation of the missing data by KNN algorithm
The k-nearest neighbours (k=10) of the missing data point (a locus) used Euclidean dis-
tance (formula 3.1) to identify loci with data, and then the missing locus was imputed by
averaging those non-missing loci of its neighbours.
d =
√√√√ n∑
i=1
(xi − yi)2 (3.1)
Here, xi and yi denote the values of loci in two samples, respectively. n is the total number
of loci on the array.
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Coefficient of determination
The coefficient of determination, R2, is the proportion of variability of a set of data ac-
counted for by the statistical model. In the linear regression model with single regulator,
R2 (formula 3.2) is the squared Pearson product-moment correlation coefficient(formula
3.3) between two samples. It ranges from 0 to 1 and an indicator of ’goodness of fit’. The
higher R2, the better the fit is of the linear regression model. Therefore, it can be used as a
measurement of consistency between duplicates in this study.
R2 =
l2xy
lxxlyy
= r2 (3.2)
r =
∑
(x− x¯)(y − y¯)√∑
(x− x¯)2√∑(y − y¯)2 = l
2
xy
lxxlyy
(3.3)
Here, X is the DMH ratio (logged to the base 2) population in one sample and Y is the
DMH ratio (logged to the base 2) population in the duplicate. x¯ and y¯ are the means of X
and Y , respectively. lxy is the sum of products of mean deviations of X and Y. lxx and lyy
are similar to lxy, which are the sum of products of mean deviations of X and X (or Y and
Y).
Mann-Whitney U test
The Mann-Whitney U test is a non-parametric method to compare two independent random
samples without the assumption of normal distribution. In two independent samples test, it
is equivalent to the Wilcoxon rank sum test and the Kruskal-Wallis test for two groups. In
the null hypothesis, the observations from two groups (X and Y populations) are combined
and ranked, and the probability of an observation from one population X higher than that
from the other population (Y ) is equal to the probability of an observation from the pop-
Chapter 3. Feasibility Study of DNA Methylation Profiling on Agilent
Custom-designed Microarray in Ovarian Cancer Cell Lines 103
ulation Y higher than that from the population X . Therefore, the probability of drawing
a random larger sample is symmetrical in both populations. The alternative hypothesis is
the probability of an observation from one population X exceeding the probability from
the other population (Y ) is not equal to 0.5. In two independent samples test, statistic U is
calculated as described below.
1. The samples from two groups (n1 and n2) are ranked from the smallest to the largest.
2. The number of times that the rank from group 1 is larger than the rank from group
2, as well as the number of times that the rank from group 2 precedes the rank from
group1 is calculated.
3. The Mann-Whitney U statistic is the smaller time. In the case of small samples
(n1 + n2 ≤ 30), the distribution of U statistics is tabulated, but for sample sizes
above 30 there is a good approximation with the use of normal distribution.
In this study, the methylation of loci were defined by DMH ratios of multiple probes
that targeted the same locus being significantly greater than unmethylated regions selected
from chromosome 16 and the mitochondrial genome. One-sided Mann-Whitney U test
was used to test the difference and the significance level was set at p < 0.0003 based on
Bonferroni correction (0.05/161, where 161 was the number of tumour samples that were
assayed in DMH in the next stage of the study (see Chapter 4). To evaluate the prediction
accuracy of methylation status and determine the minimum number of probes required to
reach this significant level, seven loci that have been examined by MSP and are targeted by
multiple probes on the microarray were used as a test set.
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Locally Weighted Scatterplot Smoothing (LOWESS)
To estimate the optimal size of the MseI fragment, LOWESS was used to show (1)the rela-
tion between the distance of the probes to the MseI recognition site and signal intensities,
where distance between the locus targeted by the probe and MseI fragment was calculated
as the distance of the start site of the probe to the start site (recognition site) of the MseI
fragment, and (2)the relationship between the DMH ratios and the length of the MseI frag-
ments. The general idea of locally weighted scatterplot smoothing is a combination of
local fitting of polynomials for smoothing and iterated weighted least square for robust es-
timation. Three parameters are crucial in LOWESS: f (0 < f ≤ 1) is the proportion of the
points used for smoothing. The increasing value of f increases the number of neighbour-
hood influential points, thus increases the smoothness; iter is the number of iterations for
performing the fitting using the adjusted weights from the previous iteration; delta is used
to speed up the computation, within which the points ofthe last computed point, are skipped
and filled by the fitted value of linear interpolation. The default values for these three pa-
rameters were used in this study (f is 2/3, iter is 3 and delta is 1/100th of the range of x)
to examine if the signals of the probes targeting different location of the MseI fragment are
similar.
3.3 Results
3.3.1 Quality control in DMH
QC features in DNA methylation study
Since the Agilent custom-designed microarray was originally designed for the detection of
copy number changes (CNA), Agilent Feature Extraction software does not provide quality
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control (QC) reports that are tailored for DNA methylation analysis. Therefore the four fea-
tures shown in Table 3.2 were used as indicators of DMH data quality, rather than using the
QC report which is generated for comparative genomic hybridisation (CGH) microarrays
by Feature Extraction. These four features indicate the outliers of non-uniformity and pop-
ulation at background and foreground in green and red channels, respectively. As shown
in Figure 3.3, the highest consistency between duplicates was achieved using these four
features to exclude probes (<5%) not fulfilling required data quality. The use of only two
flags, IsBGPopnOL and IsFeatNonUnifOL, could also reach the same reproducibility of
duplicates (Figure 3.3), and is therefore recommended when a large number of samples are
involved to save the computing power.
Features (Green) Features (Red) Types Description*
gIsFeatNonUnifOL rIsFeatNonUnifOL Boolean
Boolean flag indicating if a features
is a NonUniformity Outlier or not.
A feature is non-uniform if the pixel
noise of feature exceeds a threshold
established for a uniform feature
gIsBGNonUniOL rIsBGNonUniOL Boolean
The same concept as above but for
background
gIsFeatPopnOL rIsFeatPopnOL Boolean
Bolean flag indicating if a feature is
Population Outlier or not. Probes with
replicate features on a microarray are
examined using population statistics.
A feature is a population outlier if
its signal is less than a lower thresh-
old or exceeds an upper threshold
(1.42× IQR)
gIsBGPopnOL rIsBGPopnOL Boolean
The same concept as above but for
background
Table 3.2: Features for quality control in DMH. * Reference Guide of Agilent Feature
Extraction Software
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Figure 3.3: Average correlation between replicates of filtered probe sets within arrays.
Various combinations of flags used to filter out the poor quality probes were tested. This
analysis was performed by Dr. Volker Brenner from Oxford Gene Technology (OGT, UK)
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Methylated and unmethylated controls
In general, unmethylated controls from mitochondrial genome and a poor CG region from
chromosome 16 worked well and showed linear correlation between signals of McrBC di-
gested and undigested samples (p < 0.05), although some probes targeting mitochondrial
sequences reached signal saturation (signal>65000) (Figure 3.4B). Two distinct groups of
methylation controls were observed across all the samples in the pilot study (red spots in
Figure 3.4B and D). One had a high level of methylation and the other had medium or even
low level of methylation. Therefor, the former group would be appropriate controls to use
in future studies, while the latter would not. The majority of the methylation controls were
identified from the previous DMH study on UHN12K microarray (Chapter 2). However,
as previously described (Chapter 1), over 10% probes on the UHN12K array targeted mul-
tiple sequences in the human genome according to the annotation of UHN12K microarray
(http://data.microarrays.ca/cpg/) at the time we analysed the data. Thus,
the high methylation level of those probes observed in a UHN12K study could be a con-
founding effect of cross-hybridisation. To identify appropriate methylation controls that
would not be confounded by this effect, MLDA was applied as described in Chapter 2, in
which methylation scores representing the methylation status of the loci mapped by the
probes on duplicate arrays were calculated to each control probe based on the weighted
scoring schema in MLDA (Figure 2.4 in Chapter 2). Only the methylation controls with
an MLDA score>0, which represented methylated on duplicate arrays, across all the cell
lines were used in future study. The majority of these controls (66/89 probes) were from
the promoter CGIs (49074918-49075532, 49103473-49103955, 49065375-49065985 and
49202750-49203235) of GAGE gene family on chromosome X.
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Figure 3.4: DMH data in pilot study. A: percentage of flagged probes. Each cell line
has duplicates; B: scatter plots of raw signals of McrBC digested and mock samples in
DMH; C: negative controls and low signals. Red broken line indicates the density of the
negative controls. Red solid line indicates the cut off for low signals; D: scatter plots of
pre-processed signals of McrBC digested and mock samples in DMH. Orange line: un-
methylated regression line. Yellow spots: mitochondrial controls; Red spots: methylated
controls; Blue spots: unmethylated controls selected from chromosome 16; Grey spots: the
probes with quality issues.
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3.3.2 Reproducibility of Agilent custom-designed microarray
To measure the reproducibility, R2, the coefficient of determination of the linear regression
model constructed by duplicates was used. The independent preparation of DNA showed
similar reproducibility as technical replicates (mean± SD : 0.86± 0.07 vs. 0.85± 0.06),
suggesting that there was little variation from different DNA preparations. However, a
large variation was introduced by dye bias in the dye-swap duplicates resulted in a low R2
(mean± SD : 0.64± 0.09, Figure 3.5A). The independently isolated DNA duplicates had
a slightly higher R2 when McrBC digested sample was labelled by Cy3 and mock sample
labelled by Cy5 (dye labelling method 1) than those in dye-swap counterparts (dye labelling
method 2) (mean± SD : 0.87± 0.07 vs. 0.83± 0.04, Figure 3.5B). Therefore, technical
replicates with McrBC digested sample labelled by Cy3 and mock sample labelled by Cy5
(dye labelling method 1) was used in the later study of tumours (Chapter 4 and 5) instead
of using dye-swap duplicates, in order to minimise variability due to dye labelling.
3.3.3 Dye bias correction
The log transformed DMH ratios were corrected by MLDA (see Chapter 2 Section 2.3.4) to
reduce dye bias and improve the reproducibility of DMH assay. As shown in Figure 3.6A,
after correction the mean of log ratios of unmethylated controls in sample A2780p3 is
around 0, therefore, the methylation baseline was adjusted to zero in each sample. The cor-
relation of about 600 unmethylated controls in dye-swap duplicates was estimated before
and after the correction. Figure 3.6B shows that the average correlation of unmethylated
controls between 20 dye-swap duplicates increased from 0.36 to 0.54 after the correction
(p = 2.09 × 10−7, n = 20, paired Student’s t test) indicating the reduction of variation
introduced by dye-swap labelling.
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Figure 3.5: R square of linear regression model between replicates. A: reproducibility of
duplicates. Dye-swap: dye-swap replicates; Independent: independently prepared DNA;
Technical: hybridisation replicates. B: reproducibility of duplicates using two dye labelling
methods. Dye label 1: McrBC digested sample labelled by Cy3 and mock sample labelled
by Cy5. Dye lable 2: dye-swap labelling method of Dye label 1. Error bar: Standard Error
of Mean (SEM)
Chapter 3. Feasibility Study of DNA Methylation Profiling on Agilent
Custom-designed Microarray in Ovarian Cancer Cell Lines 111
A
lo
g 
ra
tio
Density
−
1.
5
−
1.
0
−
0.
5
0.
0
0.
5
1.
0
1.
5
0.00.51.01.52.02.5
be
fo
re
 c
o
rr
e
ct
io
n
a
fte
r c
or
re
ct
io
n
be
fo
re
 c
o
rr
e
ct
io
n
a
fte
r c
or
re
ct
io
n
0.00.20.40.60.81.0
B
pearson correlation
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
Fi
gu
re
3.
6:
D
ye
bi
as
co
rr
ec
tio
n
in
M
L
D
A
.A
:d
is
tr
ib
ut
io
n
of
lo
g
ra
tio
s
of
un
m
et
hy
la
te
d
co
nt
ro
ls
be
fo
re
an
d
af
te
rc
or
re
ct
io
n;
B
:
Pe
ar
so
n
co
rr
el
at
io
n
of
un
m
et
hy
la
te
d
co
nt
ro
ls
in
du
pl
ic
at
es
be
fo
re
an
d
af
te
rc
or
re
ct
io
n.
3.3 Results 112
3.3.4 Methylation measurement of a CpG Island by the DMH assay
In DMH assay, PCR amplification is performed following MseI digestion on genomic
DNA. In the early cycles of PCR, slight differences in amplification efficiency can pro-
duce different amount of MseI fragments, which results in changes in DMH ratios between
samples. To understand how MseI digestion influences DMH ratios and how to summarise
the methylation level of a CpG island, all of the MseI fragments were identified in the
human genome using the MseI recognition site (T/TAA) in silico. Figure 3.7A shows the
number of MseI fragments on 23 chromosomes. The average size of MseI fragment in
humans is 158bp. Among 19,029,911 fragments predicted in silico, only 642 (0.30‰) is
more than 6,000bp. The majority of fragments (92.5%) have a size of 0.1 to 2kbs, which
is the size range of MseI fragment suggested to enhance restriction enzyme methylation
analysis in recent study (Tran et al., 2009).
As illustrated in Figure 3.7B, the methylation levels of the loci targeted by the probes
were indeed similar within a given MseI fragment. Therefore, individual MseI fragment
instead of CGI was used as the unit by which the methylation level of a locus was esti-
mated. About 50% of CpG Islands targeted by our custom-designed microarray had no
MseI recognition site within the sequences, and were therefore treated as individual locus.
Other CpG islands had various numbers of recognition sites ranging from 1 to 57, and were
treated as multiple loci (MseI fragments) in the analysis.
Noticeably, the signals of the probes close to the MseI recognition size were not as high
as those further away from the recognition size. To examine if the distance of the probes
to the MseI recognition site had any influence on the signals and estimate an optimal MseI
fragment size, the probes within ±500bp of MseI cut site were identified. Figure 3.7D
shows the change of log transformed signal intensities in both green and red channels, as
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well as DMH ratio, with the distance to MseI recognition site in two independent samples.
The signals decrease at the region close to MseI cut site and reach their lowest value at
around upstream 31bp. There are about 120bp (-90 to +30bp) distance between two inflec-
tions.
A minor shift of the signal intensities of two types of probes (forward and reverse), was
observed in Figure 3.7C. The dip for forward and reverse probes is still at 31bp upstream
of MseI cut site, except signal intensities in red channel (McrBC digest sample) of forward
probes of which the dip is at -22bp. Therefore, the distance of probes towards and away
from cut site is better to be -90 to +40bp for forward probes and -90 to +30bp for reverse
complementary probes. So the minimal size of MseI fragment has to be 130bp. The log
transformed signal intensities/DMH ratios of all the probes within the fragments were av-
eraged. Average signal intensities increase with the size of MseI fragment and reach the
peak at 440 bps, then decrease with the size slowly and reach the bottom at around 2500bp
(Figure 3.7D). So the suggested size of MseI fragment that is recommended to be analysed
by DMH is 130 to 2500bps.
3.3.5 Sensitivity and specificity of DMH on Agilent custom-designed mi-
croarray
To confirm that DMH assay on this custom-designed microarray could detect the loci
known to be differentially methylated between cisplatin sensitive and resistant cell lines,
nine loci (MseI fragments) were used as a test set. These loci have been examined by bisul-
fite pyrosequencing/methylation specific PCR (performed by Dr. Jens, M. Teodoridis, Dr.
Janet Graham and Dr. Constanze Zeller in Imperial College London, UK) in both in vivo
and in vitro generated cell lines previous, and were found differentially methylated between
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three A2780 sensitive and resistant derivatives, but 5 out of 9 had no change of methylation
in in vivo cell line pairs (PEO1 vs. PEO4, PEA1 vs. PEA2 and PEO14 vs. PEO23).
The probes targeting these 9 loci were identified on the custom-designed microarray and
methylation of the loci was measured by average DMH ratios of multiple probes. The
result shows methylation of 9/9 (100%) loci is significantly different between A2780 sen-
sitive and resistant cell lines if McrBC digested samples are labelled by Cy3 and reference
samples are labelled by Cy5 (p < 0.05)(Figure 3.8A). This confirms high sensitivity of
DMH assay to detect differential methylation on the custom-designed microarray. In the
dye-swap replicate, 8/9 (89%) loci show significant differential methylation and methy-
lation of one locus close to SP5 was not identified as significant locus by Mann-Whitney
test due to larger variation of methylation within the group (Figure 3.8B). This is consistent
with the result in section 3.3.2 that showed the latter dye labelling method introduced larger
variation which could possibly mask the true differential methylation between samples.
In addition, five loci that have no differential methylation in the sensitive and resistant
cell line generated in vivo shown similar methylation level between the sensitive and resis-
tant cell lines on the arrays (Figure 3.8C and D). Therefore, the DMH assay combining the
custom-designed microarray not only has a high sensitivity but also has a high specificity
for the detection of differential methylation in ovarian cancer cell lines.
3.3.6 Correlation between DMH and bisulfite pyrosequencing
To further explore the relationship between DMH and bisulfite pyrosequencing, methy-
lation at three loci (SP5, FOXA1 and TFAP2C) in A2780p3, A2780p5, A2780p6, cp70,
MCP1 and MCP6 cell lines were tested by both methods. Average DMH ratios were lin-
early correlated with the result from bisulfite pyrosequencing (R2 see Figure 3.9A and B),
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especially when the McrBC digested sample was labelled by Cy3 (Figure 3.9A). This result
further confirms that the use of average DMH ratios could represent the methylation level
of the locus, and thus detect the differential methylation.
3.3.7 Determination of methylation status in cell line model
To quantify the methylation frequency of genes in ovarian tumours in later studies (see
Chapter 4 and 5), an appropriate method of analysis is required to determine if the locus
is methylated. Unfortunately, the use of continuous DMH ratios is not possible to achieve
this goal unless a cutoff for methylation is determined. In previous DMH studies, an arbi-
trary cut-off has been used without considering the variations in DMH assays, leading to
a potential increased in false positives or negatives. In the present study, a method based
on Mann-Whitney U test was used to estimate the methylation status using DMH ratios
of multiple probes (see Methods, section 3.2.4). The locus was identified as methylated
if the p value is less than 0.0003, based on Bonferroni correction (0.05/161, 161 is the
number of tumour samples that were assayed by DMH in the next stage of the study (see
Chapter 4)).To evaluate how many probes are required to reach this significant level, 4
loci were used that were methylated in CP70 and targeted by multiple probes on the array.
The probes were randomly selected within the loci and the number of probes used for the
Mann-Whitney test was deceased from maximum to 3. As shown in Figure 3.10, at least 7
probes are required to reach this significant level.
Seven loci examined by MSP and known to be methylated/unmethylated in A2780
and cp70 cell lines were used to evaluate this method. The result shows 6 out of 7 loci
were predicted correctly in A2780 and CP70 cell lines, while one locus (66 G 6, chr9:
95748103-95748629) was methylated in CP70 cell line but predicted as unmethylated locus
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(Figure 3-10). This may be because only 4 probes target this locus, which is not sufficient to
reach the level of p < 0.0003. Another locus in AGBL2 was also targeted by only 4 probes,
but as this locus was unmethylated in both cell lines, the unmethylated status determined by
this method could be just as a result of the poor coverage of the probes. Therefore, further
examination of the number of the probes is always necessary when the loci are predicted to
be unmethylated.
3.4 Discussion
3.4.1 Controls on the Agilent custom-designed microarray
The use of mitochondrial sequences as the unmethylated controls have been described and
discussed in detail in Chapter 2. In addition, 400 probes that mapped to a poor CG region of
chromosome 16 were also selected as unmethylated controls (yellow spots in Figure 3.4B
and D). In the DMH data pre-processing, log DMH ratios of those unmethylated controls
were adjusted to zero by MLDA. Generally, LOWESS algorithm is used in two-channel
microarrays to correct dye-bias. However, it requires the signals of the selected controls
to cover the whole range of the signal intensities on the microarray. As shown in Figure
3.4B and D, the signal intensities of the unmethylated controls only cover the low and high
signals; therefore, the linear regression model implemented in MLDA is more suitable
to reduce the dye-bias in this case than LOWESS method. The methylated controls were
selected and evaluated on the Agilent custom-designed microarray. CpG island methylation
of testis specific genes, such as MAGE, GAGE, XAGE gene families, are the predominate
mechanism of transcriptional repression of these genes in many tissues (Dunn et al., 2003;
De Smet et al., 1999). The majority of selected methylated controls are from promoter
CGIs of GAGE family (GAGE2E, GAGE2C, GAGE12J, GAGE12E, GAGE12G, GAGE4,
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Figure 3.10: Coverage of probes and significant level in one side Man-Whitney test. The
red broken line indicates the significant level p = 0.0003, i.e. −lod(p) = 3.52. The red
spots show the numbers of probes required to reach the significant level (p < 0.0003) in
one-side Mann-Whitney test.
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Figure 3.11: Methylation in DMH and MSP. Left: methylation of 7 loci tested by MSP in
A2780 (blue frame) and CP70 (orange frame). Right: number of probes targeting the locus
and methylation status determined on DMH. Red: methylated locus; Green: unmethylated
locus.
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GAGE7, GAGE8, and GAGE13) on chromosome X, but not from promoter CGI of GAGE1
that has been shown to express in ovarian cancer cell line A2780 as well as in 33.3% serious
ovarian tumours and 16.7% of endometrioid ovarian tumours (Zhang et al., 2010). It will
be necessary to further evaluate these selected methylated controls that were identified by
the methylation analysis of ovarian cancer cell lines and tumours. Therefore, it will be
important to show that they retain methylation (Chapter 4), since it has been reported that
expression of these testis specific genes are increased in certain type of tumours, potentially
indicating the loss of methylation at promoter regions of the genes.
3.4.2 Modification of DMH assay
A larger variation was introduced when McrBC digested sample was labelled by Cy5 (red)
compared to Cy3 (green), which therefore influenced the detection of differential methy-
lation between samples, particularly with the DMH assay in which distribution of data
is asymmetric and a parametric test is not applicable. As shown in Figure 3.8B, 8 loci
exhibit differential methylation using this labelling method tested by Mann-Whitney non-
parametric statistics, however, the differential methylation of one locus in SP5 was masked
by the large dynamic range of DMH ratios within the group. Meanwhile, DMH assay
labelling McrBC digested sample by Cy3 (green) performed better, as 9/9 (100%) loci
showed differential methylation between two groups of cell lines. Therefore, given that
the variation of methylation within tumour tissues is smaller than those in ovarian cancer
cell lines, the latter labelling method is suggested to be used in duplicate DMH assays in
ovarian tumour samples instead of dye-swap design. Indeed, this method appears to be
more sensitive to detect difference in methylation with an appropriate correction for dye
bias using the unmethylated controls designed on the arrays as described in the Method
section of this chapter.
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3.4.3 Modification of MLDA
Global between-array normalisation on custom-designed microarray is not recommended
for two main reasons. Firstly, methylation changes are asymmetric (see Chapter 2). Sec-
ondly, custom-designed microarrays are focused on the regions that have been shown to be
differentially methylated between ovarian cancer cell lines/tumour tissues either in our and
collaborators previous DMH work or in the literature. Thus, there may be high frequency
of methylated loci, which again biases the results away from a normal distribution of the
data. MLDA were tailored for DMH data analysis without between-array normalisation,
but this method is not applicable to use the average value to summarise the methylation
level of the whole MseI fragment given the methylation scores from MLDA are ordinal.
In this feasibility study, this algorithm has been modified (see section 2.3.4 in Chapter 2)
to correct signals of McrBC digested and mock digested samples to reduce dye bias based
on the linear regression, at the same time, the log ratios of the unmethylated controls were
adjusted to zero. Correspondingly, the ratios of the rest of the probes were adjusted using
the parameters estimated from the linear regression model. The adjusted log DMH ratios
become more comparable between arrays as shown in Figure 3.6B. Consequently, the use
of average DMH ratios estimated from the log ratios adjusted by MLDA could reflect the
methylation changes of the regions targeted by multiple probes across the samples.
3.4.4 Identification of differential methylation within MseI fragment
We observed that differential methylation between cisplatin sensitive and resistant cell lines
occurred in a small region, a so called ”hot spot”, close to the TSS of NR2E1 and WNT1
(Figure 3.12). Although the use of average DMH ratios can reflect the differential methy-
lation of the whole MseI fragment between ovarian cancer cell lines in this study, bisulfite
pyrosequencing, bisulfite sequencing or next generation sequencing of the whole MseI
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fragment would be more powerful to identify such hot spots that are differentially methy-
lated between samples, especially in tumours samples where differential methylation is not
as dramatic as that in cancer cell lines.
3.5 Conclusions
This feasibility study shows that the use of differential methylation hybridisation (DMH)
on our Agilent custom-designed 15K microarray could distinguish the regions of differ-
ential methylation between A2780 cisplatin sensitive and resistant derivatives with high
sensitivity and specificity. Several recommendations can be made for the next stage of
the study with regards to DNA methylation profiling in ovarian tumours: (1) the design of
unmethylated and methylated controls on the arrays are necessary to monitor DMH assay,
adjust for the dye bias and reduce the systematic variations in the experiments, (2) four
features that indicated the outliers of non-uniformity and population in the background and
foreground in both channels can be used to remove the poor quality probes, (3) simple du-
plicates instead of dye-swap duplicates are recommended to avoid the variations introduced
by dye-swap labelling and the extra costs incurred, (4) to quantify the quality of DMH data,
the percentage of the flagged probes, median signal intensities of McrBC mock digested
samples, the reproducibility of duplicates as well as the difference of DMH ratios between
methylated and unmethylated controls should be reported at the beginning of the analysis,
(5) ideally, at least seven probes that target multiple regions for each MseI fragment should
be designed on the microarray, (6) the suggested length of each MseI fragment included
in the methylation analysis should between 130 and 2500bp, and (7) the average DMH
ratios of the MseI fragments estimated from the log ratios of multiple probes adjusted by
MLDA should be used to reduce the number of data points, thus increasing the power of
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Chapter 4
CpG Islands Methylation Profiling in the
Wnt Pathway and Their Prognostic
Significance in Epithelial Ovarian
Cancer
4.1 Introduction 128
4.1 Introduction
Epithelial ovarian cancer (EOC) is the most lethal of all the gynaecological cancers ac-
counting for 52% of all gynaecological cancer-related deaths (Jemal et al., 2009). Patients
with advanced disease have surgical cytoreduction followed by platinum-based chemother-
apy, but there is a low 5-year survival rate of 40% (http://info.cancerresearchuk.
org). There is a need for prognostic biomarkers to assist our understanding of the molecu-
lar basis of ovarian cancer progression and of sufficient discriminatory prognostic power to
be of clinical value. The established prognostic factors of EOC at clinical presentation be-
fore primary chemotherapy are residual disease and patient age, as well as histology, stage
and grade of tumour (Cannistra, 2004; Konstantinopoulos et al., 2008; Kulasingam et al.,
2010; Agarwal and Kaye, 2003). Although many individual biomarkers in EOC have been
investigated (Berchuck et al., 1990; Havrilesky et al., 2003; Verri et al., 2005; Lee and Park,
2009), none of them have been translated as independent prognostic biomarkers of suffi-
cient value to direct clinical management. Identifying robust prognostic markers following
conventional treatment of EOC will provide a solid basis for characterising potential pre-
dictive biomarkers to novel treatment strategies and hence for stratification of patients for
targeted care in clinical practice.
Aberrant DNA methylation frequently occurs in cancer, particularly at regions gener-
ally unmethylated in normal cells, known as CpG islands (CGIs)(Illingworth and Bird,
2009). CGIs often co-localise with the promoters of genes and promoter hypermethylation
is associated with repression of gene transcription (Illingworth and Bird, 2009). Several
studies have shown that CGI methylation has potential as a biomarker for monitoring tu-
mour progression (Wei et al., 2006) and is associated with platinum-based chemoresistance
in EOC (Li et al., 2009; Chou et al., 2010). However, many of these studies are either
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limited by small sample size or lack of validation of the methylation biomarker as an inde-
pendent marker.
The Wnt pathways control a variety of biological processes including cell proliferation,
differentiation and migration, and have a crucial role in development and tissue homeosta-
sis (Boyer et al., 2009). Wnt signalling is transduced through binding of Wnt molecules to
the transmembrane Frizzled receptor proteins (Fz) and activation of downstream signalling
pathways depending on the interaction between Wnt molecules and their specific receptors.
Historically, the Wnt pathway is classified as ”canonical” and ”non-canonical” pathway
(Figure 4.1). In the ”canonical” pathway (McDonald and Silver 2009), binding of Wnt
molecules to Frizzled/LEP transmembrane receptor complex results in dishevelled phos-
phorylation and inhibition of Axin, Gsk3b and APC complex, subsequently allowing β-
catenin to accumulate in the nucleus and interact with transcription factors of the TCF/LEF
family (Ricken et al., 2002; Gatcliffe et al., 2008; van ’t Veer et al., 2002). Although muta-
tions of APC and β-catenin are frequently observed in colorectal cancer (Vogelstein et al.,
1988a; Sparks et al., 1998), they are rare in EOC (Ueda et al., 2001; Gatcliffe et al., 2008),
with the exception of endometrioid subtypes (Wu et al., 2007). Among numerous non-
canonical pathways, Wnt/planar cell polarity (PCP) signalling and Wnt/Ca2+ signalling
are involved in tumourigenesis (Miller et al., 1999; Kikuchi and Yamamoto, 2008; Wang,
2009).
In cancers where Wnt pathway gene mutations are rare, the Wnt pathway can become
disregulated through epigenetic mechanisms, such as promoter hypermethylation (Klar-
mann et al., 2008; Valencia et al., 2009; Ying and Tao, 2009).The Wnt pathway extracel-
lular inhibitors , such as SFRPs family and WIF1, are frequently silenced by promoter
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hypermethylation in cancer including EOC (Takada et al., 2004; Veeck et al., 2006; Valen-
cia et al., 2009; Yu et al., 2009; Bennett et al., 2010; Deng et al., 2010; Su et al., 2010).
However, promoter methylation of the Wnt pathway has not been comprehensively studied
in EOC. The aim of the study was to systematically profile DNA methylation at promoter
CGIs of Wnt pathway genes and evaluate their role in tumour progression by assessing
their prognostic value in EOC.
4.2 Methods
4.2.1 Patients
Fresh frozen tumour biopsies were prospectively collected from patients enrolled on an
ongoing Scottish Gynaecology Clinical Trial Group (SGCTG)/National Cancer Research
Institute (NCRI) study ”DNA Methylation as a Predictor for Response and Progression-
Free Survival in Patients with Ovarian Cancer”. Tumours included in the present analysis
were restricted to those from patients with confirmed FIGO stages Ic, III and IV epithe-
lial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy,
excluding mucinous and clear cell tumours. These latter histological tumour types were
not included due to their different clinical outcome from other more common serous and
endometrioid ovarian tumours. Progression and survival status of the patient was exam-
ined 2 monthly for the first two years post-treatment, subsequently 6 monthly to 5 years
and annually thereafter. The primary end point in this study is the association of DNA
methylation with progression free survival (PFS), which is defined as the time after pa-
tients received first line chemotherapy to the first time that patients showed the progressive
disease measured by RECIST 1.0 criteria, or had early death due to ovarian cancer or other
causes. Information was collected, if available, on bulk of residual disease, stage, per-
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Figure 4.1: Schematic graph of the Wnt pathway. This graph is regenerated from Kyoto
Encyclopaedia of Genes and Genomes (KEGG) pathway database (entry ID: hsa04310).
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formance status, tumour grade, CA125 levels pre-treatment and after treatment, type of
treatment received, response to treatment defined by RECIST 1.0 criteria, CA125 levels
during treatment and overall survival, as defined as the time from start of chemotherapy to
death due to ovarian cancer or other causes. This trial has been approved by the MREC for
Scotland (reference number 01/165) and is carried out in accordance with the Declaration
of Helsinki. Genomic DNA was extracted as previously described (Strathdee et al., 1999).
Differential Methylation Hybridisation (DMH)
Samples were assayed on Agilent custom-designed microarrays by DMH in duplicates as
described in Method section in Chapter 3. Samples with more than 10% of the flagged
probes in duplicates were excluded from further analysis. Otherwise, they were treated
as missing data point (about 3%) and imputed by KNN algorithm (k=10). Probes with
high (>65000) and low (< mean + 1.96SD of negative controls) signal intensities were
excluded in the analysis and intro-array normalisation was done using MLDA package
tailored for DMH dataset (see Chapter 2). DMH ratio is the ratio of the signals from
McrBC mock digested and digested samples. DMH dataset is available at GEO (accession
ID: GSE23240).
4.2.2 qRT-PCR
qRT-PCR was done by Jenny Harsey at Institute for Cancer Research (Sutton, UK). Total
cellular RNA was received from Gen-Probe Life Sciences and quantified by nanodrop at an
optical density of ODλ260. Up to 1.2µg of RNA was reverse transcribed and cDNA synthe-
sised in duplicate 20µl reactions using the Superscript II reverse transcriptase kit (Invitro-
gen) according to manufacturer’s instructions. For qPCR individual TaqMan gene expres-
sion assays were obtained from Applied Biosystems, FZD4 (assay no. Hs00201853.m1),
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DVL1 (assay no. Hs00182896.m1), NKD1 (assay no. Hs00263894.m1), ROCK1 (assay
no.Hs00178463.m1), NFATC3 (assay no. Hs00190046.m1) andGAPDH (part no.4326317E)
were used. TaqMan Gene expression mastermix (Applied Biosystems) containing the en-
zyme AmpliTaq Gold was used for all reactions with the recommended cycling condi-
tions. Relative expression analysis was performed according to the relative standard curve
method.
4.2.3 Target Selection on Agilent Custom-designed Microarray
Genes involved in the Wnt signalling pathway were collected from Kyoto Encyclopae-
dia of Genes and Genomes (KEGG) (entry ID: hsa04310) (Kanehisa et al., 2006, 2010).
Promoter CGIs within 2kb of the transcription start site of the genes were obtained from
UCSC database (Rhead et al., 2010) and from a genome-wide prediction of CGIs (Bock
et al., 2007) as a supplementary set, both of which fulfil the mathematical model proposed
by Gardiner-Garden to define a CGI: CG content greater than 50%, length of sequence is
over 200bp and ratio of observed to expected CpGs is larger than 0.6 (Gardiner-Garden
and Frommer, 1987). The genome positions of targets are specified by Human Mar. 2006
(NCBI36/hg18) assembly. Out of 148 genes in the Wnt pathway, 137(92.6%) had a CpG
island within 2Kb of the promoter and these are represented by 302 MseI fragments (130-
6000bp) analysed by DMH.
Furthermore, the promoter CGIs of the genes involved in other signalling pathways/families
(p53 AKT/mTOR, MMR, HR, NHEJ, BRCA1/2, FA family, igLon family and Redox)
mainly collected from KEGG database were also targeted by the array. Evaluation and val-
idation of prognostic values of the promoter CGIs in these pathways are detailed in Chapter
5.
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Figure 4.2: The principle of Pyrosequencing and the output ProgramTM . This figure is
from England and Pettersson (2005).
4.2.4 Bisulfite Pyrosequencing
Bisulfite pyrosequencing is a quantitative measurement of methylation in CpG dinucleotides.
The unmethylated cytosine (C) is converted into thymine (T) after bisulfite treatment, but
the methylated cytosine (mC) is intact. Pyrosequencing synthesize the complementary
strands of single-stranded DNA templates. In each incorporation of nucleotide, pyrophos-
phate (ppi) is released and the light emission is proportional to the number of incorporations
(Figure 4.2).
Methylation at promoter region of DVL1 (Chr1: 1275096-1275129, sequence: CGAGG
CGTTTTTTGAGGTCGCGGGGCGTTCGCG, see Figure 4.3) was quantitated using bisul-
fite pyrosequencing. This sequence contains 7 CpG sites at chr1: 1275096, 1275102,
1275115, 1275117, 1275122, 1275126 and 1275128. Briefly, ovarian tumour genomic
DNA was bisulfite treated by EZ DNA MethylationTM Kit (ZYMO research, CA, USA).
Successful bisulfite modification was tested by CALPONIN-specific primer sets prior py-
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rosequencing (Teodoridis et al., 2005). The bisulfite treated samples were amplified by
PCR using forward primer GTAGGGTAGGGGAGATTT, reverse primer TCACTCCTC-
CCATCCTAAAC and sequencing primer GGGTAGGGGAGATTTT. The PCR conditions
were 95 ◦C 6 minutes, (95 ◦C 30 seconds, 60 ◦C 30 seconds and 72 ◦C 30 seconds) × 35
cycles, then 72 ◦C 5min. The PCR product is 151 base pair.
The Sepharose beads were used to purify the PCR product using a biotin-labelled primer.
The sepharose beads containing PCR products were purified, denatured and washed using
the Pyrosequencing Vacuum Prep Tool, then the sequencing primer was annealed to the
PCR products. Pyrosequencing was done in PyroMarkTM MD system (Pyrosequencing,
USA). The methylation was quantified as the percentage of methylated cytosine over the
sum of methylated and unmethylated cytosines using Pyro Q-CpGTM software. The non-
CpG cytosine was used as internal control to verify bisulfite conversion. Each sample had
duplicates and the average of duplicates was used in the analysis.
4.2.5 Statistical Analysis
All the data analysis was done in R (2.10.1) and SPSS (version 16). The R scripts in this
analysis are in Appendix scripts.
End point
The primary end point is progression free survival (PFS), which was measured by the
time from treatment started to the progressive disease defined as either clinical evidence
of progressive disease based on response evaluation criteria in solid tumours (RECIST 1.0)
(Therasse et al., 2000) or elevated CA125 levels as defined previously (Rustin et al., 1996)
and clinical or radiographic findings indicative of progression. PFS is considered as more
objective and valuable end point to provide an estimate of biological effect of chemother-
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Figure 4.3: Genomic location of the region close to DVL1 tested by bisulfite pyrosequenc-
ing, targeted by Agilent custom-designed microarray and Illumina HumanMethylation27.
Purple circle: methylation of the region is correlated with PFS at p < 0.05 on custom-
designed microarray (Chr1: 1275054-1275113) (see Result) and Illumina HumanMethyla-
tion27 BeadChip (Chr1: 1275054-1275103). Orange circle: CpG sites tested by bisulfite
pyrosequencing (Chr1: 1275096-1275129).
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apy, thus was used a primary end point in this analysis.
Cox proportional hazards model is used to examine the correlation between methylation
(a continuous variable) and PFS, as shown in formula 4.1.
h (t) = h (t0) exp (βM) (4.1)
Here, methylation is the explanatory variable (M ). h (t0) is the baseline hazard function
and corresponds to the probability of disease progression when the explanatory variable is
zero. β is the regression coefficient giving the proportional changes that can be expected in
the hazard, related to the changes of explanatory variable. Hazard ratio is h(t)
h(t0)
, indicating
the relative hazard of disease progression in every unit increase of methylation.
The secondary end point is response measured by RECIST 1.0 criteria (Therasse et al.,
2000) and categorised as complete response, partial response, progressive disease and sta-
ble disease (see Table 1.2 in Chapter 1).
Logistic regression model is used to test the relationship between methylation and re-
sponse, as shown in formula 4.2.
P
1− P = exp (α + βM) (4.2)
Methylation is the explanatory variable (M ). α is the intercept indicating the baseline
performance when explanatory variable is zero. β is the regression coefficient representing
the change of probability of outcome (poor response in this case). exp (β) is the odd ratio
corresponding to a one unit increase of methylation.
4.2 Methods 138
Power estimation in the screening study
With PFS as the end point, the Cox proportional hazard model was used to assess the corre-
lation between methylation and survival time. Therefore, we estimated the required sample
size for the Cox model using the formula 4.3 and 4.4 described before (Schoenfeld, 1983;
Tong and Zhao, 2008).
N =
(
µ1−α/2 + µ1−β
)2
(logθ)2ϕ(1− p)p (4.3)
FDR =
piα
pi0α + (1− pi0(1− β) (4.4)
Here, µγ indicates the γ-quantile of the standard normal distribution; θ is the hazard
ratio; ϕ is the probability of an uncensored observation; p is the methylation frequency of
loci in ovarian cancer; pi0 is the proportion of true null hypotheses; α is the significant level
and 1− β is the average power expected on the microarray.
The initial screening set consisted of DMH data from 120 tumours, with 111 subse-
quently shown to have suitable data quality and 102 patients had disease progression (see
results). To estimate approximate statistical power of this screening set prior to analysis,
we assumed 5% of the loci examined in the Wnt pathway were true positives and split
patients into two groups based on the median methylation level at each locus (in the subse-
quent analysis methylation levels have been treated as a continuous variable, meaning we
are underestimating the study power). With a hazard ratio at 1.75 and false discovery rate
(FDR)(Benjamini and Hochberg, 1995) less than 50%, the estimated average power of the
screening study is 0.8 (Table 4.1).
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power FDR true positive significant uncensored (ϕ) Hazard methylation Sample
(1− β) (1− pi0) level (α) ratio (θ) frequency (p) size (N )
0.9 0.5 0.05 0.05 0.92 1.75 0.5 148
0.8 0.5 0.05 0.04 0.92 1.75 0.5 111
0.7 0.5 0.05 0.04 0.92 1.75 0.5 95
Table 4.1: Estimated power of the analysis in the screening study
Power estimation in the validation study
The subsequent validation study was independently analysed by DMH a year later and was
based on the maximum feasible within existing financial constraints. The power of analysis
for each biomarker was estimated using the formula 4.4 and 4.5 (Hsieh and Lavori, 2000).
Z1−β =
√
Nσ2(logθ)2ϕ− Z1−α (4.5)
Here, σ2 is the variance of DMH ratios of individual locus, θ is the hazard ratio of per
unit increase of DMH ratio calculated from univariate Cox model using the locus as the
covariate. Both parameters were estimated in the evaluation study. ϕ is the percentage
of uncensored data and N is the number of samples. Z1−α and Z1−β are standard normal
deviates at the desired one-sided significance level α and power 1 − β. Calculation of
the statistical power for the sample size planned (n = 50) assumed the true positive loci
rate was 40% (following on from the FDR rate observed in the screening set at p < 0.05)
and using a FDR of 10%. Sample size calculations were carried out using the observed
hazard ratios per unit change and observed variable variances from the screening data set.
Testing was one-sided as associations of interest will be in the same direction as in the
screening set. Table 4.2 gives the estimated power for individual locus. The validation
power achieved for the largest observed effect size in the screening set was 88%, but only
30% for the median observed effect size. Among the 5 loci with FDR less than 10% (see
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results) from the screening set the median power was 70%.
genes Hazard Variance Squared standardised Significant power
ratio (∆) (σ2) effect size level (α) (1− β)
(σ2log(∆)2)
FZD4 123.3 0.01 0.14 0.05 0.73
CCND1$ 3.9 0.11 0.21 0.07 0.88
NKD1 31.4 0.01 0.1 0.04 0.57
TAF8/CCND3 0.5 0.24 0.12 0.05 0.64
DVL1 12.1 0.02 0.13 0.05 0.69
FRAT1 0.3 0.05 0.08 0.03 0.39
ROCK1 2263.1 <0.01 0.09 0.04 0.49
PPP2R2B 34 <0.01 0.05 0.01 0.19
CTBP1$ 2.3 0.1 0.07 0.03 0.37
CCND1$ 48.6 <0.01 0.07 0.03 0.34
NKD2 10.6 0.01 0.07 0.03 0.35
FZD9 7.4 0.01 0.06 0.02 0.27
EEFSEC/RUVBL1 2.4 0.06 0.05 0.01 0.16
AXIN1 24.5 <0.01 0.05 0.01 0.17
C4orf42/CTBP1$ 1.9 0.13 0.05 0.02 0.22
WNT4 41.1 <0.01 0.05 0.01 0.17
LRP5 5.7 0.01 0.04 0.01 0.11
NFATC3 6.4 0.01 0.05 0.01 0.19
FRAT1 0.7 0.47 0.06 < 0.0005 < 0.007
SFRP5 51.2 <0.01 0.04 0.01 0.08
Table 4.2: Estimated power of the analysis in the validation study. $Different loci within
the promoter region of CCND1 and CTBP1 were identified.
Determination of methylation clusters
Methylation of loci were defined by DMH ratios of the probes targeting the same locus
being significantly greater than unmethylated regions selected from chromosome 16 and
the mitochondrial genome. One-side Mann-Whitney U test was used to test the difference
and the significance level was set at p < 0.0003 based on Bonferroni correction (see Mann-
Whitney Test in section 3.2.4 of Chapter 3).
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Unsupervised hierarchical clustering was performed using methylation status of MseI
fragments in each pathway using Euclidean distance and average linkage method. The
significance of the clusters was tested by bootstrap resampling method as previously de-
scribed (Shimodaira, 2004). Pearson Chi-square test was used to examine the dependency
between categorical clinical parameters (stage, grade, histology, response, and chemother-
apy) and methylation clusters. One-way ANOVA was used to examine the difference of
age in clusters. PFS and OS of the patients in the clusters were tested by log rank test. The
significance level was set at two-sided p ≤ 0.05.
Survival analysis
The workflow of the survival analysis is illustrated in Figure 4.4 (Survival Analysis). Cox
proportional hazard model was used to examine for the association between methylation
in each pathway and patient survival. The average DMH ratios were used as continuous
variable in the Cox model. The variables applied for adjustment in multivariate analysis
included histological type, FIGO stage, grade and age with potential confounding effects.
The impact of DNA methylation on patients’ progression free survival was determined by
examining the relative hazard ratios with the increase of methylation level. The signifi-
cance of estimated hazard ratios was tested by Score test.
In univariate survival analysis, the significant level was considered at the 5% level for
clinical parameters/individual biomarker and at the 10% FDR for multiple test correction
in the screening and validation study.
Kaplan-Meier curves were used to show the progression free survival in the patients
with high/low methylation at promoter CGI, as well as those with high/low methylation
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index (MI) (see ”Construction of the multivariate Cox model”). Since average methylation
frequency of the Wnt pathway genes observed is approximately 25%, the third quartile
was used as the cut-point for high/low methylation. Kaplan-Meier survival curves of two
groups were compared by the log-rank test (two-sided). The significance of log-rank test
of two groups with high/low MI was assessed by a permutation test applied to the entire
variable selection and model fitting process.
The correlation between response and promoter methylation in the Wnt pathway was
tested by logistic regression. This is restricted to patients with measurable disease at
baseline. Patients were classified as responders (complete or partial response) or non-
responders (stable disease or progressive disease) according to RECIST 1.0 criteria.
Construction of the multivariate Cox model
The DMH data of late-stage tumours from the screening and validation study were stan-
dardised across the samples within the study as Z scores. The variance of the DMH data
within the study was estimated by trimming 1% of the data at both sides, which is a robust
estimation of the variance accommodating the outlier observations. A multivariate Cox
model was constructed using Z score as a continuous variable. The covariates in the final
model were selected by likelihood ratio forward stepwise algorithm from clinical param-
eters (stage, grade, histology and age), and those DNA methylation biomarkers identified
from the univariate PFS analysis, which were independent from clinical parameters and
have been validated in an independent patient cohort. The likelihood ratio forward step-
wise method used maximum likelihood ratio test p < 0.05 for entry and p > 0.1 for
removal of the variables from the model. Therefore, only the variables with the strongest
association with PFS and independent contribution to the model were selected into the fi-
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nal model, while those variables that did not significantly improve the model were left out.
The variables included and excluded from the final model were shown in Appendix 4-1.
Subsequently, a methylation index (MI) was calculated from the multivariate Cox model.
The predictive value of MI and degree of over-fitting of the multivariate Cox model was
estimated by LOOCV as described in the next section. The workflow of this analysis in the
Wnt pathway was illustrated in Figure 4.4 (Model Construction).
The Receiver Operator Characteristic (ROC) curves considering the censored data were
generated as described before (Heagerty et al., 2000) to evaluate the sensitivity and speci-
ficity of MI and the prognostic index (PI) estimated from the prognostic factors (histology
type, stage, age and grade) that have been used in clinical practice.
Leave-one-out cross validation and permutation test
Leave-one-out cross validation (LOOCV) (Verweij and Van Houwelingen, 1993) was used
to estimate the predictive value of our final multivariate Cox model. In each iteration of
LOOCV, one sample was left out and the multivariate Cox model was constructed by the
rest of the samples using exactly the same process as our modelling procedure for feature
selection and model construction. Given both DNA methylation biomarkers selected into
the final Cox model had FDR< 10%, we simplified the feature selection process in LOOCV
using FDR< 10% as the significant cut-point, therefore, in each iteration of model con-
struction, only the biomarkers with FDR< 10% and independent from clinical parameters
were considered to be included in the multivariate model construction and likelihood ratio
forward stepwise algorithm was used to select the significant and independent covariates
into the model.
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The coefficients in the multivariate Cox model were used to calculate a MI for each
sample. In LOOCV, the omitted sample was classified as high risk of progressive disease
or low risk based on its MI predicted from the multivariate Cox model constructed using
the remaining samples above or below the third quartile of the methylation indices for the
remaining cases in the training set. The entire procedure was repeated until each case had
been omitted once and had been assigned into a risk group. Therefore, this cross-validated
risk group for each case was determined based on a model that did not use that case in the
model construction.
Kaplan-Meier survival curve was generated for the predicted risk groups for progres-
sive disease and log-rank statistic was computed. To assess the significance of log-rank
statistic and the degree of over-fitting, we performed a phenotype permutation test 500
times by shuffling among the cases and the entire cross-validation process described above
was repeated. For each random shuffling, the predicted high/low risk groups were gen-
erated as described above and log-rank statistics was calculated between two risk groups.
Permutation test provided a null-distribution of log rank test, so the probability that the log
rank statistics in the null distribution are larger than the log rank statistic between the risk
groups predicted by LOOCV without cases shuffling is the chance we obtain this log rank
statistic randomly.
4.2.6 The Cancer Genome Atlas (TCGA) Dataset
The level 3 expression dataset on Affymetrix HGU133A microarrays of serous tumours
were obtained from TCGA data portal (http://cancergenome.nih.gov/dataportal).
The microarray data have been pre-processed and normalised across the samples (see
http://tcga-data.nci.nih.gov/docs/TCGA_Data_Primer.pdf).
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4.3 Results
4.3.1 Patients
Epithelial ovarian tumours prospectively collected through a cohort study, were analysed by
differential methylation hybridisation (DMH) at 302 Wnt pathway associated loci. Muci-
nous and clear cell cancers were excluded due to their different clinical outcome from more
common serous and endometrioid EOC (Sugiyama et al., 2000; Rosen et al., 2009). In an
initial screening stage, 120 ovarian tumour samples, sequentially collected in a prospective
cohort study were used. Four samples were excluded from the analysis due to poor quality
of signal intensities in over 10% of probes in the duplicates and five samples were excluded
as methylation controls did not reach acceptance criteria. Therefore, 111 tumours remained
in the analysis. In a subsequent validation stage, 61 further tumours collected through the
same protocol were examined. Eleven samples were excluded due to not reaching accep-
tance criteria, so 50 tumours remained in the analysis. Among the loci with FDR< 10%
from the screening set the median power was 70%. In total, we examined DNA methyla-
tion at CGIs at the promoter regions of Wnt pathway genes, as defined by KEGG (entry
ID: hsa04310)(Kanehisa et al., 2006, 2010), in 161 EOC. The genes in the Wnt pathway
frequently methylated (>5%) in ovarian cancer and unmethylated in PBMC are shown in
Appendix 4.2. Following the REMARK recommendations (McShane et al., 2005), the full
details of clinical parameters in Table 4.3 and their relationship to patient outcome are pre-
sented in Table 4.4 and 4.5.
Using unsupervised hierarchical clustering of methylation status, two groups of patients
(n1 = 17, p = 0.05 and n2 = 15, p < 0.001) were identified, weakly correlated with
stage (p = 0.071), but not associated with grade (p = 0.156), histology (p = 0.106)
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Clinical Parameters 
Screening 
N=111 (%) 
Validation  
N=50 (%) 
Age Range (32,83) (44,86) 
mean (95% CI), Years 61 (59,63) 64 (61,66) 
FIGO Stage 
Ic 2 (1.8) 8 (16.0) 
III 85 (76.6) 35 (70.0) 
IV 24 (21.6) 7 (14.0) 
Grade 
G1 4 (3.6) 4 (8.0) 
G2 16 (14.4) 10 (20.0) 
G3 71 (64.0) 29 (58.0) 
unknown 20 (18.0) 7 (14.0) 
Histology 
Serous 42 (37.8) 19 (38.0) 
Endometrioid 8 (7.2) 3 (6.0) 
Other 35 (31.5) 28 (56.0) 
Unknown 26 (23.4) 0 
Chemotherapy 
Platinum 26 (23.4) 19 (38.0) 
Platinum + Taxane 67 (60.4) 24 (48.0) 
Other 18 (16.2) 3(6.0) 
 missing 0 4 (8.0) 
Response 
CR  27 (24.3) 2 (4.0) 
PR 20 (18.0) 5 (10.0) 
SD 13 (11.7) 3 (6.0) 
PD 8 (7.2) 5 (10.0) 
NE 14 (12.6) 20 (40.0) 
missing 29 (26.1) 15 (30.0) 
Overall survival 
(OS) 
Alive/censored 37 (33.3) 27 (54.0) 
Dead 74 (66.7) 19 (38.0) 
missing 0 4 (8.0) 
Median (95% CI), Years 2.52 (1.67,3.37) 2.79 (2.17, 3.41) 
Progression free 
survival (PFS) 
Not progressed 9 (8.1) 14 (28.0) 
Progressed 102 (91.9) 32 (64.0) 
missing 0 4 (8.0) 
Median (95% CI), Years 0.92 (0.76,1.08) 1.11 (0.79, 1.43) 
 Table 4.3: Patient characteristics. Response was measured by RECIST 1.0; the patients
with complete/partial response are the responders to chemotherapy, while the patients with
progressive or stable disease are those who did not response to chemotherapy CR: com-
plete response; PR: partial response; SD: stable disease; PD: progressive disease; NE: not
measurable
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and age (p = 0.726). However, two groups of patients have significant difference in PFS
(p = 0.007, log rank test) and borderline difference in OS (p = 0.048, log rank test) (Figure
4.5).
4.3.2 Methylation of the Wnt pathway and PFS
To evaluate the association between methylation at promoter CGIs of the Wnt pathway and
tumour progression, we used average DMH ratios as a continuous variable in the univariate
Cox model with PFS as the endpoint (see methods). In the screening study we identified
methylation of 20/302 loci at promoter CGIs of 17 genes that may be associated with PFS
(p < 0.05), with five loci at genes FZD4, DVL1, CCND1, CCND3 and NKD1 significant at
FDR < 10% after multiple test correction (see univariate survival analysis in Table 4.6).
In an independent patient cohort (n = 50), 14 out of the 20 loci identified in the evaluation
stage were still prognostic, p ≤ 0.05 and FDR ≤ 10% (Table 4.7).
The odds ratios of 14 loci identified as having p ≤ 0.05 and FDR ≤ 10% in univari-
ate analysis from the validation study were adjusted by age, stage, grade and histological
type and the patients were stratified into three groups who either received platinum alone,
combination of platinum and taxane, or other platinum-based treatment. Hypermethylation
at 6 loci was significantly associated with poor PFS independent from clinical parameters
(adjusted p < 0.05): CGIs at FZD4, DVL1, ROCK1, NFATC3, FZD9 and NKD1 (see mul-
tivariate survival analysis in Table 4.8 and Figure 4.6A-F).
In addition to the association with PFS observed, the patients with higher methylation
level at gene DVL1, FZD4 and NKD1 also had higher risk of death (p < 0.05, FDR ≤
20%) (Table 4.9).
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Figure 4.5: Unsupervised hierarchical clustering of binary DNA methylation data in 106
frequently methylated MseI fragments (row) in the Wnt pathway of 161 epithelial ovarian
tumours (column). Red: methylated fragment; Green: unmethylated fragment. P: Periph-
eral Blood Mononuclear Cell (PBMC); N: adjacent samples of benign tumours. Distance:
Euclidean distance; Linkage method: average linkage. Methylation frequency of MseI
fragments are from 5% to 95% and size are from 130bp to 2500bp.
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genes 
Univariate PFS analysis (n=111) 
HR1 95% CI2 p value3 FDR4 
FZD4 123.3 (8.9, 1701.30) <0.001*** <0.1& 
CCND1$ 3.9 (1.8, 8.3) <0.001*** <0.1& 
NKD1 31.4 (3.7, 268.3) 0.002** <0.1& 
TAF8||CCND3 0.5 (0.3, 0.8) 0.002** <0.1& 
DVL1 12.1 (2.6, 55.5) 0.001** <0.1& 
FRAT1 0.3 (0.1, 0.7) 0.005** 0.2 
ROCK1 2263.1 (7.5, 681782.4) 0.008** 0.3 
PPP2R2B 34.0 (2.4, 476.6) 0.009** 0.4 
CTBP1$ 2.3 (1.2, 4.3) 0.015* 0.4 
CCND1$ 48.6 (2.1,1108.6) 0.015* 0.4 
NKD2 10.6 (1.5, 74.1) 0.017* 0.5 
FZD9 7.4 (1.4, 41.0) 0.021* 0.5 
EEFSEC||RUVBL1 2.4 (1.2, 5.2) 0.021* 0.5 
AXIN1 24.5 (1.4, 423.3) 0.028* 0.6 
C4orf42||CTBP1$ 1.9 (1.1, 3.3) 0.030* 0.6 
WNT4 41.1 (1.3, 1282.7) 0.034* 0.6 
LRP5 5.7 (1.1, 30.2) 0.041* 0.6 
NFATC3 6.4 (1.1, 37.6) 0.042* 0.6 
FRAT1 0.7 (0.6, 1.0) 0.040* 0.6 
SFRP5 51.2 (1.1, 2386.6) 0.045* 0.6 
 
Table 4.6: Univariate progression free survival analysis of selected promoter methyla-
tion of Wnt pathway in the screening set (n = 111). Abbreviations: HR, hazard ra-
tio; CI, confidence interval; FDR, false discovery rate. 1Hazard ratio per unit increase
in DMH ratio (continuous variable) estimated from Cox proportional hazard regression
model.-2Confidence interval of the estimated hazard ratio. -3p value of Score test (two-
sided). -4multiple test correction based on 302 loci. &FDR ≤ 0.1; *p ≤ 0.05;
**p ≤ 0.01;***p ≤ 0.001.$Different loci within the promoter region of CCND1/CTBP1
were identified
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genes 
Univariate PFS analysis (n=50) 
HR1 95% CI2 p value3 FDR4 
FZD4 2.7 (1.0, 7.0) 0.02* <0.1& 
CCND1$ 1.2 (0.5, 3.1) 0.335 0.3 
NKD1 2.3 (1.0, 5.3) 0.025* <0.1& 
TAF8||CCND3 1.3 (0.9, 1.8) 0.07 0.1& 
DVL1 4.3 (1.3, 13.8) 0.01* <0.1& 
FRAT1 1.3 (0.7, 2.1) 0.2 0.2 
ROCK1 4.8 (1.1, 20.4) 0.015* <0.1& 
PPP2R2B 1.9 (0.1, 27.7) 0.315 0.3 
CTBP1$ 1.4 (0.8, 2.4) 0.105 0.1& 
CCND1$ 311.9 (2.7, 36132.3) 0.01* <0.1& 
NKD2 2.1 (0.9, 4.6) 0.04* <.01& 
FZD9 1.8 (0.9, 3.4) 0.04* <0.1& 
EEFSEC||RUVBL1 1.7 (1.1, 2.7) 0.01* <0.1& 
AXIN1 2.5 (1.0, 6.5) 0.025* <0.1& 
C4orf42||CTBP1$ 1.6 (0.93,2.6) 0.045* <0.1& 
WNT4 3.2 (1.23,8.55) 0.01* <0.1& 
LRP5 2.7 (1.11,6.53) 0.02* <0.1& 
NFATC3 6.6 (1.46,29.3) 0.005** <0.1& 
FRAT1 1.2 (0.94,1.49) 0.08 0.1& 
SFRP5 2.4 (0.99,5.84) 0.025* <0.1& 
 
Table 4.7: Univariate progression free survival analysis of selected promoter methylation
of Wnt pathway in the validation set (n = 50). Abbreviations: HR, hazard ratio; CI,
confidence interval; FDR, false discovery rate. 1Hazard ratio per unit increase in DMH
ratio (continuous variable) estimated from Cox proportional hazard regression model.-
2Confidence interval of the estimated hazard ratio. -3p value of Score test (one-sided).
-4multiple test correction based on 20 loci. &FDR ≤ 0.1; *p ≤ 0.05; **p ≤ 0.01.
$Different loci within the promoter region of CCND1/CTBP1 were identified
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genes 
Multivariate PFS analysis (n=111) 
HR1 95% CI2 adjusted p value3 
FZD4 37.6 (2.0, 694.6) 0.015* 
NKD1 14.7 (1.3, 168.2) 0.031* 
DVL1 7.5 (1.5, 37.2) 0.014* 
ROCK1 3092.3 (5.8, 1650876.5) 0.012* 
CCND1 5.4 (0.1, 219.4) 0.376 
NKD2 5.6 (0.8, 39.3) 0.82 
FZD9 6.4 (1.1, 36.4) 0.036* 
EEFSEC||RUVBL1 2.2 (0.9, 5.6) 0.105 
AXIN1 3.4 (0.1, 104.7) 0.48 
C4orf42||CTBP1 1.0 (0.5, 2.0) 0.901 
WNT4 4.5 (0.1, 170.0) 0.414 
LRP5 3.1 (0.6, 18.0) 0.198 
NFATC3 12.6 (2.0, 78.6) 0.007*** 
SFRP5 9.7 (0.1, 964.1) 0.333 
 
Table 4.8: Multivariate progression free survival analysis of selected promoter methylation
of Wnt pathway in the screening set (n = 111). Abbreviations: HR, hazard ratio; CI,
confidence interval. 1Hazard ratio per unit increase in DMH ratio (continuous variable)
estimated from Cox proportional hazard regression model.-2Confidence interval of the es-
timated hazard ratio. -3p value adjusted by histology, grade, stage and age. Age was used
as a continuous variable and histology, grade and stage were used as categorical variables.
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.005.
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Figure 4.6: Kaplan-Meier plots of progression free survival. High/low methylation at A,
FZD4 CGI; B: DVL1 CGI; C: ROCK1 CGI; D: NFATC3 CGI; E: NKD1 CGI; F: FZD9
CGI. The cut-off was determined by the third quartile in 157 patients (n=161, 4 patients
have PFS missing). Time is from the patients received the first line of chemotherapy.
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genes 
Univariate Overall Survival (OS) (N=111) 
HR1 95% CI2 p value3 FDR4 
FZD4 49.4 (2.5, 964.3) 0.01* 0.1& 
NKD1 21.3 (1.5, 299.2) 0.023* 0.2$ 
DVL1 14.0 (2.6, 75.0) 0.002*** <0.1& 
ROCK1 8.6 (0, 5642.9) 0.516 1 
NKD2 1.3 (0.2,11.2) 0.804 1 
FZD9 3.3 (0.5, 23) 0.224 1 
CCND1 33.4 (0.8, 1382.2) 0.065+ 0.5 
EEFSEC||RUVBL1 1.4 (0.6, 3.4) 0.505 1 
AXIN1 3.1 (0.1, 85.4) 0.506 1 
C4orf42||CTBP1 1.4 (0.6, 3.4) 0.505 1 
WNT4 5.9 (0.1, 335.6) 0.388 1 
LRP5 4.6 (0.6, 33.8) 0.13 0.9 
NFATC3 4.5 (0.6, 35.2) 0.148 0.9 
SFRP5 1.1 (0, 110.1) 0.967 1 
 
Table 4.9: Univariate overall survival analysis of selected promoter methylation of Wnt
pathway in the screening set (n = 111). Abbreviations: HR, hazard ratio; CI, confidence
interval; FDR, false discovery rate. 1Hazard ratio per unit increase of DMH ratio (con-
tinuous variable) estimated from Cox proportional hazard regression model.-2Confidence
interval of the estimated hazard ratio.-3p value of Score test.-4multiple test correction in
the validation study based on 14 validated DNA methylation biomarkers. $FDR ≤ 0.2;
&FDR ≤ 0.1; +p ≤ 0.1; *p ≤ 0.05; **p ≤ 0.01;***p ≤ 0.005
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4.3.3 Expression and progression free survival in TCGA dataset
Promoter hypermethylation is frequently associated with gene inactivation (Illingworth and
Bird, 2009), therefore, we further examined the correlation between expression and PFS of
the 6 linked candidate genes that were validated in the independent cohort and independent
from clinical parameters. This was examined in a larger independent cohort of patients
(n = 321) with serous ovarian cancer in stage III and IV generated by The Cancer Genome
Atlas (TCGA) Pilot established by the NCI and NHGRI (unpublished). Among the 6 genes,
NKD1 is not presented on the microarray. For the remaining 5 genes, low expression of
FZD4 and DVL1 indicated a higher risk of recurrent disease (FZD4: HR = 0.8; 95% CI
(0.7, 1.0); adjusted p = 0.009; DVL1: HR = 0.8; 95% CI (0.6, 1.0); adjusted p = 0.022),
independent from stage, grade, age and residual disease (Table 4.10). The reduction of ex-
pression of FZD4 and DVL1 correlating with poor PFS is consistent with promoter methy-
lation leading to the down-regulation of the genes.
RNA levels of FZD4 and DVL1 were measured by qRT-PCR in a subset of tumours, with
sufficient quality of RNA, from the SGCTG cohort. Low expression of DVL1 was signif-
icantly associated with promoter hypermethylation (n = 27, p = 0.013) and we found
weak dependence between expression and methylation in gene FZD4 (n = 25, p = 0.066)
(Table 4.11). However, no evidence of association between methylation and expression for
NKD1, ROCK1, NFATC3 was observed in this small cohort of tumours.
4.3.4 Association of methylation at DVL1 with response
To examine the role of the 6 DNA methylation biomarkers described above in chemore-
sponsiveness of ovarian cancer, we assessed the relationship between methylation and pa-
tients’ response to first line platinum-based chemotherapy and found an increased methyla-
tion of DVL1 was weakly correlated with poor response (Table 4.12). The odd ratio of the
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Gene 
Univariate PFS analysis 
 
Multivariate PFS analysis 
HR1 95%CI2 p value3 FDR4
 
HR1 95%CI2 p value5 
FZD4 0.8 (0.7, 0.9) 0.004** <0.1&
 
0.8 (0.7, 1.0) 0.009** 
NKD1 - - -  
 
- - - 
DVL1 0.8 (0.7, 1.0) 0.041* 0.1& 
 
0.8 (0.6, 1.0) 0.022* 
ROCK1 0.8 (0.4, 1.5) 0.444 0.8 
 
0.9 (0.4, 1.8) 0.709 
FZD9 0.8 (0.4, 1.7) 0.560 0.8 
 
0.7 (0.3, 1.6) 0.345 
NFATC3 1.0 (0.6, 1.6) 0.978 1 
 
1.2  (0.7, 2.1) 0.441 
 
Table 4.10: Survival analysis of expression of 6 candidate genes in the Wnt pathway in
TCGA dataset (n = 321). Abbreviations: PFS, progression free survival; HR, hazard
ratio; CI, confidence interval; FDR, false discovery rate.1Hazard ratio per unit increase in
expression estimated from Cox proportional hazard regression model.-2Confidence interval
of the estimated hazard ratio.-3p value of Score test.-4Multiple test correction based on
6 loci.-5p value adjusted by stage, grade, residual disease and age. Age was used as a
continuous variable; stage, grade and residual disease were used as categorical variables.
&FDR ≤ 0.1; *p ≤ 0.05; **p ≤ 0.01
patients with progressive or stable disease (n = 29) to the patients with partial or complete
response (n = 54) in every unit increase of methylation Z score is 1.6 (95% CI: 1.0-2.6,
p = 0.043, FDR = 15%). Again consistent with the methylation data is that decreased ex-
pression of DVL1 was related to poor response to platinum-based chemotherapy in a large
patient cohort collected by TCGA (PD+SD (n = 36) vs. PR+CR (n = 217), OR = 0.5,
95% CI 0.3-0.9, p = 0.035).
4.3.5 Wnt pathway methylation index in late-stage EOC
To identify the best methylation predictors of PFS in the ovarian tumours from both screen-
ing and validation sets, the average DMH ratio of each locus was transformed to a Z score.
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Gene Expression 
Methylation p 
value1 Hypermethylation Hypomethylation 
FZD4 
High expression 0 7  
Low expression 7 11 0.066+ 
DVL1 
High expression 0 7  
Low expression 10 10 0.013* 
NFATC3 
High expression 0 7  
Low expression 4 16 0.276 
ROCK1 
High expression 0 7  
Low expression 2 18 0.5413 
NKD1 
High expression 3 3  
Low expression 6 13 0.903 
 
Table 4.11: Correlation between expression and methylation. 1P value: Fisher’s exact test
(one sided) in cases samples in the group are smaller than 5; +P ≤ 0.1; *p ≤ 0.05
We excluded 10 Stage I tumours from 161 tumours since these may be biologically distinct
entities and patients with early-stage ovarian cancer have much better clinical outcome
than patients with late-stage cancer (Trope and Kaern, 2007). From the Z scores of 151
patients with late-stage EOC (stage III and IV), we constructed a multivariate Cox model,
of which the covariates were selected by likelihood ratio (LR) forward stepwise algorithm
from clinical parameters (age, stage, grade and histological type) and promoter methyla-
tion at FZD4, DVL1, NKD1, ROCK1, FZD9 and NFATC3 (see Methods). The final model
includes two best predictors at DVL1 (HR = 1.21; 95% CI 1.03 to 1.43; p = 0.02) and
NKD1 (HR = 1.28; 95% CI 1.05 to 1.57; p = 0.02).The hazard ratio (HR) represents the
relative risk per unit increase in Z score. The remaining variables including clinical param-
eters and 4 methylation biomarkers were not selected into the model due to not meeting the
entry criteria in forward stepwise method (see Methods). A methylation index (MI) calcu-
lated from this model (MI = 0.25ZNKD1+0.2ZDV L1, Z denotes Z score) can identify two
distinct prognostic groups using the third quartile of the index as the cut-off (HR = 2.72;
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genes 
Logistic regression (Response1: PR+CR n=54; PD+SD n=29) 
OR2 95% CI3 p value4 FDR5 
FZD4 1.3 (0.8, 1.9) 0.270 0.32 
NKD1 1.4 (0.9, 2.1) 0.115 0.23 
DVL1 1.6 (1.0, 2.6) 0.043* 0.15$ 
ROCK1 1.0 (0.6, 1.4) 0.875 0.88 
FZD9 1.3 (0.8, 2.0) 0.239 0.34 
NFATC3 1.5 (1.0, 2.0) 0.051+ 0.15$ 
 
Table 4.12: Response and methylation of 6 candidate genes in the Wnt pathway in the com-
bined analysis of screening and validation set. Abbreviations: OR, odd ratio; CI, confidence
interval; FDR, false discovery rate. 1Response to first line chemotherapy was measured by
RESIST 1.0; the patients with complete/partial response are the responders to chemother-
apy, while the patients with progressive or stable disease are those who did not response
to chemotherapy. -2Odd ratio of the patients had poor response to chemotherapy (PD+SD,
n = 29) to the patient with good response to chemotherapy (CR+PR, n = 54) per unit
increase of Z scores.-3Confidence interval of the estimated odd ratio.-4p value of score test
of logistic regression model.-5Multiple test correction. $FDR ≤ 0.2; +p ≤ 0.1; *p ≤ 0.05
95%CI (1.74, 4.25); log rank test p = 4.1× 10−6; permutation test p = 4× 10−3) (Figure
4.7). Leave-One-Out Cross Validation (LOOCV) was used to assess the predictive value of
the multivariate Cox model in 151 late-stage EOCs. As shown in Figure 4.8, the patients
with high/low predicted MI in LOOCV have distinct PFS (p = 5.75× 10−4, log rank test;
p < 0.01, permutation test).
4.3.6 Bisulfite pyrosequencing
Bisulfite pyrosequencing has been used as a ’gold standard’ in the measurement of methy-
lation, therefore, methylation at promoter region of DVL1 was examined by bisulfite py-
rosequencing in the tumours used in the screening set. Using the average methylation at
7 CpG sites targeted by bisulfite pyrosequencing, we found the correlation between DMH
ratios (chr1: 1275054-1275112) and bisulfite pyrosequencing (chr1: 1275096-1275129)
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Figure 4.7: Kaplan-Meier plots of progression free survival in the patients with high/low
methylation index (MI) estimated from the multivariate Cox model in late-stage ovarian
cancer. The cut-off was determined by the third quartile in 148 patients (n = 151, 3 patients
have PFS missing). Time is from the patients received the first line of chemotherapy.
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Figure 4.8: Kaplan-Meier plot of PFS in the risk groups predicted by leave-one-out cross
validation. MI: predicted methylation index. Blue: patients with low predicted MI. Green:
patients with high predicted /textitMI. The third quartile of MI of the training set was used
to determine the high/low MI of the test observation.
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Figure 4.9: Correlation between DMH ratios at Chr1: 1275054-1275113 and bisulfite py-
rosequencing at the locus Chr1:1275996 at promoter region of DVL1.
(n = 41, spearman correlation ρ = 0.417, p = 0.006), though methylation level at this
region is generally low (<10%)(Figure 4.9).
4.4 Discussion
We examined DNA methylation at CGIs at the promoter regions of Wnt pathway genes, as
defined by KEGG (entry ID: hsa04310)(Kanehisa et al., 2006, 2010), in 161 EOC. Using
average DMH ratio as a continuous variable we identified 6 loci (FZD4, DVL1, ROCK1,
NFATC3, FZD9 and NKD1) of which methylation was associated with PFS in screening
and validation tumour cohorts and are independent from known clinical prognostic fea-
tures.
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4.4.1 Systematic bias in DMH assay
As with any microarray experiment, systematic bias can be introduced from any of the mul-
tiple steps of DMH: such as, DNA preparation, hybridisation and image scan. In particular,
DMH based on McrBC restriction enzyme, involves extra steps of digestion, ligation and
PCR amplification. Therefore, the reproducibility of technical duplicates was evaluated
using R2 (coefficient of determination, ranging from 0 to 1) to estimate the variations in-
troduced in DMH assays. After background correction, with-array normalisation and fea-
ture selection, the average R2 of duplicate arrays in the screening set (n = 111) and in the
following validation set (n = 50) was high, 0.92 (n = 111; mean ± SD: 0.92 ± 0.04)
and 0.96 (n = 50; mean ± SD: 0.96 ± 0.02), respectively. This indicates the bias in our
DMH assays was small, especially after appropriate data pre-processing (see Chapter 3). In
addition, prior to conducting the survival analysis of the Wnt pathway, we observed a good
correlation between existing bisulphite pyrosequencing methylation data at locus (chr14:
60174197-60174329) performed by Dr. Janet Graham from Imperial College London and
average DMH ratio observed at this locus (Spearman correlation ρ = 0.87, p < 0.01)
(Figure 4.10), supporting the use of average DMH ratio as a continuous variable in the
methylation analysis.
4.4.2 Performance of methylation index in the Wnt pathway
We also evaluated methylation indices in the Wnt pathway based on these loci for sensitiv-
ity and specificity to identify patients who progressed within one year after receiving first
line chemotherapy. This group of patients benefit less from platinum-based chemotherapy
at second-line treatment than patients progressing after 12 months (Agarwal and Kaye,
2003) and may be an important patient population to treat with novel therapeutic ap-
proaches at presentation or with maintenance therapies during remission. As shown in
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Figure 4.10: Correlation between DMH and bisulfite pyrosequencing at the locus (chr14:
60174197-60174329). PBMC: Peripheral Blood Mononuclear Cell
Figure 4.11, this methylation index appears slightly better than a prognostic index esti-
mated from clinical parameters (age, stage, grade and histology type) to identify this group
of patients, though neither of them reach the satisfying specificity and sensitivity to be of
use in clinics.
Meanwhile, the regression coefficients (B = 0.68) of the predicted methylation indices
by LOOCV can be used as the shrinkage factor (Verweij and Van Houwelingen, 1993) to
estimate required sample size for validating this multivariate Cox model in the future study.
4.4.3 Expression and methylation
Two out of 5 genes examined by qRT-PCR show a correlation between CGI methylation
and expression. Further investigation is required for the genes that did not show the corre-
lation between expression and methylation because (1) tumour samples were not microdis-
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Figure 4.11: Receiver Operator Characteristic (ROC) curve. Red line: methylation index
estimated from the multivariate Cox model including two independent biomarkers NKD1
and DVL1; Black line: prognostic index estimated from the multivariate Cox model includ-
ing Grade, Stage, age and Histology type of tumours. AUC: area under curve.
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sected, which could confound the RT-PCR data or TCGA expression data due to expression
of the genes in normal infiltrating tissues and (2) it is also possible that the biomarkers iden-
tified are heterogeneously methylated in the tumour tissue, i.e. differential methylation of
those biomarkers only exist in a subset of tumour (or normal infiltrating) cells, therefore,
the changes of expression of those genes in a subpopulation are masked by the general
expression levels in the entire tumour.
4.4.4 Methylation of Wnt extracellular inhibitors in EOC
Though Wnt extracellular inhibitors are frequently methylated in EOC (Table 4.13), methy-
lation of those inhibitors have no correlation with PFS in this study except SFRP5. SFRP5
has been previously reported to correlate with poor response to platinum-based chemother-
apy (Su et al., 2010). We found methylation at SFRP5 was weakly associated with poor
PFS, but was not independent from clinical parameters (adjusted p = 0.094, n = 161),
and had no correlation with response to chemotherapy (OR = 1.1, 95% CI (0.7, 1.6),
p = 0.791). Since it has been shown that silence of SFRP5 is associated with promoter
methylation (Su et al., 2010), we further examined if expression of SFRP5 was correlated
with response to first line platinum-chemotherapy in TCGA dataset, and no association
was observed. However, we noted response was measured by both the reduction of tumour
size and CA125 concentration in the previous study, while in our study response was mea-
sured by RECIST 1.0 criteria based on the shrinkage of tumour size. Furthermore, different
composition of tumour stage and histology type in the cohort studies might also cause the
differences.
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genes 
 
methylation 
frequency  
methylation status 
in PBMC 
DKK1  13.04% U 
DKK2  3.11% U 
DKK4  0% U 
SFRP1  9.32% U 
SFRP2*  50.31% U 
SFRP2*  27.33% U 
SFRP4  42.86% U 
SFRP5  67.70% U 
WIF1  78.88% M 
 
Table 4.13: Methylation frequency of extracellular inhibitors of the Wnt pathway. *Differ-
ent promoter CGIs of SFRP2. U: unmethylated loci; M: methylated loci
4.4.5 Methylation alterations in all Wnt pathways determine the patients
with early disease progression
The methylation frequencies of 6 independent biomarkers identified in this study are var-
ied, ranging from 16% to 93% (Figure 4.12A). Given at least 7 probes are required to
determine the methylation status (methylated/unmethylated) of each locus (see more de-
tails in section 3.3.7 of Chapter 3), methylation frequency of DVL1 could not be estimated
since there is only 6 probes targeting the promoter region we identified. Three major
pathways are implicated in Wnt signalling transduction, Wnt/β-catenin (canonical), PCP
and Wnt/Ca2+ pathway (Boyer et al., 2009). Using NCI protein and interaction database
(http://pid.nci.nih.gov/), we identified the genes in the canonical, PCP and
Wnt/Ca2+ pathways. To identify methylation alterations of which Wnt pathway have ma-
jor impact on disease progression, we categorised the patients into 5 groups based on the
methylation alterations in different Wnt pathways, as shown in Figure 4.12A. Ten patients
have no methylation at all 5 loci and 39 patients (”mild Wnt/β-catenin methylation” in Fig-
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ure 4.12A) have methylation only at FZD9. This gene has been shown to be involved in Wnt
signaling transduction through Wnt/β-cateninpathway in NCI curated protein/interaction
pathway. Eighty-five patients (”Wnt/β-catenin or PCP methylatio” in Figure 4.12A) have
methylation of at least two out of four loci (FZD4, NKD1, ROCK1 and FZD9) that involves
Wnt/β-catenin pathway and/or PCP pathway. Sixteen patients (”Wnt/Ca2+ methylation” in
Figure 4.12A) have methylated promoters of NFTAC3 from Wnt/Ca2+ pathway, but not all
other 4 loci are methylated in those patients. Only 6 patients have severe methylation at all 5
loci indicating methylation alterations in all three Wnt signalling pathways. Methylation of
NFATC3 from Wnt/Ca2+ pathway is always accompanied by methylation either in canon-
ical and/or PCP pathways. ”Wnt/Ca2+ methylation” group have slightly shorter PFS com-
pared to the patients with methylation in canonical or PCP pathways (”mild Wnt/ catenin
methylation” and ”Wnt/β-cateninor PCP methylation”) and without promoter methylation
of NFATC3(Figure 4.12B and D), indicating methylation alterations in Wnt/Ca2+ pathway
probably have more impact to disease progression than those in the other two pathways
in ovarian cancer. The patients with severe methylation in three Wnt signalling pathways
have much shorter progression free survival compared to the rest four groups, especially to
the patients without any methylation (HR=10.68, 95% CI 2.63 to 43.44, p=0.001)(Figure
4.12B and D). Since all the patients in this group have disease progression within about
12 months, most of them are potentially resistant to the second line chemotherapy as dis-
cussed in previous section, while all the patients without methylation at 5 loci in the Wnt
pathway have no disease relapse in the first 6 months of treatment, so they are unlikely
to be platinum-refractory (intrinsic resistance) (Agarwal and Kaye, 2003). This shows the
importance of methylation at three major pathways for early disease relapse. Four of those
loci are excluded from the multivariate methylation model that failed to stratify the patients
with disease progression within 12 months, suggesting methylation pattern of multiple loci
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is probably more useful than the mathematical model incorporating multiple loci to identify
the patients with early disease progression. However, only the patients with no methyla-
tion changes and severe methylation in Wnt pathways have significant difference in overall
survival, and there is no significant difference in overall survival of the remaining groups
(Figure 4.12C).
4.4.6 The biological role of FZD4 and DVL1 in the Wnt pathway
We observe that the prognostic value of FZD4 and DVL1 at two molecular levels, i.e. both
increased methylation and decreased expression of FZD4 and DVL1 are correlated with
poor PFS in EOC. This indicates expression of these two genes might be tightly regulated
by promoter methylation. Both Fzd4 and Dvl1 function at the upstream of the Wnt sig-
nalling and are of importance in the Wnt signalling transduction.
Frizzled homology 4 (FZD4)
FZD4 is frizzled homology 4, one member of frizzled receptor family. Recently, FZD4
has been shown to express in granulosa cells in rat ovary (Ricken et al., 2002) and play a
crucial role in corpus luteum formation and function in mouse ovary (Boyer et al., 2009),
indicating the importance of FZD4 in the normal function of ovary.
In late-stage serous EOC (n=321, TCGA dataset), among 9 frizzled receptors (FZD1,
3 to 10) presented on the microarray, only FZD4 is co-expressed with LRP5 (ρ=0.27,
p=1.23× 10−6, Pearson correlation). Methylation of LRP5 is one of 14 validated biomark-
ers associated with PFS (hypermethylation is correlated with high risk, Table 4.6 and 4.7)
in this study, and similar to FZD4, expression of LRP5 is correlated with PFS in this patient
cohort as well (n=321, HR=0.8, 95% CI (0.6,0.9), p=0.008, TCGA dataset) (low expres-
Chapter 4. CpG Islands Methylation Profiling in the Wnt Pathway and Their
Prognostic Significance in Epithelial Ovarian Cancer 171
Fi
gu
re
4.
12
:
M
et
hy
la
tio
n
at
W
nt
/β
-c
at
en
in
,P
C
P
an
d/
or
W
nt
/C
a2
+
pa
th
w
ay
s.
A
:M
et
hy
la
tio
n
of
5
in
de
pe
nd
en
tb
io
m
ar
ke
rs
in
W
nt
/β
ca
te
ni
n,
PC
P
an
d
W
nt
/C
a2
+
pa
th
w
ay
s.
Y
el
lo
w
:p
at
ie
nt
s
w
ith
m
et
hy
la
te
d
lo
cu
s;
B
lu
e:
pa
tie
nt
s
w
ith
un
m
et
hy
la
te
d
lo
cu
s;
B
:K
ap
la
n
M
ei
er
cu
rv
es
of
pr
og
re
ss
io
n
fr
ee
su
rv
iv
al
in
5
gr
ou
ps
of
pa
tie
nt
s
in
te
rr
up
tb
y
m
et
hy
la
tio
n;
C
:K
ap
la
n
M
ei
er
cu
rv
es
of
ov
er
al
l
su
rv
iv
al
in
5
gr
ou
ps
of
pa
tie
nt
s
w
ith
di
ff
er
en
t
W
nt
pa
th
w
ay
s
in
te
rr
up
t
by
m
et
hy
la
tio
n;
D
:
ha
za
rd
ra
tio
s
of
di
se
as
e
pr
og
re
ss
io
n
an
d
de
at
h
in
5
gr
ou
ps
of
pa
tie
nt
s.
4.4 Discussion 172
sion is correlated with high risk). Therefore, FZD4 and LRP5 may function together in the
signalling transduction of the Wnt pathway in ovarian cancer.
FZD4 receptor does not mediate Wnt/β-catenin signalling, but is involved in Wnt/Ca2+
pathway, which is stimulated by Wnt5a protein (McDonald and Silver, 2009). It has been
reported that Wnt5a protein activates downstream calcium effector molecules and may in-
hibit uncontrolled the Wnt/β-catenin signalling through the activation of receptor Ror2,
processing an extracellular cysteine-rich Wnt binding domain. However, with the absence
of Ror2, Wnt5a has been shown to activate TCF/LEF transcription in the presence of Lrp5
and Fzd4, thus promoting canonical Wnt signalling (Mikels and Nusse, 2006). Therefore,
the expression of ROR2 in EOC using GeneCards (http://www.genecards.org/)
was examined and observed that this gene is under-expressed in normal ovary and ovarian
tumours. Interestingly, expression of β-catenin alone is not correlated with progression
free survival in TCGA dataset (n=321, HR=0.76, p=0.11), but the prognostic index from
the multivariate Cox model including ROR2, FZD4, LRP5 and β-catenin is a significant
predictor of disease relapse and each gene has independent contribution to this association
(m=321; ROR2, HR=0.62, p=0.025; LRP5, HR=0.77, p=0.009; FZD4, HR=0.80, p=0.006;
β-catenin, HR=0.68, p=0.033; multivariate Cox model, p=3× 10−4, score test), indicating
their co-function with β-catenin in Wnt/β-catenin. Further investigation of this pathway in
EOC will be necessary to further understand how the aberrant promoter methylation affects
the Wnt signalling pathway and contributes to ovarian cancer progression.
In addition, ovarian cancer is a highly heterogeneous disease. It has been found that
a small subset of tumour cells, known as side population, enriched for tumour initiating
capacity, expressing stem-like genes and resistant to chemotherapeutic drugs are present in
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ascites of patients with ovarian tumours. Patients with higher proportion of such popula-
tion of cells are subject to have unfavourable survival (Hu et al., 2010; Rizzo et al., 2011).
Given the variation of methylation observed in this study is generally small, especially
for the loci that increased methylation relevant to short PFS, methylation possibly occurs
in such a small population of tumour cells. Consistent with this hypothesis, FZD4, also
known as cell surface marker CD344, has been found to be significantly down-regulated
in side population compared to non-side population in IGROV1 cell line in an independent
analysis in our previous study (FDR = 0.026, rank products; fold change=0.34) (Figure
4.13). Side population cells in IGROV1 cell line are a highly tumourigenic subpopula-
tion and have been characterised with an embryonic stem-cell-associated ”NOS” signature
(Notch/Oct4/Sox2 regulated genes) (p < 10−6 and FDR < 10−4, Gene Set Analysis).
This suggests the disregulation of the Wnt pathway by promoter methylation could possi-
bly only occur in a subset of tumour cells which have more growth advantages in tumour
progression and are subject to be resistant to the chemotherapy (Hu et al., 2010).
Dishevelled, dsh homology 1 (DVL1)
Dishevelled protein is a key component of Wnt signalling and plays a central role in prop-
agating Wnt signalling to canonical and non-canonical pathways. Three dishevelled genes,
DVL1, DVL2 and DVL3 have been identified in human.Wnt3a-sensitive canonical pathway
was suppressed by knock-down of Dvl1, Dvl2 and Dvl3, but most sensitive to the changes of
either Dvl1 or Dvl3 (Lee et al., 2008). Down-regulation of DVL1 by promoter CGI methy-
lation can possibly interrupt the balance of Wnt signalling transduction between canonical
and non-canonical pathways, leading to the distortion of Wnt signalling transduction.
In addition, Dvl is an indirect negative regulator of Notch pathway (Lu et al., 2007),
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Figure 4.13: Expression of FZD4 in IGROV1 SP and NSP cells. The average expression
of FZD4 is calculated by two probes (218665 at and 224337 s at) and relative to the ex-
pression of GAPDH on Affymetrix HGU133plus2 microarray.
which has been shown activated in ovarian cancer (Hopfer et al., 2005; Rose, 2009). Further
investigation about the effect of down-regulation of DVL1 by promoter methylation on
Notch pathway is also necessary to understand the cross talk between the Wnt and Notch
pathways potentially mediated by Dvl in ovarian cancer progression.
4.4.7 Sample size required for further validation study
A limitation of the study is the low average power of the analysis in the validation set (see
Materials and Methods). The current validation study while achieving 88% power for the
loci with the greatest effect had only 30% power for the median observed effect in the initial
evaluation. However, 14 out of 20 independent biomarkers identified in the first evaluation
set have been validated in the second patient cohort. Nevertheless, those loci that have not
been validated need further investigation in a larger sample set. A further 71 tumours are
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required to reach the power of 90%, which is the power generally used in the validations
study.
4.5 Conclusions
We have shown that methylation of multiple CGIs in the Wnt pathway is frequently ob-
served in epithelial ovarian cancer and identified methylation of key loci as significantly
associated with PFS (CGIs at FZD4, DVL1, NKD1, ROCK1, FZD9 and NFATC3) that are
independent from clinical parameters and constructed a multivariate Cox model that in-
corporates two independent CGIs at NKD1 and DVL1, which can identify two groups of
patients with distinct PFS. These data support the importance of epigenetic regulation of
the Wnt pathway in ovarian cancer progression and provide novel prognostic biomarkers
that have advantages over the use of expression in ovarian tumours that are highly heteroge-
neous as a biomarker. This will be relevant for patient stratification in future clinical trials
of ovarian cancer, particularly for novel drugs targeting the Wnt pathway. Furthermore, it
should also be pointed out the samples used in this analysis was obtained before treatment,
and methylation status of these genes may changes in some of patients after treatment.
Therefore, repeat measurement of methylation at relapse or disease progression would be
necessary to further understand the association between dynamic methylation changes in
the Wnt pathway, response and clinical outcome.
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5.1 Introduction
Cancer is a disease of gene expression in which the multiple complex networks governing
homeostasis become deranged. Key alterations in a variety of processes have been im-
plicated in tumour development, including self-sufficiency in growth signals, insensitivity
to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, sustained
angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg, 2000). A limited
number of cellular pathways are altered and heritably disabled in almost all cancers (Jones,
2005; Baylin and Jones, 2006). Molecular alterations in these pathways, such as mutation
and copy number changes have been extensively studied in cancers. However, a growing
number of data suggest that heritable changes, regulated by epigenetic alterations, may also
be critical for all human cancer initiation and progression (Sharma et al., 2010). Among
the three major types of epigenetic changes include DNA methylation, histone modifica-
tion and microRNA, DNA methylation is perhaps the most extensively studied in mammals
(Zeller and Brown, 2010). DNA methylation provides a stable gene silencing mechanism
that is of importance in regulating gene expression in association with histone modifica-
tions and transcriptional repression.
Table 5.1 gives some examples in 10 key cellular pathways studied in this thesis, in-
cluding AKT/mTOR, BRCA1/2, Redox, p53, Wnt, Fanconi Anemia (FA) family, igLON
family, genes involved in homologous recombination (HR), non-homologous end joining
(NHER) and mismatch repair (MMR), disrupted in human cancers by genetic and epige-
netic mechanisms (Altomare and Testa, 2005; Majumder and Sellers, 2005; Deng et al.,
2010; Senturk et al., 2010; Wang and Yi, 2008; Hayes and McMahon, 2009; Teodoridis
et al., 2005; Levine et al., 2006; He et al., 2010; Vogelstein et al., 1988b; Sparks et al.,
1998; Boyer et al., 2009; Ying and Tao, 2009; Lyakhovich and Surralles, 2006; Lim et al.,
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2008; Sellar et al., 2003; Ntougkos et al., 2005; Pasic et al., 2010; Helleday, 2003; Evers
et al., 2010; Meindl et al., 2010; van Gent and van der Burg, 2007; Curtin et al., 2009; Sel-
lar et al., 2003; Ntougkos et al., 2005; Pasic et al., 2010). The p53 pathway is undoubtedly
among the most extensively studied pathways, which promote cell cycle arrest, apoptosis
and senescence. TP53 mutation are frequently observed in most of the common types of
human tumours (Levine et al., 2006), including almost all high grade serous ovarian cancer
(Bowtell, 2010; Ahmed et al., 2010). It has been reported that methylation at promoter
region of p14ARF , upstream of p53 pathway, were observed in gliomas, breast cancer and
ovarian cancer (Teodoridis et al., 2005; Barekati et al., 2010; He et al., 2010), and deregu-
lation of p14ARF by promoter methylation is critical in the p53 pathway since it indirectly
regulates the level of p53 protein. The other example is BRCA1/2 signalling pathway.
This pathway participates in multiple biological functions including cell cycle checkpoint
and double strand break repair. BRCA1 mutation has also been observed in high grade
serous cancer (Kobel et al., 2008), while silencing of BRCA1 by promoter methylation
have been reported in ovarian cancer and is correlated with poor survival in patients com-
pared to those with BRCA1 mutation or wild-type BRCA1 (Senturk et al., 2010). Aberrant
promoter methylation has been found in some of these pathways (Table 5.1), but have not
been comprehensively studied yet. Systematic methylation profiling of the key pathways in
ovarian cancer could provide an insight into the aberrant methylation changes of these path-
ways in primary tumours. In Chapter 4, the promoter methylation of the genes in the Wnt
pathway has been systematically examined and their prognostic value evaluated in ovarian
cancer. Subsequently, 9 key pathways/families (AKT/mTOR, BRCA1/2, Redox, p53, FA
family, igLON family, HR, NHER and MMR) were further examined for prognostic value
of methylation at promoter CGIs in ovarian cancer. Therefore, this chapter focuses on the
investigation of DNA methylation of multiple promoter CGIs of the genes in these 9 key
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signalling pathways for predicting clinical outcome in ovarian cancer.
5.2 Methods
The patients selected into this analysis are the same patients cohort used to identify the
prognostic DNA methylation biomarkers in the Wnt pathway (see Chapter 4) and anal-
ysed using the methods described in Chapter 4, except that no multivariate Cox model
including multiple DNA methylation biomarkers was constructed. In brief, fresh frozen
tumours were taken before chemotherapy. Genomic DNA was extracted as previously
described (Strathdee et al., 1999), then were assayed by DMH in duplicates on Agilent
custom-designed 60-microarray targeting the promoter CGIs of 10 key signaling path-
ways/families (p53, Wnt, AKT/mTOR, MMR, HR, NHEJ, BRCA1/2, FA family, igLon
family and Redox). The genes were mainly collected from Kyoto Encyclopaedia of Genes
and Genomes (KEGG) (Table 5.2). Unsupervised hierarchical clustering was performed
using methylation status (methylated/unmethylated) of MseI fragments defined by Mann-
Whitney U test using Euclidean distance and average linkage method. The significance
of the clusters was tested by bootstrap resampling method as previously described (Shi-
modaira, 2004).The association of DNA methylation of individual locus (MseI fragment)
with progression free survival (PFS) was examined by univariate and multivariate Cox
model adjusted by clinical parameters (grade, stage, histology and age) using DMH ra-
tios as a continuous variable in each pathway/family, separately. The difference of PFS of
the patients with high/low methylation was tested by log rank test. The significance level
was set at two-sided p ≤ 0.05. All the analysis was done in R (version 2.10.1) and SPSS
(version 16.0).
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5.3 Results
We obtained the methylation profile of 10 key signaling pathways in 161 epithelial ovarian
cancers. Among 10 signaling pathways, 69% of loci in the Wnt pathway are methylated in
EOC, significantly higher than 60% estimated from all the loci presented on the microarray
(p=0.0447). The genes frequently methylated (>5%) in ovarian tumours and unmethylated
in peripheral blood mononuclear cell (PBMC) are listed in Appendix 5.1. Using unsuper-
vised hierarchical clustering (Euclidean distance and average linkage method), only two
groups of patients were identified consistently clustered together, and confirmed by 1000
fold bootstrap resamplings (n1=10, p=0.02 and n2=26, p<0.001, respectively). The groups
identified have no difference in Stage, Grade, histology and age (Figure 5.1A). These two
groups of patients have distinct progression free survival (cluster 1: median PFS 2.05, 95%
CI (1.42, 2.67); cluster 2: median PFS 1.34, 95% CI (1.00, 1.67); p=0.017 log rank test)
but no difference in overall survival (Figure 5.1B). 9 out of 10 patients in cluster 1 are
consistent with one cluster of patients (see cluster 1 in Figure 4.5, n=17) identified using
the frequently methylated loci in the Wnt pathway on the microarray (p<0.0001), but the
patients in cluster 2 are not overlapped with any group of patients identified in the Wnt
pathway.
5.3.1 Methylation of other key pathways and progression free survival
(PFS)
Association between methylation of individual locus and PFS was tested by univariate
and multivariate Cox model adjusted by age, stage, grade and histology type. Table 5.2
lists the number of DNA methylation biomarkers identified in the key pathways in the
screening set (n=111), as well as the numbers of loci had been validated in the following
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Stage Ic
Stage III
Stage IV
Serous
E d t i id
Cluster 1 N=10 p=0.02* Cluster 2  N=26 p<0.001***
n ome r o
Other
G1
G2
G3
Stage
Histology
Grade
Methylated
Unmethylated
PN
No. at risk
Cluster 1 10 10 7 5 4 2 0
Cluster 2 25 20 7 4 4 2 0
No. at risk
Cluster 1 10 8 4 0 0 0
Cluster 2 25 18 12 5 1 0
Figure 5.1: Unsupervised hierarchical clustering of binary DNA methylation data in 411
frequently methylated MseI fragments (row) on microarray in 161 epithelial ovarian tu-
mours (column). Red: methylated fragment; Green: unmethylated fragment. P: Periph-
eral Blood Mononuclear Cell (PBMC); N: adjacent samples of benign tumours. Distance:
Euclidean distance; Linkage method: average linkage. Methylation frequency of MseI
fragments are from 5% to 95% and size are from 130bp to 2500bp.
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patient cohort (n=50). The loci identified and validated in the Wnt pathway have been
described in details in Chapter 4. In the other key pathways, methylation at 13/139 in the
p53 pathway, 5/99 in the BRCA1/2 pathway, 6/78 in the AKT/mTOR pathway, 3/63 in
the Redox pathway, 2/39 in MMR and 1/45 in HR were correlated with PFS (p<0.05) in
the screening study (Table 5.3). In the subsequent validation study, the correlation between
methylation and PFS remained in 15 loci (p<0.05 and FDR<10%), of which 4 loci are from
the p53 pathway (BAI2, BAX, LRDD, and CCND1), 2 loci from the BRCA1/2 pathway
(HDAC4 and HDAC11), 4 loci from the AKT/mTOR pathway (VEGFA, PIK3R5, AKT1
and VEGFB), 2 loci from the Redox pathway (PRDX2 and TR2IT2), 1 locus from HR
(RECQL4) and 2 loci from MMR (LIG1 and MLH3), respectively (Table 5.3). Multivariate
survival analysis shows the association between methylation and PFS at PIK3R5, AKT1 and
VEGFB from AKT/mTOR pathway, PRDX2 and TR2IT2 from redox pathway, and MLH3
from MMR are independent from grade, histology, stage and age (adjusted p<0.05) (Table
5.4).
5.3.2 Expression of other key pathway and progression free survival (PFS)
Further examination of the expression of the candidate genes associated with methyla-
tion biomarkers independent from clinical parameters (PI3R5, AKT1, VEGFB, PRDX2,
TR2IT2 and MLH3) was obtained from gene expression profiling study in ovarian cancer
on Affymatrix HGU133A microarray (TCGA dataset, unpublished). This analysis found
although none of those genes have significant correlation in expression and PFS, expres-
sion of PRDX2 and MLH3 show a trend of correlation with PFS in this patient cohort (low
expression is correlated with high risk, n=321, p<0.1) (Table 5.5).
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HR1 95% CI2
VEGFA 4.1 (0.3, 57.3) 2.94E-01
PIK3R5 15 (1.2, 184.6) 3.44E-02*
AKT1 53.7 (4.3, 674.9) 2.04E-03**
VEGFB||DNAJC4 13.4 (1.3, 141.6) 3.07E-02*
BAI1 20.4 (0.7, 592.5) 7.94E-02+
BAX 1.6 (0.6, 4.1) 3.28E-01
LRDD 8.2 (0.8, 86.6) 7.90E-02+
CCND1 1.9 (0.8, 4.8) 1.69E-01
HDAC4 3 (0.4, 21.4) 2.64E-01
HDAC11||HDAC11 4.6 (0.7, 29.7) 1.08E-01
PRDX2 3.3 (1.6, 6.6) 7.79E-04***
TR2IT1 22.4 (1.7, 298.4) 1.85E-02*
LIG1 1.7 (0.8, 3.4) 1.63E-01
MLH3 58 (1.9, 1782.3) 2.02E-02*
MMR
p53
AKT/mTRO
BRCA1/2
Redox
Multivariate PFS analysis (N=111)
adjusted p value3
Pathway/
family genes
Table 5.4: Multivariate survival analysis (PFS) of validated DNA methylation biomark-
ers in 9 key pathways. Abbreviations: HR, hazard ratio; CI, confidence interval; FDR,
false discovery rate.-1Hazard ratio per unit increase in DMH ratio (continuous variable)
estimated from Cox proportional hazard regression model.-2Confidence interval of the es-
timated hazard ratio. -3p value adjusted by histology, grade, stage and age. Age was used
as a continuous variable and histology, grade and stage were used as categorical variables.
+p < 0.1; *p ≤ 0.05; **pleq0.01;***p ≤ 0.001
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HR1 95%CI2 p value3
VEGFB 1.15 (0.83, 1.60) 0.4
PIK3R5 0.77 (0.35,1.67) 0.506
AKT1 0.88 (0.72, 1.08) 0.231
PRDX2 0.69 (0.47, 1.02) 0.063+
TR2IT1 - - -
MMR MLH3 0.73 (0.53, 1.01) 0.06+
Pathways/
Families Gene
Univariate PFS analysis (TCGA dataset, N=321)
AKT/mTOR
Redox
Table 5.5: Univariate survival analysis of expression of candidate genes in the other
pathways/families in TCGA dataset. Abbreviations: B, coefficient of Cox proportional
hazard regression model; HR, hazard ratio; CI, confidence interval; FDR, false dis-
covery rate. -1Hazard ratio estimated from Cox proportional hazard regression model.-
2Confidence interval of the estimated hazard ratio. -3p value of Score test. +p<0.1; *p≤05;
**p≤0.01;***p≤0.001
5.3.3 Methylation and overall survival/response
Among all 6 independent and validated biomarkers, only PRDX2 shows an association of
methylation to overall survival (screening set: HR=1.90, 95% CI (1.21, 2.99), p=0.006;
validation set: HR=3.22, 95% CI (1.18,9.79), one sided p=0.01). But no correlation be-
tween methylation of PRDX2 and response was observed (p=0.553). Out of 6 biomarkers,
only increased methylation of a locus close to VEGFB or DNAJC4 is significantly related
to poor response to chemotherapy in the combined analysis of screening and validation set
(Table 5.6).
5.4 Discussion
Multiple cellular signaling pathways are disordered in cancers. Though genetic alterations
of these pathways have been extensively investigated, systematic study of promoter methy-
lation of the genes in the pathways has not been done in cancers yet. In this study, methy-
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Pathway/family genes Logistic regression (Response1: PR+CR n=54; PD+SD 
n=29) 
OR22 95% CI3 P value4 FDR5 
AKT/mTOR 
PIK3R5 0.78 (0.48, 1.26) 0.305 0.672 
AKT1 0.94 (0.57, 1.56) 0.812 0.812 
VEGFB||DNAJC4 1.94 (1.11,3.40) 0.021* 0.126$ 
Redox 
PRDX2 0.87 (0.56, 1.36) 0.553 0.672 
TR2IT1 1.24 (0.77, 1.98) 0.372 0.672 
MMR MLH3 1.17 (0.69, 2.01) 0.56 0.672 
 
Table 5.6: Response and methylation of 6 candidate genes in the key pathways in the com-
bined analysis of screening and validation set. Abbreviations: OR, odd ratio; CI, confidence
interval; FDR, false discovery rate. 1Response to first line chemotherapy was measured by
RESIST 1.0; the patients with complete/partial response are the responders to chemother-
apy, while the patients with progressive or stable disease are those who did not response
to chemotherapy. -2Odd ratio of the patients had poor response to chemotherapy (PD+SD,
n = 29) to the patient with good response to chemotherapy (CR+PR, n = 54) per unit
increase of Z scores.-3Confidence interval of the estimated odd ratio.-4p value of score test
of logistic regression model.-5Multiple test correction. $FDR ≤ 0.2; +p ≤ 0.1; *p ≤ 0.05
lation profile of 9 signaling pathways/families was obtained in 161 ovarian tumours and
association between methylation and clinical outcome has been evaluated.
In a previous study, methylation frequency of 24 CpG islands of genes associated with
DNA damage responses have been examined by methylation specific PCR (MSP) in late-
stage ovarian cancer (Teodoridis et al., 2005). Eleven out of 24 CGIs are presented on
the custom-designed microarray in present study (Table 5.7). The estimated methylation
frequency in this study is generally higher compared to previous study. For example, pro-
moter CGI methylation of FANCF was found in 14.9% of patients in present study of which
majority (96%) have late-stage tumours, while promoter methylation was not detected in
late-stage ovarian cancer by Teodoridis et al., probably because the custom-designed mi-
croarray is targeting the whole CpG island by multiple probes, while MSP primers only
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cover a few CpG sites within CGI and possibly the informative loci are missed due to the
restriction of MSP primer design in Teodoridis et al. study. In addition, the tumour tissues
that is a mixture of cells, with a number of patterns of methylation could influence the
sensitivity of MSP (Smith et al., 2003). Our result is comparable to the study performed
by Lim et al. (2008), in which promoter methylation of FANCF was detected in 13.2% of
advanced ovarian cancer. Promoter region of BRCA1 was methylated in only 1.2% of pa-
tients, which is much lower than the estimation from previous study. Although the region
was targeted by 8 probes fulfilling the requirement that at least 7 probes should be used
to determine the methylation status estimated in feasibility study (Chapter3), the promoter
CGI of BRCA1 is within a large MseI fragment (2274bps). The larger the MseI fragment
is, the more likely to observe the larger variation depending on the distance between the
probes. This can potentially influence the Mann-Whitney test, and partially explain the
reason that much less methylation frequency was found at BRCA1 in our study, indicating
that fragment size bias exist in DMH assay using MseI restriction enzyme to fragmentize
the genomic DNA.
Expression and methylation at two genes (MLH3 and PRDX2) are weakly correlated
with PFS in this study, indicating promoter methylation at these two genes probably regu-
lates gene expression, though direct relation between methylation and expression of these
two genes has not been validated yet. MLH3 is a member of the MutL-homology (MLH)
family of DNA mismatch repair (MMR) genes, interacting with MLH1. Cells in culture
with dominant negative MLH3 protein have been shown exhibiting microsatellite instabil-
ity (Lipkin et al., 2000). There is no report about methylation at MLH3 so far, but it has
been shown that PRDX2 silencing caused by putative promoter region methylation can be
restored by a demethylating agent in human malignant melanomas (Furuta et al., 2006).
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Gene Pathway/Family 
Methylation Frequency 
Teodoridis et al.  Present study 
APAF1 p53 0% 11.2% 
BRCA1 BRCA1/2 12.3% 1.2% 
CASP8 p53 1.2% 1.9% 
FANCF FA family 0% 14.9% 
FAS p53 0% 1.9% 
GSTP1 redox 1.2% 13.7% 
MLH1 MMR 5.7% 3.7% 
OPCML IgLON family 33.3% 85.7%1  or 40.3%2 
CDKN2A p53 0% 0% 
CDKN1A p53 0% 67.7% 
TP73 p53 0% 83.9% 
SFRP1 Wnt 5.3% 9.9% 
 
Table 5.7: Methylation frequency of promoter CGIs of 12 genes in ovarian cancer estimated
from Teodoridis et al study and present study.-1Chr11: 132317872-132319158. -2Chr11:
132319158-132319639
This proves the dependency between expression and promoter methylation at this gene.
However, PRDX2 is observed to be up-regulated after chemotherapy and increased expres-
sion of PRDX2 is associated with cisplatin resistance in late-stage and high grade ovarian
cancer (L’Esperance et al., 2006). In contrast, we observe no association between response
to chemotherapy and methylation. Thus, methylation of PRDX2 alone has no major impact
on response to the first line platinum-based chemotherapy in ovarian cancer. Furthermore, it
should also be pointed out the samples used in this analysis was obtained before treatment,
and methylation status of PRDX2 may changes in some of patients after exposure. Among
two pairs of isogenic cell lines isolated from two patients before and after chemotherapy
(PEA1 vs. PEA2 and PEO14 and PEO23), PRDX2 is methylated in PEA1, PEA2, PEO14,
but become unmethylated in PEO23 cell line (Figure 5.2). Therefore, repeat measurement
of methylation at relapse or disease progression would be necessary to further understand
the association between dynamic methylation changes, response and clinical outcome.
Chapter 5. CpG Islands Methylation Profiling in the Other Key Pathways and Their
Prognostic Significance in Epithelial Ovarian Cancer 191
Figure 5.2: Methylation of PRDX2 in two pairs of cell lines isolated from two patients
before and after chemotherapy measured by DMH assay on Agilent custom-designed
microarrays. PRDX2 are methylated in PEA1, PEA2 and PEO14, and unmethylated
PEO23 determined using 14 probes targeting the promoter CGI by the method described
in section 3.2.4. Methylation was dramatically decreased in PEO23 compared to PEO14
(p = 7.82× 10−5, Man-Whitney test).
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In SGCTG patient cohort, the response rates of the patients received platinum alone
and platinum combined with taxane treatment, platinum combined with other agents as ad-
vised by oncologists are different (PR+CR: 40% vs. 71% vs. 80%, p=0.011) . As shown
in Figure 5.3, methylation at PIK3R5, AKT1, VEGFB, TR2IT1 and PRDX2 are varied in
the patients received different treatments, especially between the patients treated by plat-
inum alone and combination of Platinum and Taxane. Therefore, different treatments in
non-randomised clinical trial might be a confounding factor in the response analysis, sug-
gesting the correlation analysis between methylation and response should be performed in
the patients stratified by chemotherapy in a larger patient cohort.
The genes involved in the key signaling pathways were obtained mainly from KEGG
database including the classical representation of the established pathways collected from
literatures. Although KEGG provides valuable resources for selecting the targets in methy-
lation profiling study, in many cases, the boundary of the pathway is vague because the
components included in the pathway are based on the curator’s knowledge and experience
(Lu et al., 2007). Even though the core components of the pathways in different signalling
pathway database are generally similar, the additional components involved in the pathway
can be very different across different databases. For example, 148 genes are presented in
the Wnt pathway in KEGG database (hsa04310, http://www.genome.jp/kegg/),
while only 25 genes are involved in the same pathway in BioCarta (ID: H wntPathway,
http://www.biocarta.com/). Expansion of 10 signalling pathways with the ad-
ditional components that are potentially involved in the signaling transduction as well as
further classification of the components based on their specific function in a pathway are
necessary to uncover how the methylation changes of multiple components influence the
signalling transduction in the pathways.
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AKT1 0.0255*  0.2583  0.5734  
VEGFB 0.0006** 0.2917  0.0771  
PRDX2 0.0117*  0.1691  0.5734  
TR2IT1 0.0374*  0.7485  0.0826  
MLH3 0.0870  0.3712  0.8026  
 
Figure 5.3: Methylation of 6 biomarkers in the patients received different treatments. *p <
0.05 (Man-Whitney test); **p < 0.01 (Mann-Whitney test).
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In conclusion, methylation profiles of promoter CGIs in 9 key signalling pathways were
achieved and their prognostic value was evaluated in terms of association with progression
free survival in ovarian cancers. Methylation of promoter CGIs at PI3R5, AKT1, VEGFB,
PRDX2, TR2IT2 and MLH3 is correlated with poor PFS and independent from clinical pa-
rameters. Meanwhile, reduced expression of PRDX2 and MLH3 showed weak association
with unfavourable PFS in another patient cohort.
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General Discussion and Future
Perspectives
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Ovarian cancer is the leading cause of all the gynaecological cancers. Intrinsic or ac-
quired drug resistance to conventional treatment is one of major obstacles in ovarian cancer
treatment (Agarwal and Kaye, 2003). Advance of high-throughput methylation profiling
makes evaluation of the association between methylation of CGIs and acquired drug re-
sistance and identification of methylation prognostic/predictive biomarkers in large-scale
methylation studies possible (Laird, 2010). Using biostatistical analysis enhanced by bioin-
formatics approaches to identify such biomarkers in ovarian cancer has been explored in
this thesis using restriction enzyme-based methylation profiling technologies.
6.1 Association of Hypermethylation, DNA Damage and Cisplatin Treat-
ment
Using a novel method, Methylation Linear Discriminant Analysis (MLDA) (see Chapter
2), we found more aberrant hypermethylation than hypomethylation of CpG islands arose
during the exposure of ovarian cancer cell lines to cisplatin, indicating mechanisms driv-
ing the occurrence of hypermethylation, rather than hypomethylation, in the acquisition of
cisplatin resistance. DNA is the primary target of cisplatin. Formation of cisplatin-DNA
adducts interferes with DNA replication and transcription. The interstrand and intrastrand
crosslinks caused by cisplatin disrupt the DNA structure, which can be recognised by cel-
lular proteins to repair the damage (Balch et al., 2004). It is possible that the methylation
changes occur in the cancer cell lines is a consequence of DNA damage caused by cisplatin
and repair of DNA, especially double-strand repair, in the genome. Consistent with this hy-
pothesis, recent data has shown that DNA methylation at exogenous introduced sequences
can be influenced by DNA double strand breaks (DSB) in cells and DNMT1 is present at
sites of DNA repair (Mortusewicz et al., 2005; Cuozzo et al., 2007; O’Hagan et al., 2008;
Palii et al., 2008). Although it is still unclear if this occurs at endogenous genes, this could
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potentially explain why many loci become hypermethylated during acquired cisplatin re-
sistance.
6.2 More Samples are Required for the Validation Study
As shown in Chapter 4 and 5, epithelial ovarian tumours prospectively collected from a
SGCTG/NCRI cohort study have been systematically examined by DMH assay at pro-
moter CGIs of 10 key signalling pathways and we have shown that levels of methylation of
multiple CGIs have the potential to be prognostic biomarkers for progression-free survival.
Although the validation study was adequately powered for the majority of hypermethylated
loci, this was not the case for hypomethylated loci which generally had lower hazard ratios.
At least a further 70 tumours with progression events are required to reach 90% power for
all loci.
6.3 Biological Mechanisms of Methylation at the Wnt Pathways Con-
tributing to Ovarian Cancer Progression
DNA methylation at the loci that are associated with patients’ clinical outcome helps to de-
fine key genes and pathways important for ovarian cancer progression. The Wnt pathways
are especially important, given 6 independent biomarkers (FZD4, NKD1,DVL1, ROCK1,
NFATC3, FZD9) from this pathway showed the correlation with progression free sur-
vival (Chapter 4), accounting for 50% of the biomarkers that have been identified in this
project. Three major pathways are implicated in Wnt signalling transductions, Wnt/β-
catenin (canonical), PCP and Wnt/Ca2+ pathway (Boyer et al., 2009). However, the genes
relevant to the 6 biomarkers identified are involved in different Wnt pathways as shown in
Figure 6.1. As discussed in Chapter 4, based on the methylation status of 5 biomarkers
6.4 Where Shall We Look at Besides Promoter CpG Islands? 198
(FZD4, NKD1, NFATC3, ROCK1, and FZD9) (note methylation status of DVL1 could not
be determined due to the limitation of the method used, see Discussion in Chapter 4), we de-
fined 5 groups of patients (1) ”no methylation”, (2) ”mild Wnt/β-catenin methylation”, (3)
”Wnt/β-catenin or PCP methylation”, (4) ”Wnt/Ca2+ methylation” and (5) ”severe methy-
lation ” in all three Wnt pathways. ”Wnt/Ca2+ methylation” group have slightly shorter
PFS compared to the patients with ”mild Wnt/β-catenin methylation” and ”Wnt/β-catenin
or PCP methylation”, indicating methylation alterations in Wnt/Ca2+ pathway probably
have more impact on disease progression than those in the other two pathways in ovarian
cancer. However, this systematic approach does not provide a functional read-out of Wnt
pathways, so experimental investigation of specific candidate Wnt genes for their poten-
tial role in cell transformation and response to treatment in EOC is necessary, especially
for DVL1 and FZD4 that have been shown 1) methylation associates with PFS and over-
all survival in a manner that is independent from other clinical/pathological criteria, 2) an
association between methylation and expression and 3) an association between expression
and survival in independent tumour cohorts (TCGA pilot study).
6.4 Where Shall We Look at Besides Promoter CpG Islands?
Although methylation at promoter CGI is of importance in regulating gene expression, an
increasing number of studies show several regions are potentially interesting for methyla-
tion analysis. First, certain relationship between expression of the genes and methylation
within gene body but not in CGI have been observed (Zilberman et al., 2007; Maunakea
et al., 2010), indicating intragenic methylation plays a role in regulating transcription. Sec-
ond, it is estimated that about 30-40% of the genes have relatively low CpG density at
the promoter regions (non-CGI promoters), and those regions are observed to be generally
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Figure 6.1: Methylation interruption in the Wnt signaling pathways. The genes highlighted
in red are relevant to the biomarkers have been identified in the screening set and validated
in an independent cohort, while the genes highlighted in blue are relevant to the biomarkers
that have been identified in the screening set, but not validated in the following study.
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methylated in somatic tissues, not associated with activities of the genes (Shen et al., 2007;
Weber et al., 2007). However, a large number of these regions are located at alternative
promoters that are within the gene body of dominantly expressed transcript which are gen-
erally methylated in normal cells. Identification of ’true’ non-CGI promoter irrelevant to
intragenic methylation would be helpful to evaluate the relation between methylation at
such regions and expression of the relevant genes. A subset of non-CGI promoters have
been found unmethylated in the somatic tissues when the genes become active (Weber
et al., 2007), making methylation changes of these regions potentially interesting. Third,
although CGIs at alternative promoters that are annotated in Refseq database and/or UCSC
known gene database have been analysed in this study, some intragenic CGIs not asso-
ciated with known genes have not been included in the analysis. Since these CGIs are
potentially related to the alternative promoters that have not been identified yet and methy-
lation at these regions can influence the elongation of transcription (Illingworth and Bird,
2009), evaluation of methylation at these regions might be also of interest. Therefore, the
probe coverage on Agilent custom-designed 60K microarray used in the validation study
of candidate methylation biomarkers has been expanded from promoter CGI to +2k to -8kb
distance of the transcription start site of genes involved in the key signalling pathways, al-
lowing evaluation of methylation at gene body and non-CGI promoter regions in ovarian
cancer in the future studies.
6.5 Expansion of Methylation Model for Predicting Patients’ Clinical
Outcome
The prognostic values of multiple promoter CGIs were evaluated and validated individ-
ually in this study, and then a multivariate Cox model combining multiple methylation
biomarkers from the Wnt pathway was constructed. Only two methylation biomarkers
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at DVL1 and NKD1 were incorporated into the model and identified two groups of pa-
tients with favourable and unfavourable progression free survival (see Chapter 4). Given
single pathway analysis is probably too simple to accurately reflect tumour progression
and chemosensitivity which involve multiple biological mechanisms. We attempted to
explore the possibility to expand the multivariate methylation model using all indepen-
dent biomarkers identified in this project including promoter methylation at FZD4, NKD1,
DVL1, ROCK1, NFATC3, FZD9 from the Wnt pathways, PIK3R5, AKT1, VEGFB (or
DNAJC4) from AKT/mTOR pathways, PRDX2, TR2IT1 from Redox pathway, and MLH3
from MMR system. Among 12 biomarkers, 4 methylation biomarkers at FZD4, NFATC3,
VEGFB (or DNAJC4) and PRDX2 were incorporated into the model using forward likeli-
hood ratio stepwise algorithm. The methylation index (MI) calculated from this model can
identify two groups of patients with distinguished PFS and OS (PFS: p = 5.39 × 10−8,
events=134, Figure 6.2A; OS: p = 9 × 10−3, death=93, Figure 6.2B) and increased MI is
significantly correlated to the patients with poor response to platinum-based chemotherapy
(p=0.02, OR=3.32, 95% CI 1.21 to 9.17, logistic regression), suggesting the association be-
tween MI and PFS may be partly related to the likelihood of achieving good response with
fist-line chemotherapy. However, excluding the patients without response to chemother-
apy, this MI is still associated with PFS in the patients who achieved complete response or
partial response to chemotherapy (n=54, HR=3.32, 95% CI 1.82 to 5.95, p = 8.08× 10−5),
indicating the prognostic value of this MI is partly independent from response to first-
line treatment. Consistent with the prognostic value of multivariate methylation model,
the multivariate expression model constructed by FZD4, NFATC3, DNAJC4 and PRDX2
is also significantly relevant to disease free survival in patient cohort with late-stage dis-
ease generated by The Cancer Genome Atlas (TCGA) pilot study (n=321, multivariate Cox
model p=0.003; FZD4: HR=0.8, 95% CI 0.69 to 0.93, p=0.003; NFTAC3: HR=0.96, 95%
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CI 0.76 to 1.0, p=0.707; DNAJC4: HR=0.62, 95% CI 0.37 to 1.05; PRDX2: HR=0.69,
95% CI 0.48 to 1.0, p=0.052). Though the predictive values of both expression and methy-
lation models are still awaiting for further assessment either by cross-validation or ideally
by other patient cohort with adequate power, this shows incorporating multiple biological
mechanisms are potentially more valuable in prediction of patients’ outcome and response.
However, based on the ”rule of thumb” we cannot include more variables than one-tenth
of the number of events available for the analysis (Van Belle, 2008). In our case 151
patients with late-stage disease are included in the multivariate analysis with 134 events
(disease progression), suggesting at maximum only 13 loci can be incorporated into the
multivariate Cox model. Therefore, a much larger patient cohort is required to identify a
methylation signature probably including hundreds of loci using more robust method, such
as supervised gene shaving (Hastie et al., 2000), which can extract coherent methylation at
multiple promoters and gene-body regions that vary across the samples in such a way that
the methylation is correlated with clinical outcome.
6.6 Methylation as Biomarkers for Surgery Decision
Volume of residual disease following surgery is an important prognostic factor in ovarian
cancer (Bristow et al., 2002). Meta-analysis shows a positive correlation between surgical
debulk status and survival in advanced disease (Hunter et al., 1992). However, in a number
of patients who are thought to be suitable for the debulking surgery based on the preop-
erative assessment, an operation is not undertaken because disease resection will result in
long-term morbidity or patient demise. Chemotherapy is allowed to start earlier in those
patients, therefore, identification of biomarkers which can predict the resectability of tu-
mours would aid clinical decision making in terms of which patients should have primary
surgery or neoadjuvant treatment to achieve a complete macroscopic debulk . Unfortu-
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nately, only a few samples from this study have surgical annotation, though methylation
of ROCK1 did show the association with the level of residual disease following surgery
(p=0.032). We have proposed to further examine the correlation between the loci that are
shown to be associated with PFS in SGCTG cohort study, and a discovery analysis for new
candidates associated with success of surgical resection from the data generated by DMH
on Agilent 8x60K array using the samples collected in Hammersmith Hospital, UK and by
Illumina Infinium on HumanMethylation27 chips generated by TCGA pilot study. Mean-
while, development of a non-invasive method to detect methylation of multiple selected
loci in the serum or plasma of ovarian cancer patients in a robust manner with rapid assay
times will allow us to apply these findings in the treatment of ovarian cancer, effectively
and efficiently.
6.7 Identification of Aberrantly Methylated ’Hot Spots’ in Ovarian
Tumours
Methylation of a small region (about 150bps) at promoter CGI of DVL1, one biomarker
identified from the Wnt pathway, was examined by bisulfite sequencing and the result
shows that methylation at this locus is significantly correlated with DMH ratios (p=0.006,
see results in Chapter 4) in tumours, but methylation level is generally low (<10%) and dif-
ferential methylation at DVL1 among the tumours is subtle which is different from what we
observed in ovarian cancer cell line model where dramatic increase of methylation (>15%)
at the examined loci were observed in the cell lines resistant to cisplatin compared to the
sensitive ones. There are two possibilities to explain this: (1) the examined locus generally
has low methylation in all tumour cells and (2) the locus has high methylation only in a
small subset of tumour cells due to the heterogeneity of disease. If the former possibility is
the case, an extensive bisulphite sequencing of the chromosomal region targeted by DMH
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is required. Therefore, we have proposed to validate differential methylation using Illumina
GAIIx high throughput DNA sequencing of bisulfite modified DNA and PCR amplification
of target loci to define the exact location. If the latter possibility is the case, identification
of the subpopulation of tumour cells, such as drug resistant tumour stem cells, and charac-
terisation of this subpopulation is of importance to understand how this subset of tumour
cells contributes to the tumour progression and have impact on patient survival.
6.8 Methylation as Predictive Biomarkers for Treatment Decision
Combination of platinum and taxane are recommended in ovarian cancer treatment (du Bois
et al. 2005). However, some patients can not receive the combined treatment due to poor
performance status. We explored the potential of using the prognostic biomarkers identi-
fied in this study as predictive biomarkers for treatment decision making (single or com-
bined treatment regimen). Of 12 independent biomarkers, methylation at DVL1, ROCK1,
PIK3R5, AKT1, VEGFB (or DNAJC4), TR2IT1 and PRDX2 show a trend of differential
methylation between patients receiving platinum alone (n=45), combined treatment (n=91)
and other platinum-based treatment (n=21). In the patients received the combined treat-
ment, lower methylation of DVL1 and VEGFB (or DNAJC4) are found in the responders
(PR+CR, n=34) than non-responders (PD+SD, n=14) (Figure 6.3) who have significantly
higher risk of disease progression than the former group (HR=2.48, p=0.01). The number
of samples available for this exploratory analysis is small. Further evaluation and valida-
tion analyses of these biomarkers in a randomised clinical trial following a more specific
analysis plan for predictive biomarkers of platinum alone or combined treatment are clearly
essential.
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6.9 Methylation and Novel Treatments Targeting Molecular Pathways
Several molecular therapies targeting key pathways, such as poly(adenosine diphosphate-
ribose) polymerase (PARP) inhibitor (Bast and Mills, 2010; Yap et al., 2009) (Clinical-
Trials.gov ID: NCT00494442) targeting base excision repair in the patients with BRCA
mutation, Wee1-inhibitor targeting G2 checkpoint in the patients with p53 mutation (Clin-
icalTials.gov ID: NCT01164995), mTOR inhibitors targeting PI3K-AKT pathway (Clini-
calTrias.gov ID: NCT00429793), have been approved for Clinical trials in ovarian cancer.
Methylation changes identified in this study at the key pathways in the patients received
platinum-based chemotherapy will be relevant for patient stratification, in future clinical
trials of ovarian cancer, particularly for novel drugs targeting the Wnt pathway (Luu et al.,
2004), redox pathway, AKT/mTOR pathway (Yap et al., 2009) as well as MMR system.
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